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ABSTRACT 
 
VIRGINIA WANG:  Location, Location, Location?  A Study of Peritoneal Dialysis Services in the 
United States. 
(Under the direction of Shoou-Yih Daniel Lee, PhD) 
 
 
Dialysis treatment of end-stage renal disease (ESRD) has become an important health policy 
concern because of growth in the number of patients with kidney failure and the financial burden on 
patients and payers.  The development of peritoneal dialysis (PD) offered a clinically effective, more 
convenient and less expensive alternative to hemodialysis, the dominant form of renal therapy 
treatment for ESRD in the US.  Despite studies that demonstrated the appeal of PD among patients, 
providers, and payers, and Medicare program payment policies that promoted its use, utilization of 
PD has been limited.  Prior studies have examined patient and physician factors of PD utilization and 
confirmed a significant preference for PD that is not reflected in practice.  Less attention has been 
paid to the role of treatment facilities.  This study uses location theory to elucidate the mechanisms 
behind the availability and distribution of PD services over time.   
This longitudinal study uses national data on ESRD patients and outpatient dialysis facilities 
from the US Renal Data System and the Centers for Medicare and Medicaid Services.  Spatial and 
longitudinal regression methods, previously underused tools in the study of ESRD, are used to 
examine conditions associated with PD service offerings among dialysis facilities between 1995 and 
2003.   
 Throughout the study period, fewer than half of facilities offered PD.  GIS mappings 
demonstrate the availability of PD to vary temporally and geographically.  Results from multivariate 
regression models indicate that market conditions influence facilities’ decision to offer PD services, 
but in unexpected ways.  Most market conditions considered favorable for generating revenue and 
profit from a PD service line were, in fact, negatively associated with facilities’ likelihood of offering 
PD.   
The locational distribution of PD appears to reflect the effect of PD as a scarcely utilized 
service, suggesting that there may be more behind the locational distribution of PD than profit-
seeking among dialysis facilities.  Results from this study contribute to the scant literature on PD 
services and lay the foundation for further research and better understanding of the organization of 
this potentially useful therapy for ESRD.
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CHAPTER 1 
INTRODUCTION 
 
 End stage-renal disease (ESRD) occurs when an individual’s kidneys fail to remove waste 
and fluids from the body and release hormones to regulate the body’s chemical balance.  Roughly half 
a million Americans currently suffer from ESRD, a number that has increased roughly 7% between 
1991 and 2001 [1].   
Since 1973, Medicare has provided near-universal health care coverage for patients with 
ESRD, regardless of age or employment disability status.  The Medicare ESRD program is the 
primary payer of health care services for 92% of US patients suffering from ESRD [2, 3]. The 
program has grown considerably since its inception.  In 2005, patients in the ESRD program 
represented 1.2% of the Medicare beneficiary population, and their care constitutes 8.2% of all 
Medicare expenditures ($21.3 billion) [4].   
 In order to survive, failed kidneys need to be replaced through kidney transplantation.  If 
kidney transplantation is not available, individuals require dialysis or renal replacement therapy 
(RRT), a procedure that replaces the work of healthy kidneys to remove excess fluid and waste from 
the blood.  With the dearth of available kidneys for transplantation, roughly 70% of Medicare ESRD 
beneficiaries receive dialysis therapy [1].  There are 2 treatment modalities for dialysis:  hemodialysis 
(HD) and peritoneal dialysis (PD).   
 Since its development in the 1960s, HD has been the predominant treatment for ESRD.  
During HD treatment, blood is removed from the body and filtered through a machine that removes 
toxins and excess fluid and returns cleansed blood to the body.  HD is performed for 3 to 5 hours at 
least 3 times a week, usually in a dialysis facility staffed by trained professionals.  PD was developed 
 
as an alternative form of dialysis in the 1970s and introduced into routine clinical practice in the early 
1980s.  During PD treatment, waste is filtered through the body’s own peritoneal cavity membrane.  
The procedure involves the injection of a cleansing solution into the abdominal cavity to draw waste 
from membrane blood vessels and its subsequent drainage from the body.  With training, patients can 
perform PD on their own for 30 to 40 minutes roughly 4 to 5 times a day, at home or work [5]. 
The development of PD offered the promise of a convenient, clinically effective, and less 
expensive alternative to HD.  PD is not suitable for all ESRD patients and is therefore not necessarily 
a better modality of dialysis than HD.  In cases where there are no clear indicators suggesting 
otherwise, PD may be considered equivalent or complementary to HD.  Studies demonstrated the 
clinical appeal of peritoneal dialysis for ESRD patients as well as providers and payers.  The 
availability of PD has the potential to meet patients’ demand for dialysis services and their preference 
for a clinically effective, convenient, and less expensive form of dialysis that is conducive to 
independent lifestyles, which could result in reduced frequency of visits and travel time as well as 
increases in patient satisfaction and clinical outcomes.  For dialysis facilities, PD allows facilities to 
maintain their patient base, diversify their services, while reducing fixed costs of care.   
Recognizing the clinical and economic advantages of PD, Medicare provides incentives to 
promote the use of home-based dialysis.  For dialysis patients enrolling in Medicare based on ESRD, 
the standard 3-month wait for benefit coverage to begin is waived for patients on home-based 
dialysis.  In 1983, the Medicare program enacted a payment policy to dialysis facilities, furnishing 
equal payment for services regardless of modality.  By increasing providers’ profitability from 
dialysis services, this new payment structure was predicted to promote the use of home-based 
dialysis.   
 Several characteristics of ESRD and the dialysis industry over the last 20 years were also 
expected to facilitate increased adoption of PD services by dialysis providers.  The advent of PD 
afforded an opportunity for dialysis providers to meet the escalating demand for services, brought on 
by growing populations of incident and prevalent ESRD patients.  Increasing demand for dialysis was 
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also filled by a rising number of dialysis providers.  This growth was fostered, in part, by Medicare 
coverage and reimbursement policy, which provides equal payment for services regardless of 
modality and whose rates have remained relatively fixed.  During this time, dialysis providers 
developed efficiencies in their services, enabling facilities to increase their savings on costs and 
generate additional profits, inciting further growth in the dialysis industry [2, 3, 6, 7].  Thus, along 
with the epidemiological trends in ESRD and operational factors of ESRD care that would 
theoretically motivate efforts for more facilities to offer PD as a clinically complementary, effective, 
patient-friendly and convenient form of dialysis, regulatory and economic factors would also promote 
the widespread use of PD as the less costly and more profitable treatment modality for dialysis 
providers. 
Despite its appeal to patients, providers, and payers, however, PD remains a highly 
underutilized treatment for a growing American ESRD population.  PD prevalence increased shortly 
after its introduction in the early 1980s.  It quickly reached a peak of 14% incidence (of all ESRD 
treatments) in 1985 and started to decline to its current rate of 6%.   This unusual pattern of diffusion 
is interesting in spite of the facts that PD was developed in the US and that the domestic rate of PD 
adoption is low relative to that of other countries.  While 6% of US ESRD patients were newly treated 
with PD in 2003, Asian and European countries reported up to 82% PD incidence [8, 9].  The low 
utilization of PD, in spite of a significant preference for PD among patients and appropriateness 
among physicians, suggests that the provision of PD services in the US deserves greater scrutiny [9-
14].     
 The published literature has examined individual determinants of PD treatment use, but little 
is known about other relevant factors associated with PD service delivery and use. In particular, the 
availability of PD services at dialysis facilities, an antecedent of PD utilization, warrants a systematic 
investigation because physicians and patients cannot consider or select PD if it is not made available 
to them.  Fewer of the nation’s ESRD providers are offering PD services.  Shortly after PD received 
clinical approval from the Federal Drug Administration in 1978 and Medicare instituted the equal 
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reimbursement for HD and PD in 1983, 71% of ESRD facilities offered PD [1, 15].  Currently, less 
than half of the nation’s 4,500 ESRD facilities offer PD services [1].  Why? 
 Several studies have examined the role of dialysis providers (i.e., dialysis facilities) in the 
provision of PD.  With few exceptions, those studies adopted a cross-sectional design and failed to 
examine how different dialysis modalities have been distributed over time.  Moreover, the distribution 
of PD and the mechanism that underlies these distribution patterns over time remains unexplored.     
 
Study Purpose 
 This dissertation explores the role of healthcare provider organizations in the underutilization 
of PD treatment in the United States.  This work is a departure from directly studying utilization, but 
instead focuses on availability of PD services as the necessary condition for utilization to occur.  I 
apply location theory to examine the distribution patterns of PD services and the organizational and 
environmental conditions associated with the availability of PD services among US dialysis facilities.  
Location theory was developed in the field of industrial economics to predict the location(s) of 
production that would maximize firm profits.  This framework rests largely on the concept of the 
profit motive of firms.  According to the theory, firms are likely to locate services in areas that would 
maximize their revenue and profit.  Location theory has been applied to the location choices and 
distribution of physician services and can be extended to examine the choices of PD in dialysis 
facilities. 
 Using national, longitudinal data on ESRD patients and provider organizations from the US 
Renal Data System (USRDS) and the Centers for Medicare and Medicaid Services (CMS), I apply 
spatial and longitudinal analytic methods to identify environmental and organizational factors 
associated with the availability of PD services between 1995 and 2003 – the time period in which the 
PD incidence rate begins its decline.  This empirical study of PD services employs longitudinal data 
and spatial analysis methods, previously underused tools in the study of practice patterns for ESRD, 
to examine the following research questions: 
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Q1.  Where are PD treatment services available in this US?  What is the distribution of 
dialysis facilities’ PD services and how has this distribution changed over time? 
Spatial analysis methods are used to examine the distribution of PD services in the US 
over time.  Facility offerings of PD services are combined with ESRD patient data, to 
track differences in the provision of PD over time by geographic region in relation to 
ESRD prevalence and patient sociodemographics.   
Q2. What is the effect of local market conditions (e.g., competition, provider density, 
facility regulations) on dialysis facilities’ provision of PD services? 
I examine the association of local market forces and sociodemographics on dialysis 
facilities’ provision of PD services.  Following location theory, I would expect that 
dialysis facilities, acting in their own self-interest, strategically choose to make PD 
available in strategically and competitively advantageous locations.  Longitudinal 
logistic regression analysis is used to test hypotheses that dialysis facilities offer PD in 
locations where PD is needed most and in locations that potentially increase dialysis 
facilities’ revenues and profits. 
Q3. How and to what degree are dialysis facilities’ PD treatment services concentrated 
over time?  Does concentration of PD services explain the decline of PD availability 
among dialysis facilities? 
Several factors challenge the assertion in the literature that PD services be available in 
all dialysis facilities.  Since PD patients visit dialysis units less frequently than their 
HD counterparts, distance to dialysis facilities may be less important to PD patients, 
and also to dialysis facilities considering a PD service line.  Anecdotal evidence from 
practitioners confirms this and further questions the necessity of PD services in all 
dialysis facilities.  From an operational perspective, it may not be feasible for a facility 
to open a service line for a minority of patients.  Instead, facilities may consider it 
worthwhile to transfer their patients to another facility within a regional dialysis 
network.  Altogether, these factors suggest alternatively that concentrations of PD be 
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available within a region.  This may, in fact, explain what has happened over time, as a 
decreasing proportion of dialysis facilities have provided PD services since the mid-
1980s.  Spatial analysis methods are used to examine the degree to which PD services 
have been concentrated within service regions over time.   
 
 Medicare’s near-universal provision of dialysis treatment to an increasing population with 
ESRD in the current health care environment – marked by limited resources, inequalities in access, 
and growing concern about quality – makes this study an important area for research.  The growth in 
the ESRD population and the limited number of kidneys available for transplantation, will result in 
increasing demand and federal outlays for dialysis services.  When all societal costs are considered, 
PD may be less costly than HD.  Starting more patients on PD would not only curtail Medicare’s 
costs considerably [16-19], but, from a quality of care perspective, would also better align ESRD care 
with patient preferences.  By understanding how PD services are distributed over time and the 
mechanisms behind its availability, health planners and policymakers will determine the extent to 
which PD is actually accessible to ESRD patients.  The study will also determine the extent to which 
market-level conditions facilitate and deter the availability of PD, with implications on future 
regulatory efforts to mitigate further decline of availability in PD therapy.  Thus, the results of this 
study will have implications on the cost of ESRD care; the way we think about access to PD 
treatment services; new approaches to encourage increased availability of PD treatment services and 
utilization; and the marketing and management of PD by dialysis providers. 
 
Organization of the Dissertation 
 This dissertation is divided into 7 chapters.  Following this introduction, Chapter 2 provides 
background information on ESRD and dialysis treatment.  Differences between hemodialysis and 
peritoneal dialysis, their coverage and payment by the Medicare program are described.  Trends in 
dialysis utilization and the factors associated with these trends are discussed, leading to this study’s 
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research questions.  In Chapter 3, I review the empirical literature on dialysis provider markets and 
PD service strategies.   Based on methodological and conceptual gaps from the published literature, I 
develop opportunities for further research.  The section concludes with a discussion of this study’s 
contributions to the study and practice of ESRD and its implications on policy and practice.  Chapter 
4 describes the conceptual framework and empirical rationale for the specification of the models 
estimated in this study, including the hypotheses about the ways in which market and organizational 
conditions influence a dialysis facilities’ choice to provide PD services.  Chapter 5 follows with 
discussion of research design and results from analyses are presented in Chapter 6.  Chapter 7 closes 
this dissertation with discussion of hypotheses, my research findings, and possible explanations.  
Implications for health policy and practice and areas for further study are explored.   
CHAPTER 2 
BACKGROUND 
 
End-Stage Renal Disease 
ESRD occurs when an individual’s kidneys fail in their two main functions: to remove waste 
and fluids from the body and release hormones to regulate chemical balance in the body.  Roughly 
half a million Americans currently suffer from ESRD, a number that has steadily increased 8 to 14% 
annually over the last 20 years.  Improvements in preventive care and advances in technology have 
slowed the growth of the ESRD population and improved survival and increased prevalence rates of 
those with ERSD.  Moreover, due to projected growth in the incidences of diabetes and hypertension, 
which commonly cause kidney failure, and the aging of the population, significant increases are 
predicted in the number of Americans with ESRD [1, 4, 20].   
In order to survive, failed kidneys need to be replaced through kidney transplantation.  If 
kidney transplantation is not available, individuals require dialysis (otherwise known as renal 
replacement therapy or RRT), a procedure that replaces the work of healthy kidneys to remove excess 
fluid and waste from the blood.  Due to the limited availability of kidneys for transplantation, the 
majority of patients receive dialysis therapy.  In 2005, 29% of ESRD patients received a functioning 
kidney transplant and the other 71% of Americans with ESRD received dialysis [4].  There are 2 
treatment modalities for dialysis:  hemodialysis (HD) and peritoneal dialysis (PD).   
 
Dialysis Treatment:  HD and PD  
Since its development in the 1960s, HD has been the dominant form of treatment for ESRD.  
During HD treatment, blood is sent through a machine that filters away waste products and returns 
 
cleansed blood to the body.  HD is performed 3 times a week, with each treatment lasting 3 to 5 
hours, usually in a dialysis facility staffed by trained professionals.  PD was developed as an 
alternative form of dialysis treatment in the 1970s and introduced as a routine clinical practice in the 
early 1980s.  During PD treatment, waste is filtered through the body’s own peritoneal cavity 
membrane.  A cleansing solution (dialysate) is injected into the abdominal cavity that draws waste 
from membrane blood vessels, and is subsequently drained from the body.  The cavity is then refilled 
with fresh dialysate for the cleansing process to begin again.  With training, patients can perform PD 
on their own 4 to 5 times a day, for 30 to 40 minutes per treatment, at a location of their convenience 
[5]. 
 The differences in HD and PD’s clinical implementation highlight differences in the 
modalities’ suitability for different ESRD sub-populations (Table 1).  In certain patients, it may not be 
possible to offer both types of dialysis therapy.  PD is appropriate for patients with residual renal 
function, including those who have been seen by a nephrologist earlier in the pre-ESRD period. Both 
methods of dialysis require a physical access site for dialysis treatment; access for HD is established 
in the vasculature and PD access is established in the peritoneal cavity.  Patients who have diabetes, 
vascular disease, or who are lacking adequate vascular access (or preserving it for later use) may be 
restricted to PD.  In contrast, patients with numerous co-morbidities, digestive disease, or 
compromised abdominal health (e.g., from extensive abdominal surgery) may be limited to HD [5, 8, 
21-33].  
The differences in HD and PD’s clinical implementation also highlight differences in the 
modalities’ logistical implementation.  HD is typically performed on an outpatient basis in a dialysis 
facility, where, under the direction of a physician, trained nurses and technicians perform the 
treatment using a dialysis machine.  PD is usually performed daily by patients trained to perform their 
own dialysis, at a location of their convenience (commonly, at home).  Although they may be in 
frequent contact with dialysis facility staff, PD patients require fewer visits to dialysis facilities (e.g., 
typically once per month) than HD patients.  Given this, HD is often preferred for patients with 
9 
significant physical disability, as well as those who have low levels of available social support, 
literacy, autonomy, or self-efficacy.  In contrast, PD is often advantageous for ESRD patients who are 
young, actively employed, have a need for autonomy and control, lacking adequate transportation, or 
living long distances from dialysis providers [5, 8, 22-25, 27-29, 31, 32]. 
Table 1.  Comparison of dialysis treatments: Hemodialysis and peritoneal dialysis  
 HEMODIALYSIS PERITONEAL DIALYSIS 
Treatment  Machine-assisted 
 3 exchanges per week, 3-5 hours 
per exchange  
 Performed in dialysis facility 
 Manual or machine-assisted 
 Continuous ambulatory PD: 3-5 
exchanges per day, 30-40 minutes per 
exchange  
 Continuous cycler PD: daily exchange, 
overnight  
 Performed in location of patient’s 
convenience (typically, home) 
Clinical 
limitations 
 Vascular accessibility 
 Severe dietary restrictions 
 Compliance 
 Good abdominal health 
 Limited number of co-morbidities  
 Cognitive and physical function to 
learn/perform therapy  
 Dietary restrictions less severe than HD 
Logistical 
advantages 
 Treatment assistance by trained 
staff 
 Convenient for the disabled, 
cognitively impaired, or those 
lacking social support at home 
 Preserves vascular access for later use 
 Conducive to independent lifestyles  
 Convenient for those lacking adequate 
transportation or living far from dialysis 
facility 
Mortality and 
survival Equivalent and complementary to one another 
Clinical 
complications 
 Infection 
 Blockage from clotting 
 Poor blood flow 
 Peritonitis (abdominal infection) 
 Membrane-related problems 
Facility cost ~ $2,100 per patient per month ~ $1,350 per patient per month 
Medicare 
spending 
~ $72,189 per patient per year ~ 53,277 per patient per year 
Reimbursement Equivalent 
 
Studies comparing HD and PD do not yield definitive conclusions about the clinical efficacy 
of one modality over the other.  In fact, there is on-going debate over the relative merits of HD and 
10 
PD [34].  Few, if any, prospective randomized control trials comparing HD to PD have been 
conducted [13, 35-37], leaving much of the comparative research to observational studies using data 
from dialysis registries.  Early findings from studies using registry data yielded mixed findings of 
PD’s relative advantage over HD, claiming worse, better, and neutral differences in outcomes [13, 38-
46].  These disparate findings were due to differences in data source, sampling, case-mix adjustment, 
and analytical method, factors which may suggest that when comparing identical types of patients, 
mortality would be generally the same between the two modalities [13, 23, 35, 47, 48].    
More recent studies, conducted with better adjustment for co-morbidities, find that the two 
modalities may be considered generally equivalent, with little difference between PD and HD [21, 28, 
36, 37, 49-51].  Studies further suggest that, after controlling for factors such as co-morbidity and 
patient demographics, patients on PD experience fewer hospitalizations from treatment complications 
[52, 53] and have better rates of survival, especially when PD is used in the first two years of dialysis 
[13, 19, 23, 28, 36, 37, 47-49, 54-69].  Conclusions from these and other dialysis outcomes studies 
demonstrate the benefit of increased PD use in particular patient groups than is seen in current 
practice [28, 68, 70].  From these equivocal findings, it can be concluded that neither the data nor the 
analyzed differences in outcomes between HD and PD are strong enough to 1) suggest that these 
differences are causally related to modality or 2) establish one modality as superior to the other [13].   
Advocates of an integrated approach to ESRD care suggest a clinical benefit from the use of 
both modalities of dialysis to treat renal failure.  Researchers further found an early survival 
advantage for those beginning RRT with PD first then switching to HD when clinically necessary, 
compared to those remaining on their initial treatment of either HD or PD [23, 35, 36, 65, 71-74].  
Among a certain subset of patients, simultaneous use of PD and HD has also been found to improve 
clinical conditions experienced with one modality alone [75, 76].  In this way, it is suggested that HD 
and PD not be considered mutually exclusive, but instead as complementary treatments for dialysis, 
making it appropriate to move patients from one treatment to the other or use both if one technique 
fails [36, 51, 69, 75-77].  Further, proponents of this integrated approach maintain that HD, PD, and 
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renal transplantation should be offered to patients and that all three modalities may be a part of 
treatment during a patient’s lifetime [23, 64, 78].   
 Differences in clinical and logistical implementation of HD and PD are also reflected in the 
cost of the 2 modes of treatment.  International studies examining the cost of dialysis care have 
generally found HD to be more expensive and less cost-effective than PD [17, 79-88].  In the US, 
lower Medicare ESRD costs were found in hospital and capitated provider settings [89] and in regions 
[16] where PD is more prevalent than where PD is less common.  Domestically and abroad, the 
largest differences in cost are seen in providers’ overhead expenditures for each modality, as the 
capital labor costs required for HD are more expensive than for PD [17, 28].   
 Other US-based studies find other cost savings of PD over HD treatment.  PD patients 
experience fewer hospitalizations related to dialysis care and accrue fewer hospital costs, compared to 
those on HD [52].   Annual Medicare expenditures are 23 to 27% lower for ESRD patients who 
initialize and continue dialysis using PD.  Cost savings even occur in patients who initialize and 
remain on PD for a year and then later switch to HD [90], supporting the use of PD and the ESRD 
integrated care approach.   
 
Trends in Dialysis Treatment 
Coverage and Payment.  Patients with ESRD have been eligible for Medicare regardless of 
age or employment disability status since 1973.  This remains the only federal entitlement program 
that provides near-universal, disease-specific eligibility for health care coverage.  As such, Medicare 
has been the primary payer for health care services for 92% of US patients suffering from ESRD [2, 
3].  The program has grown considerably, from 10,000 patients in 1973 to nearly 400,000 patients in 
2004, which constitutes 1% of the Medicare beneficiary population [1, 9].   
Total costs for ESRD amounted to $32 billion in 2005 (a 9.1% increase from the previous 
year), 67% of which was born by the Medicare program [9].  Currently, ESRD spending makes up 
8.2% of all Medicare expenses, having grown threefold from $5.5 billion in 1991 to $21.3 billion in 
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2005 [4].  This rise in overall costs appears to be driven by increases in outpatient costs.  While 
inpatient and Part B costs grew 200% between 1991 and 2004, the most notable change was 
experienced with outpatient expenditures, which rose 266% to nearly $7 billion in 2004 [1, 4].   
Roughly 71% of Medicare ESRD beneficiaries receive dialysis therapy.  As with overall 
ESRD costs, Medicare spending for dialysis also continues to rise, more than tripling 1991 levels to 
$17 billion in 2005.  Overall ESRD dialysis expenditures per patient increased 72% between 1991 
($39,821) and 2005 ($68,585), largely influenced by 5 to 7% annual growth in the mid-1990s.  In 
more recent years, however, Medicare outpatient and Part B costs for dialysis increased 8.5 and 
10.8%, respectively [1, 4, 9].  In 2005, Medicare spent $69,758 per HD patient per year and $50,847 
per year on PD patients [4]. 
In 1983, Medicare enacted a payment policy that reimburses providers of dialysis services 
under a composite rate system in which the composite rate is prospectively determined and covers the 
costs of routine drugs, tests, and supplies related to outpatient dialysis treatment services.  Unlike 
other Medicare prospective payments, the ESRD composite payment rate is not subject to annual 
inflation adjustment and has undergone minimal change.  The 1983 average composite rate of $131 
was paid to hospital-based facilities and $127 for freestanding facilities, compared to the 2006 
payment of $132 to hospital-based facilities and $128 for freestanding facilities [25].  This policy also 
includes the provision that this composite rate payment be furnished equally across dialysis 
modalities.  Thus, Medicare’s payment to dialysis facilities for PD treatment services is identical to 
that of HD.   
Utilization.  Given the lower costs of PD [11, 16-18, 34, 52, 79, 89-92], it was anticipated 
that Medicare’s composite payment to dialysis facilities would increase the use of PD by ESRD 
providers and patients1 [34].  And as with many other innovations, the cumulative adoption of PD 
would be expected to follow an S-shaped curve – initially slow, followed by faster adoption as the 
                                                 
1 Medicare’s composite rate payment policy is not the only incentive CMS provides to promote the use of 
home-based dialysis.  For dialysis patients enrolling in Medicare based on ESRD, the standard 3-month wait for 
benefit coverage to begin is waived for patients on home-based dialysis, like PD.   
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number of incident users increase, and eventually reaching a plateau (Figure 1).  However, this did 
not happen. 
Figure 1. Typical S-shaped diffusion curve 
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Rather, use of PD in the US increased shortly after its introduction in the early 1980s.  It 
quickly reached a peak of 14% incidence (of all forms of ESRD treatment) in 1985 and started to 
decline ever since (Figure 2) to its current incidence rate of 6% [4, 22, 25]. This unusual pattern of  
Figure 2.  Incident peritoneal dialysis [1] 
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diffusion is interesting in light of the facts that PD was developed in the US and that the domestic rate 
of PD adoption is low relative to that of other countries (Figure 3).  While 6% of US ESRD patients 
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were treated with PD in 2003, Asian and European countries reported up to 82% PD incidence (with 
an average of 21 percent) [8, 9, 72, 93].   
Figure 3.  International peritoneal dialysis incidence rates, 2003 
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Source:  Compilation of data from various national end-stage renal disease registries  
 
Factors Contributing to PD Underutilization 
Clinical Factors.  As previously mentioned, clinical factors such as co-morbidity, medical 
contraindications (i.e., intra-abdominal foreign body, scarring of peritoneal membrane), or physical 
disability would disqualify some patients from using PD [5, 8, 22-24, 26-32, 94, 95].  However, a 
recent study of PD underutilization found that despite clinical improvements among incident PD 
patients, decline in PD use could not be explained by patient characteristics over time [14].  
Moreover, their findings suggest and confirm previous assertions of the involvement of other, non-
medical factors associated with PD’s declining use [14, 47]. 
Another possibility is related to when patients begin dialysis.  As will be discussed below, 
patient and physician preferences for PD are significant in cases where pre-ESRD conditions are 
detected [51, 96].  Early identification provides time for patient and providers to consider options and 
develop a plan for RRT.  Oftentimes, though, renal failure is detected late and discovered upon arrival 
in hospital emergency departments.  When this occurs, ESRD patients are almost always not fully 
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informed of their treatment options and started on emergent HD [23, 24, 95, 97-101].  Once renal 
function is controlled and stabilized, switching to PD can be done safely [99].  However, this option 
is rarely presented by their physician or the dialysis facility, and ESRD patients usually remain on 
their original form of therapy [97]. 
Patient Preferences.  Treatment modality may also be determined by sociodemographic 
factors as well as personal preference [22, 29, 34, 94, 95, 102].  Studies have demonstrated that, when 
informed of all their treatment options, pre-ESRD and dialysis patients prefer PD [28, 64, 96, 101, 
103-106].  Of those undergoing dialysis treatment, patients on PD report better quality of life and few 
negative effects with aspects of life than HD patients [28, 60, 70, 107-109].  Despite these findings, 
an overwhelming number of patients (up to 75%), do not recall the option of PD discussed at the time 
that dialysis is initiated by their physicians [18, 101, 110].   
Physician Preferences.  It is argued that treatment modality is ultimately determined by 
physician referral.  These referrals are influenced by physicians’ education and training, which some 
assert lacks sufficient education and training for PD [13, 31, 111, 112], personal preferences [11, 22, 
95] and their access to a diverse mix of treatment options for their patients.  Two landmark studies 
conducted in the mid-1990s, which found higher death rates among elderly patients, diabetics, and 
females on PD [38, 39], tarnished the reputation of PD in the medical community as an adequate 
long-term renal replacement therapy [11, 24, 34].  However, this does not adequately explain the 
decline in Medicare’s PD utilization in the years preceding the publication of these studies (as shown 
in Figure 2).  More recent research also suggests that this stigma of PD may no longer exist, as 
between 33 to 40% of nephrologists believe PD to be the more appropriate treatment for roughly half 
of their patients’ optimal clinical outcomes, cost-effectiveness, and quality of life [31, 61, 95, 113, 
114].   
Organizational Factors.  Dialysis provider organizations also influence physicians’ and 
patients’ choice of treatment [114, 115] and treatment outcomes [10, 55, 66, 116, 117].  Several 
studies have consistently found higher PD utilization among adult and pediatric ESRD patients in 
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facilities that offer multiple modalities (e.g., facilities also offering transplant services in addition to 
HD) [118], are not-for-profit owned [118-120], and independent (not affiliated with chain) 
organizations [120].  PD utilization is also more common among facilities in local markets with high 
population density [118] and few competing providers [120].   
In summary, despite the clinical, logistical, and cost advantages of PD, the low incidence of 
PD utilization is puzzling.  The conflicting evidence comparing the efficacy of PD and HD cannot be 
reasonably used to steer ESRD patients away to any one choice in dialysis modality [13].  PD is not 
necessarily a better modality of dialysis than HD, as it is not appropriate for all ESRD patients. But, 
except when there are clear indicators for a specific course of treatment, PD may at least be 
considered a clinical equivalent to HD.  Survey research of physicians indicates a larger proportion of 
ESRD patients are appropriate for PD than actual use reflects.  If presented with the option of PD, 
most ESRD patients would prefer it.  From the preponderance of evidence on the clinical and 
individual factors driving PD utilization, we would expect increasing PD utilization, not the 
decreasing trends experienced in the US.   Although the published literature has examined individual 
determinants of PD treatment use, these explanations are not adequate.  There may be other 
explanations for this bewildering trend.  Relatively little is known about other relevant factors 
associated with PD service delivery and use.  In particular, the availability of PD services at dialysis 
facilities warrants further investigation because it also determines physicians’ and patients’ choice of 
treatment [22, 95].   
Figure 4 depicts the general process of ESRD treatment modality selection and highlights 
dialysis facilities’ influence in choice of dialysis modality.  In cases where pre-ESRD conditions are 
detected early enough to allow a physician and patient the time to develop a treatment plan, a 
facilities’ availability of PD services may be a determining factor in dialysis modality choice [121].  
Patients whose ESRD condition is otherwise discovered late are often immediately referred to HD 
treatment, but may later consider other modalities of treatment.  In both cases, the dialysis facility 
plays an additional role in counseling patients to consider other modalities of ESRD treatment.  
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Overall, it is unlikely for physicians and their patients to consider the PD modality if it is not made 
available to them.  As result, the availability of PD treatment services, at the facility-level, is a large 
influence in its subsequent use (Figure 5). 
Figure 4.  Process of ESRD treatment modality selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Factors of ESRD treatment modality selection 
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The next section explores the availability of PD services by dialysis facilities.  A review of the 
empirical literature on PD service strategies and a history of the market for dialysis providers reveals 
gaps in our understanding of dialysis providers’ response to epidemiology, regulatory, and economic 
forces with regard to PD service delivery. 
 
CHAPTER 3 
LITERATURE REVIEW 
 
Dialysis Industry and the Market for PD Services 
From the perspective of dialysis facilities, providing PD services is a potentially desirable and 
profitable service.  PD can meet patients’ demand for dialysis services and their preference for a 
clinically effective, convenient form of dialysis that is conducive to independent lifestyles and 
increases in patient satisfaction.  A PD service line would also allow facilities to diversify their 
services, and either maintain their patient base while reducing fixed costs of care or expand their 
patient base while minimizing additional fixed costs [78, 79, 94].   
Likewise, several characteristics of ESRD and the dialysis industry over the last 20 years 
were also expected to facilitate increased adoption of PD services by dialysis providers.  PD afforded 
an opportunity for dialysis providers to meet the escalating demand for services brought on by 
growing populations of incident and prevalent ESRD patients.  Increasing demand for dialysis was 
also filled by a rising number of dialysis providers.  This growth was fostered, in part, by Medicare 
coverage and reimbursement policy, which provides equal payment for services regardless of 
modality and whose rates have remained relatively fixed.  Efficiencies in the production of dialysis 
enabled facilities to increase their savings on costs and generate additional profits, inciting further 
growth in the dialysis industry [2, 3, 6, 7].  Thus, the epidemiological trends in ESRD and operational 
factors of ESRD care would theoretically motivate efforts for more facilities to offer PD as the 
clinically effective, patient-centered and convenient form of dialysis, then too would the regulatory 
and economic factors also promote the widespread use of PD as the less costly and more profitable 
treatment modality for dialysis providers. 
 
Surprisingly, fewer of the nation’s ESRD providers are offering PD services.  Shortly after 
PD received clinical approval from the Federal Drug Administration (FDA) in 1978 and Medicare 
instituted the equal reimbursement for HD and PD in 1983, 71% of ESRD facilities offered PD 
services [1, 15].  Over the next 20 years, the numbers of dialysis facilities in the US grew fourfold 
and the industry experienced an increasing presence of for-profit ownership, consolidation, and 
acquisition by chains.  These provider organizations typically have more access to capital, purchasing 
power, and economies of scale, compared to not-for-profit and independently-owned ESRD facilities. 
Given the potential profitability of PD services, we would expect the availability of PD to accompany 
the growth of these profit-oriented dialysis providers.  During this time, however, a decreasing 
proportion of dialysis facilities offered PD (Figure 6).  Currently, less than half of the nation’s 4,500 
ESRD facilities offer PD services [1].  To date, no study has systematically investigated factors 
associated with these trends. 
Figure 6.  Dialysis facilities PD services, by sub-type [1] 
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Note:  Home-based PD modalities are Continuous Ambulatory (CAPD) and Continuous Cycler-assisted 
(CCPD).  In-unit self care PD and staff-assisted PD are facility-based modalities of PD.  
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Review of the Empirical Evidence 
A scant number of investigations examined organizational determinants of PD service 
availability, a necessary condition of service utilization.  Findings from the studies mirror the results 
of PD utilization research and are described in detail below.    
Schlesinger, Cleary, and Blumenthal [118, 122] examined the effects of facility ownership on 
clinical decision making of treatment for ESRD, testing whether profit-motivated providers 
encouraged more use of profitable, but not necessarily socially desirable services.  Using Medicare 
administrative data from 1981, the researchers studied the ownership of ESRD facilities on the use of 
seemingly less profitable but socially desirable services such as kidney transplantation, home HD, and 
PD treatment.  Their cross-sectional analyses modeled the likelihood of any patient receiving these 
alternative modalities (vis-à-vis in-center HD) and the proportion of patients receiving these treatment 
modalities at an ESRD facility. The former model is of particular interest, as the authors assumed that 
absence of any patients for transplantation, home HD or PD was unlikely to occur on purely clinical 
grounds, but instead a result of policies that discouraged the use of particular modes of treatment.  It 
is therefore possible to consider this dichotomous model (1= any patients on alternative modality, 0= 
no patient on alternative modality) as a model of service availability (1= alternative modality 
available, 0= no alternative modality).  The authors found that patients in not-for-profit facilities, 
offering multiple modalities [118] were more likely to have (any patients use their) PD services than 
their investor-owned, and single modality (HD only) counterparts.  Facilities with (patients on) PD 
were also more likely to be located in regions with a high population density, with young and 
educated patient populations [118]. 
Kendix [122] conducted a similar cross-sectional study of the provision of home-based 
dialysis treatments among freestanding dialysis facilities.  Standard neoclassical economic theories 
about profit-maximizing firms were applied to generate hypotheses about facility and patient 
determinants of dialysis facilities’ availability of home-based dialysis modalities (home HD, and 2 
forms of PD).  Using administrative data in logistic regression models, Kendix found that among 
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freestanding ESRD facilities in 1992, not-for-profit and independently-owned facilities with a larger 
patient base were more likely to offer PD services than investor-owned and chain-affiliated facilities 
with a smaller patient census.  Providers of PD were also more likely to be located in regions with a 
lower density of dialysis providers.         
PD service availability was most recently studied by O’Hare and colleagues [123] in the 
context of health disparities between patients in urban and rural locations, and Pozniak [124], in the 
context of organizational consolidation and acquisition by chain organizations.  A sub-study of a 
larger analysis comparing care between urban and rural ESRD patients, O'Hare’s descriptive analysis 
used cross-sectional data on dialysis facilities.  Although home-based therapies (notably PD) have 
theoretical advantages for patients residing in remote areas, dialysis providers in rural locations were 
less likely than urban facilities to offer PD [123].  In the only longitudinal study conducted on PD 
services, Pozniak analyzed the effects of chain-acquisition on selected practice patterns of 
freestanding dialysis facilities between 1997 and 2003 [124].  Results indicated that formerly 
independent, newly chain-acquired dialysis facilities offering multiple dialysis modalities were more 
likely to discontinue non-HD treatment offerings after the first year of acquisition by a dialysis chain, 
compared to dialysis facilities that remained independent throughout the study period.   
While these studies provide a general understanding of the structures that influence the 
availability and eventual utilization of dialysis treatment modalities, several methodological 
weaknesses limit the relevance of their findings to clinicians, payers, and policymakers.  First, study 
findings are based on older data and therefore not reflective of recent phenomena in the US dialysis 
industry.  Schlesinger and colleagues’ study [118] was based on administrative data in the early years 
of PD (1981) and Kendix’s analysis [122] used data from 1992, when PD utilization appeared to 
stabilize.  PD incidence rates fluctuated slightly before a continuous decline after 1995 and since then, 
we have learned little more about how or why PD services are provided across the United States.   
Second, most analyses used cross-sectional data, which have limited ability to explain how 
organizational factors affect units’ provision of PD services over time.  An overwhelming majority of 
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the empirical literature on ESRD services is cross-sectional [16, 118, 119, 122, 123, 125-134].  Few 
studies have examined the dynamics of dialysis services longitudinally [54, 124, 135, 136], and only 
one study used longitudinal research design to examine PD service availability [124]. 
Third, disparate methodologies used to model dialysis facilities’ provision of PD services 
provide an incomplete description and explanation of dialysis providers’ decision to provide PD 
services.  Studies differ in their sampling and use of covariates to study the availability of PD services 
in dialysis units.  For example, Schlesinger and colleagues’ study examined hospital-based and 
freestanding facilities [118], compared to Kendix’s [122] and Pozniak’s [124] studies of only 
freestanding facilities.  In addition, studies use different sets of covariates, omitting potentially 
important organizational characteristics in their analytical models of PD service offerings, such as 
facility age and size, as well as local environmental characteristics like provider competition and 
urban locale [118, 122].     
In addition to methodological issues of the prior studies, several conceptual assumptions 
weaken the meaning of their findings.  Prior studies implicitly assumed that PD be as equally 
available as HD services.  This assumption is consistent with the literature on ESRD disease 
management and PD underutilization, which recommends that PD services be increasingly offered to 
all patients and cites unavailability as a culprit of PD underuse [8, 13, 14, 18, 23, 64, 73, 78].  These 
assertions suggest a problem of inadequate access to PD treatment services and assume that PD 
services should be available in more, if not all, dialysis facilities.  However, none of the prior studies 
have systematically investigated these issues.   
Instead, prior studies treat the 2 modalities as clinical equivalents, but fail to consider the 
different ways in which PD and HD services are delivered, and their implications on the way care is 
organized for these 2 modalities.  In one example, Kendix suggests that PD availability in areas with 
low density of facilities is explained by facilities’ consideration of patients’ travel time and quality of 
life [122].  This explanation is tenuous, since PD provision may not necessarily be patient-driven, but 
rather provider-driven.  The thrice weekly visits required under HD make patients’ distance, 
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transport, and travel time to dialysis facilities important factors influences providers’ strategic 
location of HD services.  In contrast, proximity to dialysis facilities is less important for patients on 
PD and also to dialysis facilities considering the addition of a PD service line.  Anecdotal evidence 
from practitioners confirms this and further questions the necessity of PD service in all dialysis 
facilities [24]. 
From an operational perspective, it may not be financially feasible for a facility to open a 
service line for a minority of patients.  Dialysis facilities invest a lot of labor and capital for their units 
and once HD is in place, there are economic pressures for a facility to reconcile this investment by 
operating at or close to maximum capacity.  In these cases, the marginal cost to providers of treating 
an additional HD patient may be less than treating the same patient with PD, especially if a facility’s 
PD program is relatively small.  Providers may not perceive to have enough potential candidates for 
PD to justify further investment in the infrastructure (e.g., PD nurses and on-call support) required to 
realize the efficiencies and cost savings of PD [10].  Instead, facilities may consider it worthwhile to 
transfer their few patients to another facility with a larger PD patient base within a regional dialysis 
network.  Altogether, these factors suggest alternatively that “concentrations” of PD be available 
within a region.  Results from Pozniak’s study of dialysis chain acquisitions, which found a decline in 
PD services among dialysis facilities newly acquired by chain organizations, may support 
centralization. The statistical significance of decline, after only the first year of chain acquisition and 
not in the second through fifth years of follow-up, may be explained by clustering of non-HD 
treatments from other facilities affiliated within the chain organization [124].  This notion of 
concentration or clustering, aided by the relative unimportance of distance and patient travel time for 
PD treatment, is a promising but untested explanation behind the decline in PD services.   
Models from the previous studies are premised on the profit motive of ESRD provider 
organizations, a seemingly valid explanation behind facilities’ service strategies.  A second 
conceptual limitation in the existing literature is their a priori and untested assumption regarding the 
general lack of profitability in PD.  The dearth of reliable cost information by dialysis providers 
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prevents us from determining the relative profitability of PD, but cost studies and provider anecdotes 
reveal PD to be the less costly service compared to HD [16, 17, 24, 79, 80, 82-87].  Since both forms 
of dialysis are reimbursed at the same rate, the lower costs of PD result in higher profits for dialysis 
providers and therefore call the validity of this general assumption into question. 
The findings from the 4 previous studies are consistent in detecting organizational 
characteristics associated with the provision of PD services, an important step in understanding 
structural influences on dialysis care.  However, the results are only meaningful to the extent of 
demonstrating who is likely to provide PD, but do not convincingly explain why facilities choose to 
make PD services available.  The extant research has not provided adequate rationale for the 
“anomalous” not-for-profit and independently-owned facilities that do not offer PD and likewise, the 
for-profit and chain-affiliated ESRD facilities that do.   
Finally, none of the studies have specifically addressed availability of PD services or the 
decline in PD availability over time.  The exception may be Pozniak’s study of dialysis chain 
acquisitions, which found a decline in PD services among dialysis facilities newly acquired by chains 
[124].  Her study empirically demonstrated an important temporal association between organizational 
ownership and PD service provision, but only under the condition of recent acquisition.  Thus, the 
study’s focus on the condition of chain-acquisition provides limited understanding of the underlying 
conditions of dialysis units’ provision of PD services over time.  Moreover, the omission of hospital-
based facilities in the analysis leaves a small, but still relevant, factor of PD service availability 
unaccounted for.  Thus far, no study has systematically investigated the decline of PD and explored 
mechanisms of this decline at the organizational level.   
In summary, the empirical literature and Medicare program data clearly demonstrate 
differential offerings of PD treatment services among dialysis provider organizations in the US.  
Interpreted individually and collectively, findings from the 4 previous studies are consistent in 
detecting organizational characteristics associated with the provision of PD services, but several 
methodological and conceptual limitations of these empirical analyses do not adequately explain the 
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disparate choices of facilities to offer PD treatment services and how these strategic choices have 
changed over time.  Still, more fundamental questions about PD services remain unaddressed. 
 
Opportunities for Further Research 
Given the appeal of PD over HD treatment but unrealized expectations of PD utilization, 
further exploration of PD services is needed.  Although much of the published literature has examined 
individual determinants of PD treatment, surprisingly little attention has been paid to organizational 
determinants of PD services [95].  In particular, availability of PD services at dialysis facilities 
warrants further investigation because it determines individuals’ choice of treatment.  Few studies 
have examined dialysis facilities’ provision of PD treatment services, and several gaps in this paucity 
of literature remain.         
No prior studies have systematically investigated the decline of PD service availability over 
time or examined the underlying mechanisms of this, at the organizational level.  To address these 
issues, it is necessary to consider the different ways in which HD and PD are delivered and organized.  
In the existing literature on PD underutilization, researchers focused on the profit-motivated 
behaviors of dialysis facilities, but overlooked the manner in which PD services are organized and 
distributed – equally important factors related to incentives of profits.   
Besides the concern of declining PD service availability, it is still not clear where PD services 
are available in the US and how these patterns of distribution have changed over time.  Are PD 
therapies available in areas where they are presumably needed most, such as regions with high 
incident and prevalent ESRD patients, with young and employed ESRD patient populations, or in 
rural locations?  Spatial mapping of geographic distributions for PD services can illustrate these 
patterns over time.   
Possible explanations behind patterns of PD availability among dialysis facilities have also 
not been explored.  Findings from the empirical literature are consistent with location theory, which 
posits that firms strategically choose to offer services in strategically and competitively advantageous 
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locations.  Location theory has also been applied to the location choices and distribution of physician 
services [137] and can be extended to examine offerings of PD services in dialysis facilities.  In 
particular, the theory questions a common assumption in current literature that PD services should be 
available in all dialysis units.  Due to treatment patterns for PD patients, who visit dialysis units less 
frequently than their HD counterparts, distance to dialysis facilities may be less important to PD 
patients, and also to dialysis facilities considering a PD service line.  Anecdotal evidence from 
practitioners confirms this and further questions the necessity of PD services in all dialysis facilities.  
From an operational perspective, it may not be feasible for a facility to open a service line for a 
minority of patients.  Instead, facilities may consider it worthwhile to transfer their patients to another 
facility within a regional dialysis network.  Altogether, these factors suggest alternatively that a 
limited number of concentrations of PD services be available within a region.  This may explain what 
has happened over time, as a decreasing proportion of dialysis facilities are providing PD services.  
No prior study has determined whether or not PD services have been concentrated, and if such 
occurrences explain the overall decline in PD availability. 
This dissertation proposes to address these gaps in the literature.  To explore the role of health 
care provider organizations in the underutilization of PD treatment in the United States, I examine the 
availability of PD services among US dialysis facilities.  The following questions are addressed: 
Q1.  Where are PD treatment services available in this US?  What is the distribution of 
dialysis facilities’ PD services and how has this distribution changed over time?   
 
Q2. What is the effect of local market conditions (e.g., competition, provider density, 
facility regulations) on dialysis facilities’ provision of PD services? 
 
Q3. How and to what degree are dialysis facilities’ PD treatment services concentrated over 
time?  Does concentration of PD services explain the decline of PD availability among 
dialysis facilities? 
 
Concepts from location theory are used to examine the distribution pattern of PD services and dialysis 
facilities’ PD location choices between 1995 and 2003, the time period in which the PD incidence rate 
begins its continuous decline.  
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 Contributions 
 This empirical study of PD services employs longitudinal and GIS methods, previously 
underused tools in the study of practice patterns for ESRD.  By exploring dialysis facilities’ 
placement of PD services and examining mechanisms explaining these disparate offerings of PD 
training and treatment, results from these analyses will contribute to the scant literature on provider 
organizations’ role in access to PD services.   These findings will also lay the foundation for further 
research on organizations’ role in the underutilization of PD therapy. 
 
Implications on Policy and Practice 
Medicare’s near-universal provision of dialysis treatment to an increasing population with 
ESRD in the current health care environment – marked by limited resources, inequalities in access, 
and growing concern about quality – makes this proposed project an important area for research.  
Roughly half a million Americans currently suffer from ESRD.  Currently, Medicare is the primary 
payer for health care services for an overwhelming majority of US ESRD patients.  Projected 
increases in populations with diabetes and hypertension, common causes of kidney failure, will raise 
the number of Americans with ESRD to an estimated 2 million by the year 2030 [138] and 
consequently, federal expenditures to care for this emerging ESRD population.  Given the limited 
number of kidneys available for transplantation, increases in demand and expenditures for dialysis 
services are expected.  Relatedly, increased demand for services will also increase staffing demands 
that accompany HD provision [94].  At a time of nursing shortages and high turnover rates of nurses, 
aides, and patient care technicians, it may make sense for facilities to put more effort into increasing 
the availability of PD services [139].    
When all societal costs are considered, PD may be less costly than HD.  Starting more 
patients on PD would not only curtail Medicare’s costs considerably [16-19], but would also better 
align ESRD care with patient preferences.  By understanding how PD services are distributed over 
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time and the mechanisms behind its availability, health planners and policymakers may determine the 
extent to which PD is actually accessible to ESRD patients.  Examining the effect of market forces on 
dialysis facility’s PD treatment offerings improves our understanding of the underlying mechanisms 
and strategic decisions behind the delivery of ESRD services.  The study also determines the extent to 
which market-level conditions facilitate and deter the availability of PD, with implications on future 
regulatory efforts to mitigate further decline of availability of PD therapy.  Thus, the results of this 
study may have implications on the cost of ESRD care; the way we think about access to PD 
treatment services; new approaches to encourage increased availability of PD treatment services and 
utilization; and the marketing and management of PD by dialysis providers. 
 The next section describes the theoretical basis and empirical rationale for the specification of 
the models estimated in this study.  Hypotheses about distribution patterns and the ways in which 
market conditions influence a dialysis facility’s choice to offer PD services are also developed.   
CHAPTER 4 
CONCEPTUAL FRAMEWORK 
 
 The conceptual framework for this study draws from the literature on industrial organization 
economics, which focuses on the influence of market conditions on the behavior of firms.  Within this 
field of work, I use modifications from location theory to examine the declining availability and 
distribution of PD services.  With the support of organizational theory, hypotheses about the 
availability, location, and geographic distribution of PD treatment services among dialysis facilities 
over time are developed and detailed in this section. 
 
Location Theory 
 Among viable locations for economic activity, some locations are more favorable than others.  
Location theory is rich in history and perspectives on the factors influencing the location decisions of 
firms and entire industries.  Initially developed from the study of the location of industrial plants and 
centers, various models of industrial location have been developed at different stages over time.  Due 
to its depth and breadth of concepts, location theory is now considered an integral component of 
fields such as industrial economics, economic geography, spatial economics and regional science.  It 
informs macroeconomic aspects of location, such as the identification of attributes and sites for 
manufacturing industries (e.g., steel, chemical, wood products, and women’s apparel), the 
development of industrial centers and their relationship to urban centers, and the evolution of such 
centers over time [140-142].  Location theory also considers microeconomic aspects of industrial 
activity for individual firms, which is particularly relevant to this study.  The following discussion 
 
does not attempt to provide an exhaustive account of the history and models of location theory, but 
draws on concepts that inform the study’s research questions.   
 Generally, location theory is the study of the interaction of space and the organization of 
economic activity [140, 143, 144].  Although location theory is commonly used to identify optimal 
locations for production, its concepts are also useful in studying past location decisions, 
understanding past patterns of locational decision making, and explaining the spatial distribution of 
economic activities [143-145].  Modern location theory represents an amalgam of various models of 
industrial location developed over time.  Among these frameworks, there is a shared 1) assumption 
that the prices of economic activity are variable by and dependent on location and 2) concept of the 
profit motive of firms, such that firms locate their services in areas that maximize their profit [140, 
146, 147].  What distinguishes these various models from each other, however, is their emphasis on 
the factors involved in firms’ pursuit of optimal profit.  In other words, the frameworks within 
location theory approach the “location problem” in different ways and under different conditions.  
Many of these theories comprise 2 general approaches to firm location, least-cost and market area 
approaches, which inform the research questions in this study.  
The least-cost approach represents the initial stage of development in location theory.  Study 
of location in the early 1800s was spearheaded by von Thunen, who examined differentials in land 
and land use as the underpinning condition of agrarian production [143, 148].   Building on this work 
over the next century in a nascent industrial economy, Launhardt and Weber shifted the focus on the 
locational characteristics of inputs and outputs of production.  Least-cost theory was based on the 
notion of a purely competitive environment in which buyers were concentrated at a fixed point and 
sellers were free to locate near the buying center.  By holding inputs, demand, and price factors fixed 
in a marketplace, considerable attention was paid to the variation in transport costs associated with 
assembling raw materials and delivering finished products to the market from potential production 
sites.  The site incurring the minimum cost was therefore the optimum location for an industry or firm 
[140, 141, 143, 146-150].   
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 Over time, several assumptions of this least-cost framework exposed weaknesses in the 
model’s ability to reflect microeconomic realities of production.  First, the least-cost approach 
assumed firms’ linear production function and a lack of geographic variation in the characteristics of 
raw material [146, 151].  Second, this model was based on the condition of perfect competition in a 
market, where firms’ demand and market price are constant, and on the assumption that all outputs 
can be sold regardless of location and actions of their competitors.  Third, least-cost theory was 
predicated on the notion of a concentrated market at a single point or buying center [146].  As such, 
least-cost approach aims to identify a single best location for a firm [141, 149].  These assumptions 
are problematic in several ways.  In reality, the quality and prices of raw materials vary by location, 
which affect demand and prices for a product [151, 152].  Under these conditions of variable demand 
and pricing, least-cost theory’s condition of perfect competition is therefore not met.  Moreover, the 
existence of variable demand and pricing suggests a multitude of potential markets that vary by size, 
preference, demand, and the presence of competing firms [140, 153].  Finally, if firms consider input 
and market characteristics as substitutable factors, the identification of a single best location for 
production under the least-cost framework is not adequate.  Rather, profit maximization is derived not 
simply from cost, but rather configurations of inputs, outputs, location, and price to identify many 
potentially optimal locations [141, 151, 154].  
 Concerns raised by critics of the least-cost approach aided in the advancement of models that 
increasingly called attention to demand and market factors.  These works [151, 155-157] led location 
theory to its second stage of development, the market area approach.  Here, the overarching idea is 
that production location is determined by costs of production and also where potential sales (either by 
size of the consumer population or by price) are greatest [141, 149].  Specifically, buyers are 
dispersed across space and firms will move to locations situated closest to the centers of markets to 
maximize potential revenue and exert some control over sales (i.e., quantity and price) that area.  In 
contrast to the least-cost approach, market area analysis no longer treats costs as variable but fixed at 
all potential sites so that the focus of attention is on the nature of demand in the market [147].   
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 Hotelling’s theory of spatial competition expanded the market area approach to include 
competitive aspects of firms’ locational behavior [158].  As demand grows for services of an industry, 
new firms enter the market and locate in places where preceding firms are – oftentimes the central 
location of demand.  Sellers will cluster for several reasons, including the opportunity to attract the 
most customers and to learn from and complement the competencies of other firms [153].  Over time, 
firms in the industry will gravitate toward the median of the market, until production is decentralized 
into other locations, where the process begins again [140, 141, 146, 147, 158].  To maintain control 
and compete with rival firms in their local markets, firms differentiate themselves from their rivals by 
modifying optimization strategies such as physical proximity to consumers, pricing, quantity or 
quality of product offerings – decisions which depend on the situation of its competitors [140, 144, 
147, 158-164].  Largely ignored in the least-cost approach, this interdependence between firms and 
their competitors elucidates the factors by which firms in a market are mutually attracted or repulsed 
to each other in their pursuit to maximize demand [146]. 
 In summary, while the least-cost and market area approaches share the perspective that firms’ 
location decisions are explained by the profit maximization motive of firms, these approaches differ 
on the factors and conditions that enable firms to maximize profit.  Another way of thinking about the 
unique aspects of these frameworks is through the profit equation, where profit is the result of 
subtracting firm revenues from costs.  By assuming factors of revenue as fixed across locations, the 
least-cost framework emphasizes the minimization of costs among viable sites to identify a location 
that maximizes the profit of a firm.  In contrast, the market area approach treats costs as fixed at all 
potential sites so that the focus of attention is factors of locations that maximize potential revenue 
(i.e., demand and competition) and profit of firms.   
 Organizations’ locational behavior is extremely complex.  And while no one theory of 
locational behavior is adequate, combining the various principles contained within the least-cost and 
market area schools yield explanations and insights about firm behavior that are generally applicable 
to all location dilemmas [141, 143, 146, 147]. Location theory was originally developed to inform the 
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location problems of agricultural and manufacturing firms and industries (examples include producers 
of steel, automobiles, and computer microprocessors).  In keeping with evolutionary change in 
industrial economies, location theory has more recently been developed and applied to the study of 
non-manufacturing firms in the retail and service industries [162, 163, 165].  The strong relationships 
found between health care and other economic activities suggest that the healthcare services industry 
responds to similar locational factors as other products and services [166].  Thus, the least-cost and 
market area approaches of location theory are useful in explaining the location behavior of healthcare 
providers.   
 
Application to Health Care 
 Location theory has been used by health planning and policy-making agencies and in health 
services research to examine the organization and distribution of health care resources 2[167].  Such 
distributions have been a public policy concern because of its implications not only on patient access, 
utilization, and health outcomes, but also its impact on local economies.  In the absence of reliable 
information on costs and prices of health care services, location theory has been modified for health 
services research to examine the influence of demand and competition factors on locations for health 
care services.  Much of the health services research (directly or indirectly) guided by location theory 
finds many locational factors of demand to explain the locations of provider practices.  Specifically, 
the geographic distribution of clinicians is positively associated with locational characteristics that 
connote potential for high demand and revenue, such as population size [137, 166, 168-174], income 
or buying power [173, 175, 176], educational attainment [168, 171, 176], employment [169, 170, 
173], proximity to patients [177], and urbanized markets [172, 175].  These tendencies explain, in 
part, the geographic distributions of primary care physicians and specialists [137, 166, 168, 169, 172-
                                                 
2 Health planning and policy-making agencies typically look to location-allocation models for identifying sites 
that maximize or minimize objective functions, such as minimizing patient travel or maximizing coverage of 
services, but this normative method is not particularly useful for understanding locational phenomena of 
existing facilities and services. 
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179]  and mental health care providers [170, 171, 173].  Moreover, studies of the geographic 
distributions of different types of mental health providers suggest that favorable third party coverage 
and payment for services is an important factor for providers of specialty services [170, 171].  
However, explanations of provider location and service availability are not limited to factors of 
demand.  Many of these same studies found geographic distribution of physician services were also 
explained by competition in healthcare markets. 
 Geographic distribution patterns of physicians are influenced by the competition among 
clinicians providing similar and complementary services.  Newhouse and colleagues [137, 172, 178] 
apply location theory to demonstrate that distributions of physicians are explained not only by market 
size, but also by the numbers of competing physicians in the market, competitors’ area of 
specialization, and the substitutability of the types services provided by these competitors.  Concepts 
from Hotelling’s theory of spatial competition may be seen here, where specialists have the tendency 
to cluster in the central-most site to maximize demand.  Specialists in the market also provide basic 
medical services that generalists also produce.  This substitutability of practitioners poses a 
competitive threat among generalists, who subsequently tend to locate in smaller markets.  In short, 
physician competition in densely populated markets results in diffusion of providers to less populated, 
unmet locations of demand.  Other studies suggest that interdependence between providers in a 
market also influences locational patterns of healthcare practices.  Lawlor and Reid [166] found that 
in comparison to their less specialized counterparts, highly specialized physicians tend to be dispersed 
less widely and located in markets with a broad base of general population (i.e., to optimize demand) 
and less specialized physicians (i.e., for referrals and support), demonstrating a hierarchical structure 
of locational patterns among types of physicians.  In their examination of the geographic distribution 
of rural physicians, Connor and colleagues [169] found evidence of the Hotelling effect of spatial 
competition among physicians clustered in rural areas and synergistic (i.e., interdependent) 
relationships among physicians and between physicians and hospitals in rural markets.   
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 Little, if any, of the health services literature explores the locational behavior of healthcare 
organizations.  McLafferty’s study of the spatial organization of hospitals in New York City [180] 
linked characteristics of neighborhood location to hospitals’ corporate strategies (e.g., closure, 
merger, or facility expansion).  Upon examining health maintenance organizations’ (HMO) product 
offerings, Wholey and Christianson found the decision to offer a broader health care product as 
functions of the location of the HMO and the degree of competition faced to the firm [181].  Although 
grounded in organizational theory, Fennell’s studies of hospital clusters [182, 183] reflect concepts 
from location theory, wherein most urban centers are commonly characterized as having one or more 
concentrated geographic clusters of hospitals with other hospitals distributed evenly throughout the 
remaining area.  Furthermore, the tendency for hospitals in competitive clusters to differentiate 
themselves from others by increasing their range of services suggests the influence of spatial 
competition [184].  The positive association between hemodialysis services and market supply of 
physician specialists in Cleary and colleagues’ study [125] demonstrates the interdependent 
relationship between dialysis providers’ proximity to other medical providers, as sources of referral 
and complementary expertise for non-renal problems.    
 
Application to PD Services 
 Several features make this study a departure from most traditional applications of location 
theory.  The aim of the study is not to prospectively identify optimal locations of dialysis providers, 
but rather to understand past patterns of location decisions and distributions of PD services.  And 
while most applications of location theory focus on new entrants to an industry, this study examines 
providers, in new and existing locations, in their decision to offer PD. 
 With further modification, location theory can be extended to examine geographic 
distributions of PD service availability among US dialysis facilities over time.  This application is 
appropriate for several reasons.  Lacking reliable information on dialysis facilities’ costs of services, 
we can examine other observable factors other than cost.  Considering that 1) the majority of 
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payments for all modalities of dialysis treatments are fixed and paid by Medicare and/or state 
Medicaid programs and 2) relative to HD, PD is generally the least-cost modality for dialysis 
facilities, the profit margin from PD services would be appealing enough to justify more of its 
provision among dialysis facilities.  That fewer dialysis provider organizations are offering PD 
suggests that service provision based on least-cost factors does not adequately explain the distribution 
of PD services over time.  Given the geographic variation in ESRD populations and healthcare 
markets, there is sufficient reason to believe that dialysis provider organizations’ locational strategies 
to maximize PD profits and/or reduce the cost of PD provision are based on demand and competition 
[122, 128, 131, 134].  Generally, in order for dialysis facilities to maximize profit from a PD service 
line, optimal locations for PD service availability are in areas with high market potential, that is, 
markets likely to generate the most volume, revenue and profit.   
 Since PD and HD may be considered equivalent forms of RRT, facilities offering PD look for 
the same optimal, profit-maximizing locations as facilities offering HD services.  But the decisions 
driving location selection for PD services is different than that of HD services.  While the focus of the 
study is not to compare the locational strategies of PD relative to HD services, consideration of these 
differences is useful in addressing this study’s central aim of identifying the locational factors 
associated with providers’ location of PD services.  HD is currently the mainstay of any dialysis 
organization’s menu of services.  For the most part, PD is an optional service that providers willingly 
make available in addition to their HD services.  This optionality affords facilities flexibilities in their 
service strategies.   
 The distinguishing feature of location decisions of PD services is based on the clinical and 
logistical differences between PD and HD services.  Patient proximity to thrice weekly, facility-based 
HD services may be a primary driver for HD utilization, influencing facilities to locate their services 
in proximity to their patients.  In contrast, the relatively infrequent visits required for PD makes 
patients’ proximity to a facility a less important factor for PD, reducing the necessity of facilities to 
locate their services close to their patients.  As a result, whereas facilities’ move HD services to 
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patients, patients move to facilities’ PD services.  Under these circumstances, the location decisions 
of PD providers are more flexible.  For example, unlike HD services, PD services located in an urban 
area would not preclude rural patients from dialyzing through PD.  This allows facilities considering a 
PD service line to be more selective in their location decisions. 
 Given the historical reputation and trends of PD in the US, there are fewer patients – 
informed, willing, and/or interested to dialyze through PD – to capitalize on.  Thus, there is more of 
an imperative for facilities to strategically and selectively locate their PD services in a manner that 
maximizes potential for revenue and profit.  Such factors include locating PD to areas where 1) more 
patients are eligible for treatment and less expensive to treat and 2) market conditions are favorable to 
increasing volume of services and sustaining alternative modes of dialysis treatment.  These factors 
are considered and hypotheses are developed in the section that follows. 
 
Hypotheses: Market Conditions and Provision of PD Services 
Based on concepts from location theory and evidence in the ESRD literature, I expect the 
availability of PD services to vary in dialysis facilities across the country, depending on facilities’ 
market characteristics. In accordance with research questions 2 and 3 of this study, hypotheses are 
developed and detailed below. 
Patient Populations.  This study hypothesizes that dialysis providers locate their PD services 
in markets with considerable demand for PD.  In general, dialysis facilities’ PD services are expected 
to be located in markets with a sizable patient base to maximize potential revenue and subsequent 
profit.  It follows that locating PD in regions with the largest numbers of prevalent ESRD patients 
improves a facility’s probability of creating a PD patient base large enough to sustain PD operations.   
Hypothesis 1 (H1): Facilities’ PD service availability is positively 
associated with the prevalence of ESRD patients in markets.   
Among the population of ESRD patients, dialysis providers will target their PD location in markets 
with ESRD patient population characteristics considered ideal for PD.  Results from prior cross-
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sectional research on PD services indicate a tendency for facilities to target their service offerings in 
markets with PD-appropriate patient populations [118, 122].  ESRD patients who are eligible for and 
select the PD modality are oftentimes white, younger, and have fewer co-morbid conditions than their 
peers on HD [5, 21-23, 26, 29, 32, 122, 185].  It therefore follows that dialysis facilities are likely to 
locate their PD services in markets with these patient characteristics.   
Hypothesis 2 (H2):  Facilities’ PD service availability is positively 
associated with the proportion of white ESRD patients in markets.   
Hypothesis 3 (H3): Facilities’ PD service availability is positively 
associated with the proportion of young, non-elderly ESRD patients in 
markets.  
Hypothesis 4 (H4): Facilities’ PD service availability is negatively 
associated with the amount of comorbid conditions among ESRD 
patients in markets. 
One of the benefits of PD treatment is the autonomy of dialyzing several times a day in a 
location of the patient’s convenience, rather than HD’s thrice weekly treatments in dialysis units, each 
running several hours at a time.  The treatment regimen of PD is therefore conducive to active 
lifestyles, work schedules, and the maintenance of stable employment.  Compared with HD patients, 
most PD patients are also more likely to be actively employed [29].  For dialysis facilities, employed 
patients are ideal, since they tend to have more resources to pay the (Medicare) co-insurance for 
treatment services [125].  Furthermore, ESRD patient employment signals to dialysis facilities the 
potential presence of private (i.e., third-party) insurance coverage – a main source of reimbursement 
for the first three months of dialysis treatment, before ESRD Medicare coverage begins and 
thereafter, a secondary source of reimbursement for dialysis that supplements existing Medicare 
coverage. 
Hypothesis 5 (H5): Facilities’ PD service offerings are positively 
associated with the proportion of employed ESRD patients in markets. 
Similarly, ESRD patients’ dual-eligibility of Medicare and either private, employer-based group or 
state Medicaid insurance coverage supplements Medicare payment and assures payment for dialysis 
co-insurance.   
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Hypothesis 6 (H6): Facilities’ PD service availability is positively 
associated with the proportion of ESRD patient population in markets 
with Medicare dual-coverage. 
Market Characteristics.  Classic location theory is focused on demand-related factors of 
travel distance and travel.  While PD may be ideal for patients in rural locations, the fewer 
visits to dialysis facilities required under PD, patients’ proximity and travel time to dialysis 
units are less important factors of PD service availability, compared to HD services.  Instead, 
dialysis facilities’ access to a large pool of revenue sources, namely patients and their referring 
providers, is optimal.  Prior research indicates that most ESRD patients and health care 
providers are located in urban markets [1, 128, 131, 132, 134].    To maximize opportunities for 
increased PD patient and treatment volume, facilities are therefore more likely to locate PD 
services in locations with sizable urban markets. 
Hypothesis 7 (H7): Dialysis facilities’ PD service availability is 
positively associated with the proportion of urban residents in markets.   
Correspondingly, markets with high per capita income are attractive markets for facilities seeking 
secure sources of revenue from PD.  Although research has found a negative association between the 
number of HD stations and average income in markets [125], studies examining home-based dialysis 
suggest another trend.  Cross-sectional studies demonstrated the availability and use of home-based 
dialysis modalities to be positively associated with average income in markets [122, 125].   
Hypothesis 8 (H8): Dialysis facilities’ PD service offerings are positively 
associated with per capita income in markets. 
The location of facilities’ PD services are also influenced by the degree of interdependence 
among healthcare organizations – that provide complementary services to patients and between 
competing dialysis facilities – in markets.  First, the viability of a facility’s PD service location is also 
dependent on the availability of resources available in a market [186-188].  Prior research 
demonstrates health care providers’ tendency to also locate in markets with a high density of other 
medical personnel and providers [125, 168-170, 178], as proximity with other providers of health 
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services in local markets is a predictable, stable source of referral.  In order to capitalize on these 
health resources, it follows that PD services would be available in locations with a high density of 
hospitals and nephrologists, who typically refer ESRD patients to dialysis services.      
Hypothesis 9 (H9): Dialysis facilities’ PD service availability is 
positively associated with density of health care providers in markets. 
Second, decisions to locate PD services are markedly influenced by competition, another 
factor of service demand [140].  Similar firms compete on the basis of their products and 
services.  When prices are fixed by regulation, firms compete on non-price factors.  And in 
markets that populated with competing organizations, non-price competition results in product 
differentiation or strategies to distinguish their services from those of their competitors [140, 
144, 147, 158-163].  For dialysis provider organizations, such strategies may include the 
development of efficient practice patterns, offering features such as evening hours or more 
clinical staffing, or broadening a facility’s range of services [128, 131, 132, 189].  In practical 
terms, HD is the mainstay of most dialysis facilities in the US dialysis industry.  And within a 
market, all dialysis units face the same increasing demand for dialysis services, the dearth of 
innovations in dialysis care over the last 20 years, a shortage of registered nurses, and high 
turnover rates of nurses, aides, and technicians [94, 139] in health care organizations, making it 
difficult for dialysis units to differentiate themselves from one another.  Widening the range of 
dialysis to include PD may be an appealing and minimal-cost solution for facilities in 
competitive markets.   
As with all dialysis providers, facilities offering PD services compete on a host of similar 
factors, but have an added advantage of offering amenities that facilities exclusively servicing 
HD patients cannot – preserved vascular access, convenience, autonomous lifestyle, and better 
quality of life associated with the PD modality.  In addition, facilities may strategically choose 
to offer PD services not only to distinguish from their dialysis providers in competitive 
markets, but to also attract and fulfill as wide an array of patient and physician preferences as 
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possible.  Lastly, a PD service line may enhance dialysis facilities’ performance and survival 
over time.  While expertise in HD-only services may enhance organizational performance, PD 
services in competitive markets to diversify and enhance dialysis provider competencies may 
buffer facilities from system shocks and environmental change in the long term.   
Hypothesis 10 (H10): Dialysis facilities’ PD service availability is 
positively associated with dialysis market competition.   
Organizational trends and prior research of PD service patterns suggest that a trend of 
concentration has emerged over time [1, 124], which may be best explained by the phenomenon 
previously described, called the Hotelling effect.  PD represents somewhat of a departure from the 
details of Hotelling’s theory of spatial competition, where concentration typically emerges due to 
increasing and unmet demand for a product or service.  In the case of PD, historical trends in 
utilization and service availability among US dialysis facilities suggest that for various reasons, 
demand for PD remained stagnant, making it less feasible for facilities to continue competing in the 
market for PD services.   Facilities with a census of PD patients too small to justify continued 
provision of PD may instead find it worthwhile to transfer their patients to another facility within a 
regional referral network or service area.  Under these circumstances, we may observe a Hotelling-
like effect, where the availability of PD services is concentrated or less dispersed over time.  This 
concentration (or decrease in dispersion) explains the overall decline in PD service availability among 
dialysis facilities in the US.  In this study, geographic concentration is represented by a measure of 
spatial dispersion (e.g., the inverse condition of concentration), and for the ease of interpretation, the 
formal hypotheses are stated in terms of dispersion.  
Hypothesis 11 (H11): The geographic dispersion of dialysis facilities’ 
PD services in markets decreases over time.   
Hypothesis 12 (H12): Dialysis facilities’ PD service offerings are 
positively associated with spatial dispersion of PD service availability in 
markets.  
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A summary of the hypotheses to be tested in this study is provided in Table 2.  The next section 
describes the research design, including discussion about the data, variable construction, and analytic 
approaches for the aims of the study.   
Table 2. Summary of study hypotheses 
Market characteristics Hypothesized effect on 
PD service availability 
ESRD Patient Population  
H1. ESRD prevalence + 
H2. Percent white  + 
H3. Percent non-elderly  + 
H4. Co-morbid conditions - 
H5. Percent employment + 
H6. Percent with Medicare dual-coverage    + 
General Population  
H7. Percent urban + 
H8. Per capita income + 
H9. Healthcare density + 
H10. Dialysis market competition + 
H12. Geographic dispersion of PD                + 
CHAPTER 5 
RESEARCH DESIGN 
 
This study uses a longitudinal panel design to examine the availability of PD services.  The 
analysis follows the population of participants in the Medicare ESRD program from 1995 to 2003, 
examining factors associated with PD service availability.  Unlike cross-sectional design, longitudinal 
analysis captures the dynamics of environmental and organizational change and availability of 
healthcare services as they occur over time.  Moreover, because the temporal ordering of the 
relationships between market characteristics and PD service availability, longitudinal analysis 
provides stronger causal inference than cross-sectional design [190, 191].   
 Research methods of the study are described in this chapter.  The first section describes the 
study population and sampling.  The second section specifies the unit of analysis for each research 
question of the study.  The third section describes the sources and structure of the data used for this 
analysis, followed by definitions of variables and measurement in the fourth section.  Lastly, the fifth 
section explains the analytic approach for each component of the study.   
 
Study Population 
 The study examines PD service offerings from among outpatient dialysis providers 
participating in the Medicare ESRD program between 1995 and 2003.  Facilities which 1) are 
federally-owned (e.g., military or VA), 2) exclusively provide kidney transplant or inpatient dialysis 
services, and 3) are located outside the 50 US states are excluded from this analysis. 
 
 
Unit of Analysis 
 Analyses for this study are primarily conducted at the facility-level.  Geographic distribution 
patterns of PD services (Q1) are reported at the market-level.  For the purposes of this study, dialysis 
facility markets are defined at the level of hospital referral region (HRR).    
Although most of the prior literature on ESRD services defined markets at the county-level 
[118, 122, 125, 131, 132, 134, 135], there is sufficient evidence to suggest HRR to be the more 
appropriate market boundary for PD therapy services.  Developed by Wennberg [192] to approximate 
the geographic extent of healthcare markets for tertiary care, HRRs consist of zip codes in which a 
significant number of hospital referral admissions occur.  Since these regions are based on 
observational data indicating where people receive services (e.g., cardiac care and neurosurgeries), 
they are more valid measures of hospital markets than municipal designations such as counties or 
metropolitan statistical areas.  HRRs are particularly appropriate for studies of ESRD services for 
several reasons.  First, services for ESRD patients are not limited to dialysis care.  In addition to 
dialysis, ESRD patients receive a significant amount of specialized non-dialysis care (e.g., cardiac 
and diabetes) in tertiary-care settings [16].  Second, given the dearth of available PD services and 
since PD patients are more likely than HD patients to travel outside county boundaries for their care, 
HRR appears to better reflect PD service areas.  Lastly, HRRs are favorable, since even the smallest 
HRRs have sufficient numbers of patients with ESRD to appropriately examine PD service 
availability [16].  While 51 counties in the US had no prevalence of ESRD patients per 10,000 
population in 1999, all HRRs had an ESRD prevalence of at least 3 per 10,000 population. 
 
Data Sources and Structure 
This study draws upon multiple secondary data sources, most of which originate from CMS.  
The US Renal Data System (USRDS) is a CMS-contracted repository of all ESRD-related 
information. USRDS maintains and distributes much of this data on an annual basis.  To maximize 
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data consistency across the various sources, this study relies on data provided by USRDS, whenever 
possible. Descriptions of data files and their sources are provided in Table 3 and described below.     
 Dialysis Providers.  Facilities approved by Medicare to provide services specifically to ESRD 
patients are required to submit an Annual Facility Survey (CMS-2744, hereafter AFS).  The AFS 
captures information regarding facility characteristics (e.g., ownership, chain affiliation) and 
operating statistics (e.g., patient and clinical volume).  As participants in the Medicare program, 
ESRD facilities are also required to submit annual licensure and certification data, which is contained 
in Provider of Service (POS) files.  
 There were significant changes in the dialysis industry between 1995 and 2003.  Many 
facilities opened, closed, or were purchased by other organizational entities during this time period.  
Particular attention is paid to facilities that were purchased and sold between 1995 and 2003.  CMS 
assigns new provider identification numbers to facilities undergoing changes in ownership.  Thus, a 
facility may have the same provider number for several years, be purchased by a different owner, and 
receive a new provider number, even though its physical location and staffing remains intact.  This 
study is specifically interested in physical location of PD service availability, and as a result, it is 
necessary to track changes in facilities over time.  The analytic data structure takes these changes into 
account, by augmenting AFS data with POS data to track changes in address, ownership and chain 
affiliation.   
 The merge of USRDS and POS files also improved the accuracy and quality of data.  A 
number of facility observations (approximately 5,000 facility-year observations between 1995 and 
2003) were duplicate submissions of data (i.e., redundant) or contained invalid provider identification 
numbers.  These cases were removed from the analytic sample.  Few facilities (less than .48% of 
sample) were missing annual AFS data for one or multiple years during the study period.  To retain as 
many facility observations as possible for analysis, data was imputed.  Imputations were based on 
submitted data from preceding or following years of missingness (or the average of both, if available).  
Further detail and description of this study’s analytic file construction can be found in Appendix A.     
47 
ESRD Patients.  Since 1995, Medicare requires ESRD facilities to complete a Medical 
Evidence Report (CMS-2728, hereafter MER) for all incident dialysis patients, regardless of payer.  A 
new MER is required for all patients beginning or re-entering dialysis treatment or kidney 
transplantation services in ESRD facilities.  The form reports patient residence (i.e., zip code 
location), demographic information, insurance coverage, and comorbid conditions, noting any 
changes in this information over time.  Data from this patient registry between 1995 and 2003 
resulted in roughly 4.9 million patient-year observations (Appendix A).  These observations were 
then used to develop measures of ESRD incidence and prevalence and patients’ sociodemographic 
characteristics aggregated to the market-level (HRR) for each year of the study period.  
Markets.  County-level demographic characteristics, are available in the Area Resource File 
(ARF), maintained by the Health Resources and Services Administration (HRSA).  The ARF dataset 
consists of a comprehensive list of population characteristics for all counties in the US, including 
population counts, personal income, and land statistics.  Demographic statistics at the HRR-level are 
generated by first converting ARF county-level statistics to zip code-level statistics (based on land-
area weighting) and then aggregating zip code data to their designated HRRs.     
Hospital and physician data for markets are available from the American Hospital 
Association’s (AHA) Annual Hospital Survey and the American Medical Association’s (AMA) 
Physician Masterfile, respectively.  A census of hospital characteristics in each HRR is available for 
all study years (1995-2003).  Supply of nephrologists in HRRs is available for years 1996, 2001, and 
2003. Since the supply of nephrologists appears to be low and relatively stable between 1996, 2001, 
and 2003, these years of available data will be used to impute values for missing years.  Thus, 1996 
nephrology supply data is applied to years 1995 and 1997, 2001 data is used for 1998 through 2000, 
and 2003 data is applied to 2002.  
Data of zip code assignments to hospital referral regions are contained in the geographic 
boundary files from the Dartmouth Atlas of Health Care [193].  Facility, patient, and market 
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demographic zip code data are assigned to HRRs and aggregated to generate to HRR market-level 
statistics.   
Geographic coordinates for each facility address were geocoded using ESRI StreetMap 
locator software [194].  Addresses that did not initially match to a latitude and longitude coordinate 
were verified and in some cases, corrected.  Any facility address not matched to coordinates after the 
second round of verification were assigned coordinates of the address zip code’s centroid.  These 
coordinates were used to verify the accuracy of facilities’ geographic location to HRR assignment and 
for the development of spatial measurement for analysis. 
Table 3. Data sources and file descriptions* 
Data File Description  CMS File Origin Data Source 
FACILITY  Annual Facility Survey data regarding dialysis 
facility operating statistics 
CMS-2744 USRDS 
POS Provider of Service data of licensure and 
certification information on all Medicare-
approved facilities 
POS CMS 
PATIENTS Medical Evidence Report data of individual 
patients’ basic demographic and ESRD-related 
information 
CMS-2728 USRDS 
RESIDENC Medical Evidence Report data of individual 
patients’ residence zip code(s) 
CMS-2728 USRDS 
MEDEVID Medical Evidence Report data of individual 
patients’ start(s) of chronic renal dialysis 
CMS-2728 USRDS 
ARF County-level general and healthcare 
population demographics 
 HRSA 
AHA American Hospital Association (AHA) Annual 
Survey of Hospitals data regarding hospital 
location and operating statistics 
 AHA 
AMA American Medical Association (AMA) 
Physician Masterfile data on physician location 
and specialty of medical practice 
 AMA 
HRR Hospital Referral Region (HRR) geographic 
boundary assignment and zip-code crosswalk 
files 
 Dartmouth Atlas 
* See also Appendix A for detailed descriptions of analytic file construction. 
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Variables and Measurement 
Table 4 displays sample measures, descriptions, and data sources for each variable.  The 
motivation behind their inclusion in this study and operational definitions are explained in detail 
below. 
Dependent Variable.  The dependent variable of interest is a dichotomous variable indicating 
the availability of any PD service at a dialysis facility (pdsvc).  This indicator is coded “1” if a 
dialysis provider offered at least one of either continuous ambulatory PD (CAPD) or continuous 
cycler-assisted PD (CCPD) during the calendar year and coded “0” if it does not offer any of these 
types of PD service.  Staff-assisted and in-unit self-care PD are excluded from this analysis because 
these services are unit-based and rarely offered. 
Independent Variables. This study incorporates up to 20 explanatory variables for analysis.  
As explained in the previous chapter, I anticipate characteristics of a region’s ESRD patient 
population and healthcare market characteristics to be associated with PD service offerings among 
dialysis facilities.   
Patient Characteristics.  The USRDS patient data files from the MER are the basis for patient 
socio-demographic statistics, aggregated at the HRR-level.  Their definitions of measurement are 
detailed as follows:  
• ESRD prevalence (prevlnt) is the proportion of the general population with ESRD (new and 
existing cases) in a HRR, based on date of ESRD onset and residence zip code for a given year.   
• The percentage of white patients (white) is defined as the proportion of patients whose race is 
reported as “white” and ethnicity “non-Hispanic” in the MER.   
• The percentage of non-elderly ESRD patient population (noneld) represents the proportion of 
patients younger than 65 years of age in the respective year of the study.  For example, ESRD 
patients who are 59 years old in 1995 will be identified as non-elderly ESRD patient for years 
1995 through 2000, and elderly for the remainder of the study period or date of death 
(whichever occurs sooner).   
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• Percentage of employed patients (employed) is defined as the proportion of ESRD patients 
reporting full- or part-time employment in the MER.   
• The average co-morbidities in a HRR (avgcomorb) represents the average number of reported 
co-morbid conditions for all ESRD patients in a region.   
• The percentage of Medicare dual-coverage patients (dualcov) is defined as the proportion of 
ESRD patients with medical insurance coverage by a combination of Medicare and either 
Medicaid or employer group health insurance, as reported in the MER.  
Market Characteristics.  The majority of the HRR-level market characteristics come from 
county-level healthcare market data contained in the ARF dataset, which are then converted to zip 
code (based on land-area weighting) and aggregated at the HRR-level.     
• The proportion of urban HRR population in a market (pcturb) refers to the percentage of the 
HRR population residing in urban locations in 2000.  Urban population and total population in 
the county-level ARF files are used to generate a percentage of urban residents per HRR. 
• Per capita income is defined as the total personal income of the residents of a HRR divided by the 
resident population of the HRR.   
• Healthcare density (hcdens) refers to the amount of healthcare resources available in a HRR.  
For the purposes of this study, this measure is based on two measures of healthcare provider 
density per HRR square mile.  Density of hospital providers (hospdens) is defined as the total 
number of community-based hospital beds per HRR square mile, as reported in the AHA 
Annual Survey of Hospitals.  The second measure, density of physicians (mddens), represents 
the total number of physicians specializing in nephrology per HRR square mile, based on 
physician census data from the AMA Physician Masterfile.  These two measures of healthcare 
provider density are highly correlated (overall correlation coefficient, r= 0.968 for the entire 
study period) and inclusion of both measures may introduce problems of multicollinearity in 
regression analyses.  To address this, factor analysis was performed on the two healthcare 
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provider density measures using Stata Version 8 [195].  For each year of the study period, the 
variables strongly loaded to a single factor (eigenvalue range = 1.95 – 1.97) and no other factor 
had an eigenvalue greater than one, confirming high correlation of the density measures.  After 
confirming hospital and nephrologist density loaded to a single factor, the score procedure was 
used to create an annual, continuous variable based on the factor loadings.  This continuous 
healthcare density variable is used in multivariate analyses.   
• Market competition is calculated using the Herfindahl-Hirschman Index (HHI), which is equal 
to the sum of the square of each competing facility’s market share3 based on the number of 
dialysis patients seen at (and unique to) each facility. Facility operating statistics reported in the 
AFS are used to develop this measure.  The HHI measures range from 0, indicating nearly 
perfect, unconcentrated competition to 1, reflecting monopolist competition in a market [196].   
• Geographic dispersion (dispers) is represented by the nearest-neighbor index (NNI).  Index 
values less than 1 and approaching 0 indicate spatial clustering (i.e., concentration) and values 
greater than 1 exhibit dispersion.   Additional detail on the methodology used to generate this 
measure is discussed in further detail below (see analytic approach for Q3).     
Facility Characteristics.  Other characteristics, believed to also influence a dialysis unit’s PD 
service offering, operating at the facility-level are included in the model as control variables.  These 
facility characteristics include ownership, chain-affiliation, setting, urban location, age, size, HD 
occupancy, and ownership change. 
• Ownership is represented by a dichotomous variable, indicating whether or not a dialysis facility 
is a not-for-profit or for-profit entity (forprofit).  Since the overwhelming majority (> 70%) of 
                                                 
3 Much of the ESRD services literature, which largely focuses on HD treatment, defines facility size in terms of 
the numbers of HD stations (similar to how hospital size is based on the number of beds in a hospital) or the 
numbers of treatments provided to patients in a facility.  For the purposes of this study, the number of HD 
stations is not an adequate measure of facility size, as it discounts PD treatment.  Second, instructions for the 
AFS do not clearly define how numbers of PD treatments should be reported (i.e., numbers of exchanges or 
treatment days equivalent to HD).  Facility treatment load based on potentially discrepant units of PD and HD 
treatment may not accurately reflect facilities’ size and therefore bias my results.  For the purposes of this study, 
facility and market size will be based on the numbers of patients seen at and unique to a facility.  
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dialysis providers are for-profit owned, public and private not-for-profit ownership was 
collapsed into one not-for-profit category.  This variable is coded “1” if a facility is a for-profit 
entity and “0” otherwise.   
•  Chain-affiliation (chain) is defined as facility ownership by a chain organization.  The USRDS 
definition of chain affiliation is limited to ownership only by the 6 largest chain organizations in 
the country [1], and therefore misidentifies facilities affiliated with smaller regional chains and 
independent entities.  To address this limitation, the chain affiliation indicator for this study is 
also derived from 2 other sources of chain data, found in the CMS administrative POS file.   A 
coding of “1” indicates facility ownership by a chain provider organization or “0” otherwise.     
• Facility setting is indicated by a dichotomous indicator of freestanding dialysis facilities (freest), 
which is coded “1” if a facility operates independently of a hospital.  Facilities coded “0” are 
hospital-based and located either on the hospital premises or at a remote location.   
• Facilities’ urban location (urbfac) is based on a facility’s metropolitan designation.  Facilities 
located in a Metropolitan Statistical Area, as defined by the Office of Management and Budget, 
are considered to be located in an urban area and coded “1” or “0” otherwise.     
• Facility age (age) represents the number of years a facility has participated in the Medicare 
ESRD program, according to year of certification by CMS. 
• Facility size 3 (size) is defined as the number of annualized patients seen at and unique to a 
facility. 
• HD occupancy (hdoccup) represents the annual occupancy rate of a facility’s HD stations.  This 
rate is the total number of in-unit HD treatments provided divided by its total possible HD 
treatments available for use (based on the number of HD stations in a facility, an average of 3 
shifts of potential usage per station per day, a six day week, and operating 51 weeks of the year).  
For the facilities reporting over 100% occupancy (< 10% of the overall sample), occupancy is 
truncated at 100%. 
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• Dialysis facilities undergoing change in ownership in the current, previous year, and previous 2 
years (ownchng0, ownchng1, and ownchng2, respectively) are identified from the recorded dates 
of ownership change in the CMS-POS file.  This variable is coded “1” if a change in ownership 
took place within the specified time frame and “0” if ownership remained the same. 
Table 4.  Data specification and file sources 
Variable Measure / Description Data File Source 
Dependent Variable 
anypd Facility availability of PD service  FACILITY 
Market-level characteristics 
prevlnt ESRD prevalence PATIENTS 
white % white ESRD patient population PATIENTS 
noneld % non-elderly ESRD patient population PATIENTS 
avgcomorb Average number of ESRD patients’ co-morbid 
conditions 
PATIENTS 
employed % employed (Full or Part-time) ESRD patient pop PATIENTS 
dualcov % with Medicare dual-coverage (Medicaid or 
private insurance) 
PATIENTS 
urban % urban population ARF 
hospdens Hospital beds per square mile AHA 
mddens Nephrologists per square mile AMA 
hcdens Healthcare density: hospital beds and 
nephrologists per square mile 
AHA, AMA 
HHI Dialysis market competition (Herfindahl Index) FACILITY 
dispers Geographic dispersion of PD services FACILITY, POS 
Facility-level characteristics 
forprofit For-profit ownership FACILITY, POS 
chain Chain affiliation FACILITY, POS 
freest Freestanding facility  FACILITY  
urbfac Facility urban location POS 
age Facility age FACILITY, POS 
size Facility size (# treatments, annual) FACILITY 
hdoccup HD station occupancy rate FACILITY 
ownchng Ownership change FACILITY, POS 
 
 Data for this study are merged to construct pooled, annual time-series observations of dialysis 
units during the study period [197].  The resulting data set for the first study aim (Q1) consists of 
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4,688 facilities, of no more than 9 repeated observations per dialysis unit, constituting 32,253 facility-
year observations for analysis.  Since the effects of covariates on the dependent variable are unlikely 
to be instantaneous and in order to enhance causal explanation for such analyses for the second and 
third research questions (Q2 and Q3), explanatory variables are lagged by one year.  For example, 
covariates from 1995 will be used to predict 1996 outcomes.  This final dataset consists of 8 years of 
observations and a total of 27,497 facility-years. 
 
Analytical Approaches and Model Specifications 
 Q1. Distribution Pattern of PD Service Availability.  For this research aim, spatial analysis 
methods are used examine the distribution of PD services among dialysis facilities in the US.  
Choropleth maps display the spatial distribution of PD service availability, by HRR, in the US 
between 1995 and 2003.  Patterns of PD service availability over time are also examined in relation to 
ESRD prevalence rates and sociodemographic characteristics of ESRD patient populations.  
Choropleth maps of ESRD patient demographics, lagged by one year, overlay maps of PD 
availability.  For example, maps of ESRD patient characteristics in 1995 overlay 1996 PD service 
offerings.  From these annual maps, general patterns of distribution and changes of these patterns over 
time can be detected. 
 Q2. Market Conditions and Provision of PD Services.  To examine the effect of local market 
forces and ESRD patient sociodemographics on dialysis facilities’ provision of PD services over time, 
discrete-time logit modeling will be used for this analysis.  This method analyzes longitudinal data 
with a dichotomous dependent variable and multiple independent variables of interest.  Moreover, 
discrete-time logit modeling accounts for left truncation (i.e., entry of new facilities) and right 
censoring (i.e., facility merger or closure) during the study period [198, 199].  Logit modeling is also 
preferred over continuous time models when the exact date of PD service availability is not known 
(data indicates availability during the calendar year, with no exact PD service start or end date) and 
when large time intervals such as calendar year are being used [197-199].  For this study, the logit 
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model will estimate the conditional probability that a facility provides PD service (a mutually 
exclusive category) during annual time intervals, given the covariates for those facilities that are 
operational during the calendar year.  A simple form of the model is: 
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where P(t) is the conditional probability that a dialysis facility will offer PD services in year t, Xk are 
covariates; and βk are the estimated parameters [197-199].   
My analytic approach will also address 2 shortcomings of longitudinal logistic modeling, 
which may lead to incorrect estimations of regression parameters.  First, parameter estimates of a 
binary dependent variable result in non-constant variances and therefore violate ordinary least squares 
assumption of normally distributed error terms [200, 201].  Second, analysis of longitudinal data, 
composed of repeated observations of facilities, does not account for correlations among repeated 
observations when estimating regression parameters.  Ignoring these non-normal error distributions 
and correlations within facilities results in underestimated standard errors and incorrect inferences 
about regression coefficients [190, 200, 202, 203].  This study uses generalized estimating equations 
(GEE) to account for these sources of bias in the logistic model.  A quasi-likelihood method based on 
generalized linear models, GEE separates the effects of within facility-correlations from the 
estimation of regression coefficients to yield consistent population-averaged parameter estimates 
[190, 199, 200, 202-206].  The longitudinal, multivariate GEE model is estimated using the PROC 
GENMOD procedure in SAS [207].   
 Q3. Geographic Dispersion of PD Services.  To examine the extent of dispersion (or 
concentration, the inverse of dispersion) of PD services in a market, spatial analysis methods are 
employed.  Geographic information systems (GIS) have a unique capability of visualizing and 
exploring geographical evidence of event clustering.  Identifying locational patterns of PD services 
and fluctuations in these distributions over time, GIS provides additional insight into the likelihood of 
facilities to make PD services available.   
56 
 First, a measure of market-level spatial dispersion of PD services in a market is developed.  
Annual measures are generated for each HRR in each year of the study.  For the purposes of this 
study, dispersion is based on a measure known as the nearest-neighbor index (NNI).  This spatial 
statistic considers the relationship between location points (e.g., dialysis facility locations) in a 
defined area (e.g., HRR).  These point patterns are classified on a continuum, where spacing between 
points is at a minimum when points are clustered and at a maximum when points display dispersion 
[208].  The index was developed by ecologists to quantify the distribution patterns of various plant 
species [209], and has been used by crime analysts to explain dispersion of crime in areas [210] and 
by public health researchers to examine clustering of infectious disease [211].  Among the various 
methods used to describe spatial patterns, the use of the NNI in this study is appropriate for a few 
reasons.  Other measures of concentration or distance are based on an area centroid (in this study, a 
HRR’s mean center).  However, clustering of dialysis facilities PD services may not necessarily take 
place in the centermost point of its respective HRR.  The NNI is based on the distance between point 
locations (irrespective of direction), relative to HRR area size.  Moreover, the nearest-neighbor index 
provides a concise measure of dispersion in a single value [167, 209, 210, 212].   
 The index is a ratio of nearest-neighbor distances.  First, the distances between each facility 
offering PD services within a HRR are generated to identify each facility’s distance to its nearest 
neighbor.  These distances between pairs of nearest neighbors are added and divided by the total 
number of facilities to generate a HRR-specific, observed mean nearest distance.  Next, the value of 
the mean nearest distance that would be expected if PD facilities were randomly distributed is 
calculated.  This expected mean distance to nearest neighbor is based on the number of PD facilities 
in and the areal extent of a HRR.  The index is thus a ratio of the observed to the expected mean 
distance and represents the departure of PD facilities location from randomness within a HRR.  If the 
means are the same, a NNI of 1 indicates random distribution.  Values between 0 and 1 indicate 
clustering, where more clustered patterns (i.e., concentration) are valued closer to 0.  For the purposes 
of this analysis, HRRs with only a single facility offering PD represent ultimate clustering and are 
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assigned a value of 0.  NNI values greater than 1 indicate a dispersed observed distribution [208-210, 
212].   
 Lastly, the annual, market-level NNI values are used to examine trends in spatial dispersion 
over time and its effect on dialysis facilities’ decision to offer PD services.  This measure of spatial 
dispersion of PD is incorporated into the discrete-time logit model from Q2.    
CHAPTER 6 
RESULTS 
 
 There were 4,688 Medicare-participating outpatient dialysis facilities located in the 50 US 
states (and Washington, DC) between 1995 and 2003.  The average facility had 9 repeated 
observations per dialysis unit (out of a possible 9 years), resulting in 32,253 observations for analysis.  
These observations constituted the sample for the first research question’s descriptive analysis.     
 Over the entire study period, 46.5% of facilities offered PD services (Table 5).  Facility 
locations varied widely, by ESRD patient and general market characteristics.  Dialysis facilities were 
located in markets with an average ESRD prevalence of 21 per 10,000 population.  The average 
facility provided services in HRRs with ESRD patient populations characterized as mostly non-White 
(29.5% were identified as White, non-Hispanic), non-elderly (59.6%), and reporting an average of 
1.34 co-morbidities.  The mean proportion of employed and Medicare-dually covered ESRD patients 
was generally low in an HRR for the average facility (7.3% and 9.9%, respectively), not unreasonable 
given that, at most, only a third of ESRD patients in any HRR were employed (20.7%) or had 
Medicare dual-coverage (34.2%) throughout the study period.   
 In terms of general market characteristics, the average dialysis facility served a general 
population of largely urban residents (mean of 77.2%; CI= 26.8% – 100%).  The per capita income of 
the average facility’s HRR was $22,765 per year, slightly more than the 1999 national statistic.  The 
average dialysis facility was located in a competitive market for the dialysis industry (Herfindahl 
index of 0.12) with roughly 4.67 community hospital beds and .04 nephrologists per square mile.   
 With regard to facilities own characteristics, the majority of dialysis provider organizations in 
this study are for-profit owned (75.2%), affiliated with a chain (66.7%), freestanding units (80.6%), 
 
and located in urban settings (75.7%).  The average facility has participated in the Medicare ESRD 
program for 9.7 years, with few undergoing ownership change in a given year (4.3%).  Facility sizes 
vary widely, but between 1995 and 2003, the average dialysis facility provided care to 68.4 unique 
PD and HD patients and had a 55.9% occupancy rate of their HD stations.  
Table 5. Q1 descriptive statistics, overall (facility-year)  
N=32,253  Freq (%) Mean S.D. Min Max 
Any PD service, % 46.48     
Market-level characteristics (HRR)      
ESRD patient population      
ESRD prevalence (per 10,000)  21.20 9.45 3.38 80.90 
% White, non-Hispanic  29.47 15.58 1.45 77.52 
% Non-elderly  59.60 5.08 29.55 75.07 
Comorbid conditions  1.34 .47 .13 3.04 
% Employed  7.30 3.66 0 20.69 
% With Medicare dual coverage  9.92 5.01 0 34.15 
General population      
% Urban population  77.19 16.89 26.80 100.00 
Per capita income   22,765 4,638 8,719 47,841 
Hospital bed density  4.67 18.05 .001 146.32 
Nephrologist density  .04 .19 0 1.56 
Healthcare density *  -6.38e-10 .99 -.25 7.02 
Dialysis market competition  .12 .14 .01 1 
Facility-level characteristics      
For-profit ownership, % 75.20     
Chain-affiliation, % 66.74     
Freestanding facilities, % 80.57     
Urban location, % 75.72     
Facility age  9.69 7.36 .04 26.25 
Facility size   68.38 53.15 0 494 
HD station occupancy rate  55.95 26.82 0 100 
Ownership change, % 4.31     
* Healthcare density is a composite measure of regional supply of hospital beds and nephrologists per square 
mile.  For illustrative purposes, hospital bed and nephrology physician densities are presented.     
 
Availability and Distribution of PD Services among US Dialysis Facilities 
 The availability of PD services varies significantly, both temporally and geographically.  
During the study period, the proportion of facilities with PD services increased to a high of 49.6% in 
1996 (n=2,942) and continually declined to 44.4% (n=1,919) in 2003 (Table 6).   
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Table 6.  Total ESRD facilities, by year 
Year Total 
Facilities 
Total  
PD Facilities 
% PD 
Facilities 
1995 2737 1215 44.39% 
1996 2942 1459 49.59% 
1997 3188 1575 49.40% 
1998 3414 1658 48.56% 
1999 3640 1774 48.74% 
2000 3837 1790 46.65% 
2001 4000 1771 44.28% 
2002 4171 1831 43.90% 
2003 4324 1919 44.38% 
 
As depicted in Figure 7, although more facilities entered the market (from 2,737 in 1995 to 4,324 in 
2003) and the total numbers of facilities offering PD grew (from 1,215 in 1995 to 1,919 facilities in 
2003), PD did not grow in proportion to overall growth in the dialysis industry.  Geographically, the 
regional variation and patterns of PD service availability shift over time.  All regions of the US 
experienced a low and declining proportion of PD service offerings between 1995 and 2003 (Figure 
8). 
Figure 7.  Total ESRD facilities, by year 
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Figure 8.  Regional affiliation of ESRD facilities: 1995, 1999, 2003 
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 Choropleth maps of PD service availability better illustrate temporal and geographic trends of 
PD services during the study period. There are several ways to present distributions of PD service 
availability, each with distinct advantages and disadvantages.  Geographic distributions of PD 
services, in terms of the total numbers of facilities offering PD (Figure 9) show that for many markets 
across the county, facilities offering PD services were more numerous in metropolitan cities, the 
South, and less available in the Northwest and rural regions.  After adjusting for HRR size, the 
distribution of PD service availability, as a proportion of all dialysis facilities in a market, is presented 
in Figure 10.  With the exception of the HRRs in the mountain states of Utah, Colorado and New 
Mexico, where PD had a sizable presence, the general trend in availability persists.   
 Both sets of maps display a temporal trend, nationally, where availability of PD appeared to 
increase between 1995 and 1999 (i.e., HRRs tend to develop dark shading), followed by a gradual 
decline in the latter half of the study period (i.e., HRRs lose their shading from 1999 to 2003).  This is 
confirmed upon examining choropleth maps that display the amount of change in the proportion of 
facilities offering PD services between years of the study period (Figure 11).  Choropleth maps 
displaying the differences in the percentage point change in the proportion of facilities offering PD in 
1995, 1999, and 2003 are consistent with trends noted earlier.  Overall, PD services increased (as 
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indicated by gradations of green shading) until 1999 and decreased thereafter (shown in gradations of 
red).  Despite minor exceptions in the Northwest, Midwest, and Texas, most HRRs experienced a 
higher proportion of facilities with PD between 1995 and 1999 and then a lower proportion between 
1999 and 2003.   
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Figure 9. Facility counts of PD service availability, by HRR: 1995, 1999, 2003 * 
1995
1999
2003
Legend
None
1 - 2
3 - 5
6 - 10
11 - 85
* With the exception of the first category (“None”), categories are based on the 2003 quantile distribution of values.  Maps 
illustrating annual distributions of PD services by HRR for each year of the study can be found in Appendix B. 
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Figure 10. Percent PD service availability in dialysis facilities, by HRR: 1995, 1999, 2003 * 
1995
1999
2003
Legend
0 - 20%
20 - 40%
40 - 60%
60 - 80%
80 - 100%
* Maps illustrating annual distributions of PD services by HRR for each year of the study can be found in Appendix B. 
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Figure 11. Percentage point change in PD service availability, by HRR: 1995-1999 and 1999-2003 
1995 to 1999
1999 to 2003
1995 to 2003
Legend
66 - 100% fewer
33 - 66% fewer
.0001 - 33% fewer
No change
.0001 - 33% more
33 - 66% more
66 - 100% more
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 The geographic and temporal variation of PD service offerings does not appear to be fully 
explained by patients’ demand-side factors.  Given the large numbers of ESRD patient characteristics 
and number of years in the study period examined, only a limited number of choroplethic maps are 
displayed in Figures 12 through 14.  These maps illustrate distributions of proportions of facilities 
offering PD services and one-year lagged ESRD patient characteristics in the first and last year of the 
study period (e.g., the 1995 distribution of ESRD prevalence rate overlays or transposes the 1996 
distribution of PD service availability overlays in Figure 12).   
 For ease of interpretation, both distributions are categorized into low, medium, and high 
categories, based on tercile values for a respective year of data.  Congruency of PD availability and 
PD patient characteristics would be found in darker shaded HRRs (i.e., more PD service offerings) 
bearing a starker hatched pattern (i.e., higher ESRD patient population with the characteristic).  White 
shaded HRRs with no hatching pattern would indicate congruent areas with low levels of PD 
offerings and ESRD patient characteristic. 
 Visual inspection of the mapped distributions suggests that PD availability did not readily 
correspond to HRRs in which ESRD patients are more likely to have characteristics that favor PD 
use, such as ESRD prevalence (Figure 12), the proportion of White, non-Hispanic ESRD patients in a 
HRR (Figure 13), or the percentage of full- or part-time employed ESRD patients (Figure 14).  As 
depicted in Figure 12, PD was more abundant in the mountain states, where there was less ESRD 
prevalence.  Figure 14 shows that HRRs with a low to moderate amount of PD services were in areas 
where a relatively high proportion of employed ESRD patients reside.  Furthermore, these 
incongruities between PD availability and all the ESRD patient characteristics in this study appeared 
to increase over time.   
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Figure 12. Distributions of % dialysis facilities offering PD and ESRD prevalence, by HRR 
1996
2003
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Figure 13. Distribution of % dialysis facilities offering PD and % White, non-Hispanic ESRD 
Patients, by HRR 
1996
2003
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Figure 14. Distribution of % dialysis facilities offering PD and % ESRD patient employment, by HRR 
1996
2003
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Effect of Market Conditions on Provision of PD Services 
 For the remaining research questions in this study, the study sample was limited to facilities 
with complete dependent and one-year lagged independent variables for each year in operation during 
the study period.4  A total of 4,431 facilities, each with no more than 8 observations (a total of 27,497 
facility-year observations) constitute the analytic sample for Q2 and Q3.  Descriptive statistics of this 
sample is presented in Table 7.  The previously discussed trends generally persist in this sample.  
Table 7. Q2 descriptive statistics of covariates, overall (facility-year)  
Covariate (one-year lagged value) 
N=27,497 
Freq (%) Mean S.D. Min Max 
Dep var: Any PD service, % 47.78     
Market-level characteristics (HRR)      
ESRD patient population      
ESRD prevalence (per 10,000)  20.82 9.32 3.38 80.90 
% White, non-Hispanic  28.02 15.01 1.49 72.94 
% Non-elderly  59.68 5.08 .13 75.07 
Comorbid conditions  1.27 .47 .13 2.86 
% Employed  6.73 3.46 0 19.33 
% With Medicare dual coverage  9.38 4.95 0 34.15 
General population      
% Urban population  77.22 16.91 26.80 100 
Per capita income   22,911 4,645 9,003 47,841 
Hospital bed density  4.75 18.31 .002 146.32 
Nephrologist density  .04 .19 0 1.56 
Healthcare density *  .001 1.00 -.25 7.02 
Dialysis market competition  .12 .14 .01 1 
Facility-level characteristics      
For-profit ownership, % 74.82     
Chain-affiliation, % 65.01     
Freestanding facilities, % 79.94     
Urban location, % 75.77     
Facility age  9.49 7.24 .04 25.25 
Facility size   69.00 53.61 0 494 
HD station occupancy rate  56.59 26.77 0 100 
Ownership change, % 4.91     
* Healthcare density is a composite measure of regional supply of hospital beds and nephrologists per square mile.  
For illustrative purposes, hospital bed and nephrology physician densities are presented. 
                                                 
4 After lagging covariates, 52 facility-year observations were found to have incomplete data, due to missing a 
year of survey data.  Since this missingness appears to be random and constitutes less than .2% of the overall 
sample, these observations were dropped from the final analytic sample.    
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 Bivariate Analysis.  Two bivariate analyses were conducted.  In the first analysis, Chi-square 
and t-tests indicated statistically significant differences (p < .01) between facilities offering and not 
offering PD services (Table 8).  With the exception of the proportion of white, non-Hispanic ESRD 
patient population and the ownership change in the previous year, differences were found across the 
majority of facilities’ market and internal characteristics used in this study.  During the study period, 
facilities offering PD were located in HRRs with less ESRD prevalence than facilities with no PD 
(20.6 versus 21.1 ESRD patients per 10,000 population).  PD facilities’ average market tended to 
have a smaller proportion of non-elderly, employed, and Medicare dually-covered ESRD patient 
population with fewer co-morbid conditions than facilities with no PD. Based on the large sample 
size, these differences, however small (mostly 1% or less), were expected to be significantly different.   
Notable differences were found in ESRD-non-specific market and facilities’ internal 
characteristics. On average, provider organizations offering PD were located in urban settings (84% 
versus 68%), and served HRRs consisting of a larger urban population (79% compared to 75.6%), 
higher per capita income ($1,000 more), and healthcare dense markets, relative to non-PD facilities.  
Relative to facilities with no PD services, fewer facilities with PD were freestanding (77.8%), for-
profit owned (71.2%), and affiliated with a chain organization (59.2%).  In terms of internal 
operations, facilities with PD services were on average larger (dialysis patient load of 87.9 compared 
to 51.6) and reported higher HD occupancy rates than non-PD facilities (59.2% versus 54.2%). 
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Table 8. Q2 descriptive statistics of covariates, by PD service availability (facility-year)  
Covariate (one-year lagged value) 
Facilities with no PD 
N=14,360 
 Facilities with PD 
N=13,137 Sig Diff 
Mean S.E. Mean S.E. 
Market-level characteristics (HRR)       
ESRD patient-specific       
ESRD prevalence (per 10,000) 21.05 .08  20.56 .08 * 
% White, non-Hispanic 27.96 .12  28.09 .13  
% Non-elderly 60.11 .04  59.22 .04 * 
Comorbid conditions 1.29 .004  1.25 .004 * 
% Employed 6.97 .03  6.46 .03 * 
% With Medicare dual coverage 9.50 .04  9.24 .04 * 
General population       
% Urban population 75.59 .14  78.99 .14 * 
Per capita income  22,417 37.27  23,450 41.66 * 
Hospital bed density 4.18 .15  5.37 .17 * 
Nephrologist density .04 .002  .05 .002 * 
Healthcare density a -.03 .01  .03 .01 * 
Dialysis market competition .12 .001  .13 .001 * 
Facility-level characteristics       
For-profit ownership, % 78.12   71.20  * 
Chain-affiliation, % 70.35   59.17  * 
Freestanding facilities, % 81.87   77.83  * 
Urban location, % 68.20   84.05  * 
Facility age 7.80 .05  11.33 .07 * 
Facility size  51.66 .33  87.94 .53 * 
HD station occupancy rate 54.22 .21  59.18 .24 * 
Ownership change % 4.84   4.98   
* p< .01   Differences detected by t-test for continuous variables and Chi-square test for dichotomous variables.   
a Healthcare density is a composite measure of supply of hospital beds and nephrologists per HRR square mile.  
For illustrative purposes, hospital bed and nephrology physician densities are presented. 
 
 In the second bivariate analysis, correlations were used 1) to examine the relationships of 
market and facility characteristics with PD service availability and 2) to check for multicollinearity in 
the GEE models due to high correlations among study variables.  The correlation matrix is presented 
in Table 9.  Correlations greater than .008 or less than -.01 are significant (p< .05).  Of the 10 market 
characteristics examined, only the proportion of white, non-Hispanic ESRD patients is not 
significantly related to facilities’ PD service availability.  Consistent with expectations derived from 
location theory, facilities in markets with ESRD patients reporting fewer co-morbid conditions (r= -
73 
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.046) and having higher proportions of urban residents in the general population (r= .100) were more 
likely to offer PD services.  Moreover, facility PD service availability was positively correlated with 
HRR per capita income (r= .111) and healthcare density (r= .028).  However, contrary to 
expectations, prevalence of ESRD (r= -.026) and the proportions of non-elderly (r= -.088), employed 
(r= -.074), and Medicare dually-covered (r= -.026) ESRD patient populations in markets were 
negatively correlated with PD service availability.  The positive correlation between dialysis market 
competition and PD services (r= .052) should be interpreted such that, as the Herfindahl index 
increased (i.e., competition decreases), PD services increased.  This is the opposite of what I 
hypothesized. 
 Correlations of dialysis provider organizational characteristics and PD service are also 
presented in Table 8.  During the study period, for-profit (r= -.08), freestanding (r= -.05), and chain-
affiliated (r= -.117) facilities were less likely to offer PD services.  Organizational attributes 
positively associated with PD service offerings included facility location in urban areas (r= .185), 
facility age (r= .243), size (r= .338), and occupancy rate of HD stations in the facility (r= .093). 
 However, the significant correlations of market and organizational characteristics with 
facilities’ PD service availability are preliminary.  The market-level covariates are themselves 
correlated with each other and with other covariates in the model.  This suggests that the effects of 
market conditions on PD availability should be considered in the multivariate context, which controls 
for dialysis facilities’ internal characteristics and the markets where these facilities are located.   
Table 9.  Q2 correlation matrix of model variables      
N=27,497 1 2 3 4 5 6 7 8 9 10 11 
1. PD Service 1.0000           
2. Prevalence -0.0264 --          
3. % White, non-Hisp 0.0042 -0.2418 --         
4. % Non-elderly -0.0878 -0.0657 -0.3968 --        
5. Comorbid conditions -0.0457 0.1028 0.6789 -0.2529 --       
6. %  Employed -0.0736 -0.0033 0.5597 0.0511 0.6880 --      
7. % Dual coverage -0.0263 0.1126 0.4809 -0.1222 0.7002 0.3984 --     
8. % Urban population 0.1003 0.2570 -0.2605 -0.1206 -0.1633 0.0736 -0.2739 --    
9. Per capita income 0.1111 0.0912 -0.0975 -0.1856 -0.2177 0.0753 -0.2268 0.6156 --   
10. Hospital density 0.0326 0.3244 -0.1978 0.0488 -0.1239 -0.0655 -0.0330 0.3085 0.3619 --  
11. Physician density 0.0231 0.2721 -0.1660 0.0378 -0.0890 -0.0334 -0.0020 0.2801 0.3559 0.9679 -- 
12. Healthcare density 0.0284 0.2997 -0.1842 0.0441 -0.1098 -0.0525 -0.0197 0.2970 0.3635 0.9943 0.9874 
13. Dialysis market comp 0.0519 -0.2711 0.2169 -0.0516 -0.0135 -0.0609 -0.0669 -0.3473 -0.2078 -0.1255 -0.1232 
14. For-profit -0.0796 0.0923 -0.0433 0.0172 0.0917 0.0239 0.0514 0.0583 -0.0977 -0.1115 -0.1046 
15. Chain affiliation -0.1171 0.0912 0.1118 -0.0061 0.2345 0.1681 0.1721 -0.0513 -0.1362 -0.1614 -0.1503 
16. Freestanding -0.0503 0.1023 -0.0560 0.0532 0.0788 0.0062 0.0711 0.0348 -0.1086 -0.1155 -0.1064 
17. Urban location 0.1847 0.1281 -0.1197 -0.0679 -0.0874 0.0050 -0.1398 0.5017 0.3337 0.1347 0.1220 
18. Facility age 0.2434 0.0792 0.0241 -0.0228 0.0584 0.0701 0.0478 0.0579 0.0720 0.0986 0.0926 
19. Facility size 0.3381 0.0947 -0.1265 0.0079 -0.0452 -0.0098 -0.0371 0.1989 0.1533 0.1485 0.1316 
20. HD Occupancy  0.0927 0.0335 -0.0304 -0.0377 -0.0325 0.0304 -0.0423 0.1525 0.1507 0.1212 0.1077 
21. Ownership change  0.0032 -0.0307 -0.0245 0.0005 -0.0320 -0.0458 -0.0413 -0.0027 -0.0101 -0.0221 -0.0237 
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N=27,497 12 13 14 15 16 17 18 19 20 
13. Dialysis market comp. -0.1255 --        
14. For profit -0.1096 -0.1370 --       
15. Chain affiliation -0.1582 -0.1266 0.4451 --      
16. Freestanding -0.1124 -0.1426 0.7109 0.5093 --     
17. Urban location 0.1295 -0.1513 0.0268 -0.0063 0.0510 --    
18. Facility age 0.0961 0.0183 -0.3212 -0.1131 -0.2664 0.1085 --   
19. Facility size 0.1416 0.0184 -0.0459 -0.0064 0.0526 0.3056 0.3865 --  
20. HD Occupancy  0.1158 0.0335 -0.1050 -0.0339 -0.0435 0.1384 0.2810 0.5853 -- 
21. Ownership change  -0.0230 0.0152 0.0724 0.0120 0.0667 0.0003 -0.0340 -0.0018 0.0194 
 
Table 9.  Q2 correlations matrix of model variables (continued) 
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 Eleven correlations in Table 9 were particularly strong (r> .500).  Of these, 3 related to the 
amount of healthcare resources available per HRR (i.e., healthcare density), which was addressed 
earlier in the design of this study.  The remaining 8 correlations of concern included the proportions 
of white, non-Hispanic ESRD and the average number of reported co-morbidities (r= .679) and the 
percentage of employed (r= .560) ESRD patients in a HRR.  Average HRR co-morbidity was also 
correlated with the amount of employment (r= .688) and Medicare-dual coverage (r= .700) among the 
ESRD patient population.  Percentage of urban residents in a HRR was positively correlated with per 
capita income (r= .616) and dialysis facility urban location (r= .502).  Freestanding facilities were 
likely to be for-profit owned (r= .711) and chain-affiliated (r= .509).  Lastly, facility size was highly 
positively correlated with facilities’ HD station occupancy rate (r= .585).  These high correlations 
may cause mutlicollinearity and bias in multivariate results.   To examine this, various GEE models 
were run – with and without multicollinearity-threatening variables.   If multicollinearity exists due to 
high correlation of these specified variables, there would be significant reduction in the standard 
errors of covariates when the selected variables were removed from the model.  Results of these 
models are shown in Appendix C.  Although the standard errors in the full and tested models are 
different, the changes were minimal, indicating no immediate concern of multicollinearity.  Based on 
these findings, no explanatory or control variables were eliminated in the GEE model. 
 Multivariate Analysis.  Tests of the effects of market conditions on PD service availability, 
modeled using GEE, are shown in Table 10.  Specification tests were performed to assess the 
appropriateness of model type.  Intraclass correlations (ICCs) determined the extent to which 
correlation of facilities within markets would affect model estimates and standard errors (not shown).  
Since the ICC from the full model could not be obtained by either the SAS PROC GLIMMIX [207] 
or the gllamm procedure in Stata [213] (presumably due to lack of convergence from little, if any, 
variation in facilities’ PD services over time), the ICC from the unconditional model of just the 
dependent variable was examined.  The ICC from the unconditional model indicated that only 8.9% 
of the variation in PD service was explained by markets.  Given the large number of market-level 
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covariates in the full model, the ICC was expected to decrease and not affect model estimates.  The 
GEE model that accounts for correlation of repeated facility-level measures was therefore adequate.  
Wald tests were used to determine the joint significance of groups of covariates in the model.  The 
entire group of market-level covariates – ESRD patient population attributes and general market 
characteristics – were all jointly significant (χ2 ≥ 92.93, p< .001).  The group of facility-level control 
variables were also significant (χ2= 422.51, p< .001), indicating adequate model fit. 
Dialysis facilities’ likelihood of offering PD were expected to increase in markets with a 
large patient base, with populations of patients appropriate for PD, and whose general conditions 
were conducive to increasing volume of services and sustaining alternative modes of dialysis 
treatment.  Tests of individual covariates indicated that general market conditions dominate ESRD 
patient-driven demand in facilities’ likelihood of offering PD.  Three of the 6 ESRD-patient-specific 
market covariates were statistically significantly associated with the provision of PD services.  
Contrary to expectations derived from location theory, facilities’ PD service availability was 
negatively associated with ESRD prevalence (β= -.011, p< .05) and the proportion of employed 
ESRD patients (β= -.998, p< .01).   Consistent with H2, offerings of PD among dialysis facilities was 
positively associated with the proportion of white, non-Hispanic ESRD patients in a HRR (β= .204, 
p< .01). 
 All 4 general attributes of HRRs significantly predicted dialysis provider organization’s 
likelihood of having PD, but not all in the ways I had anticipated.   In accordance to concepts from 
location theory, the percentage of urban residents (β= .073, p< .10) and per capita income (β= .032, 
p< .05) of HRR residents was positively associated with PD availability.  Contrary to my hypotheses 
of HRR healthcare market attributes, density of referral sources (i.e., healthcare density, β= -.119, p< 
.01) and dialysis market competition (β= .585, p< .10) were both negatively associated with facilities’ 
decision to offer PD. 
 Several control variables of dialysis provider organizational attributes were also significant.   
Facility location in urban settings (β= .284, p< .01) and age (i.e., the number of years of participation 
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in the Medicare program) is positively associated with PD availability (β= .043, p< .01).  Chain-
affiliated facilities were less likely to offer PD (OR= .592, β= -.524, p< .01) than independently 
owned dialysis units.  And although increasing patient load (facility size, β= .217, p< .01) increased 
the likelihood of facilities to offer PD, increases in the occupancy rate of HD stations did not (β= -
.202, p< .01). 
Table 10.  Q2 GEE results 
Depend var:  PD Service   N=27,497      
Covariate (one-year lagged value) OR† β S.E. χ2 
Market-level characteristics (HRR)    92.93*** 
ESRD patient-specific    48.37*** 
ESRD prevalence .989 -.011** .005  
% White, non-Hispanic (10s) 1.226 .204*** .054  
% Non-elderly (10s) .941 -.061 .122  
Comorbid conditions .977 -.023 .166  
% Employed (10s) .369 -.998*** .184  
% With Medicare dual coverage (10s) 1.157 .146 .113  
General    26.16*** 
% Urban population (10s) 1.076 .073* .037  
Per capita income (1,000s)  1.032 .032** .014  
Healthcare density  .888 -.119*** .044  
Dialysis market competition  1.795 .585* .304  
Facility-level characteristics    422.51*** 
For-profit ownership 1.010 .010 .116  
Chain-affiliation .592 -.524*** .081  
Freestanding facilities 1.043 .042 .124  
Urban location 1.329 .284*** .103  
Facility age 1.044 .043*** .006  
Facility size (10s) 1.242 .217*** .017  
HD station occupancy rate (10s) .817 -.202*** .014  
Ownership change, during year 1.097 .092 .079  
* p<.10      **p<.05      ***p<.01 
† Odds ratios do not lend useful interpretation for continuous covariates and are therefore not presented in this 
table.  Marginal effect interpretation of statistically significant continuous covariates are presented in the text.   
Note: Selected covariates were rescaled (denoted in parens) to produce meaningful coefficients. 
 With any non-linear regression, the marginal effects of the probability of facilities to offer PD 
are not constant and differ across the distribution of covariate values.  Upon examining the magnitude 
of these effects at each covariate’ distribution mean, I found the marginal effects of the significant 
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covariates’ effects to be rather small (Table 15). Among variables with more than a difference of 
Pr=.02, a 10 percentage point increase in white, non-Hispanic ESRD patients in a HRR results was 
associated with a .04 average increase in the probability of a facility offering PD, ceteris paribus.  
Strikingly, the larger marginal effects were found in dialysis providers’ organizational attributes.  
Chain affiliation decreased the probability of PD availability in a facility by an average of .106.  The 
probability of PD availability in urban dialysis facilities was .06 greater than facilities in non-urban 
areas.  Facilities that increase their patient load by 10 patients had an average .048 increased 
probability of offering PD.  However, increasing HD occupancy by 10 percentage points was 
associated with .037 a reduced probability of offering PD, on average. 
 
Effect of Geographic Concentration of PD Availability on Provision of PD Services 
 Much like PD services, the geographic dispersion of PD, measured by the NNI, varied 
temporally and geographically.  Over the entire study period, 140 facilities were located in HRRs 
with no PD services available.  These observations, representing only .5% of the analytic sample from 
the previous multivariate analysis (Q2), were subsequently dropped from the sample.  Of the 
remaining 27,305 facility-year observations with complete information on covariates, the mean NNI 
for facilities’ HRRs was .74 (Table 11), indicating a somewhat concentrated regional distribution, but 
with wide variance (s.d.= .47) and range of values (0, 5.02).  Examining facility-year average NNI by 
year (Figure 15) it appeared that, contrary to my hypothesis, PD services were more dispersed in 
markets over time.   
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Table 11.  Q3 descriptive statistics of covariates, overall (facility-year) 
Covariate (one-year lagged value) 
N=27,305 
Freq (%) Mean S.D. Min Max 
Dep var: Any PD service, % 48.11     
Market-level characteristics (HRR)      
ESRD patient population      
ESRD prevalence (per 10,000)  20.85 9.33 3.38 80.90 
% White, non-Hispanic  27.93 15.49 1.45 72.94 
% Non-elderly  59.69 5.04 31.61 75.07 
Comorbid conditions  1.27 .46 1.34 2.86 
% Employed  6.72 3.45 0 19.33 
% With Medicare dual coverage  9.36 4.94 0 34.15 
General population      
% Urban population  77.31 16.87 26.80 100 
Per capita income   22,929 4,647.55 9,003 47,841 
Hospital bed density  4.78 18.37 .002 146.32 
Nephrologist density  .04 .19 0 1.56 
Healthcare density *  .003 1.00 -.25 7.02 
Dialysis market competition  .12 .14 .01 1 
Geographic dispersion of PD  .76 .47 0 5.02 
Facility-level characteristics      
For-profit ownership, % 74.86     
Chain-affiliation, % 65.07     
Freestanding facilities, % 79.99     
Urban location, % 75.95     
Facility age  9.49 7.25 .04 25.25 
Facility size   69.09 53.67 0 494 
HD station occupancy rate  56.61 26.80 0 100 
Ownership change, % 4.91     
* Healthcare density is a composite measure of regional supply of hospital beds and nephrologists per square mile.  
For illustrative purposes, hospital bed and nephrology physician densities are presented. 
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Figure 15. Trend of annual spatial dispersion of PD services 
over all HRRs (overall mean, one-year lagged value) 
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Choropleth maps of annual NNI show that dispersions vary by region (Figure 16).  It appears 
that NNI may be related to the amount of PD availability in HRRs.  When comparing the geographic 
distribution of NNI (Figure 16) to earlier choropleth maps of PD service distributions (Figures 9 and 
10), those HRRs with extreme numbers or percentages of PD services (i.e., the lowest and highest 
categories of availability) were also HRRs with extreme NNI.  For example, the darker shading in the 
numbers and proportion of PD facilities in HRRs in Figures 9 and 10 are the less clustered, more 
dispersed markets for PD in Figure 16.  
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Figure 16. Spatial concentration of PD facilities, by HRR: 1995, 1999, 2002* 
1995
1999
2002
Legend
No PD Facility
High concent (NNI = 0)
Med concent (0 > NNI > 0.50)
Low concent (0 > NNI > 1.0)
Dispersion (NNI > 1)
* Each year of lagged covariates were used to predict PD service availability in the next year. 
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 Bivariate analysis demonstrated that facilities with no PD services were, on average located 
in markets where PD services had a more concentrated geographic distribution than the average 
facility offering PD (NNI= .72 and .80, respectively, Table 12).  Inspection of the correlation matrix 
(Table 13) from this new sample did not reveal any new trends.  
Table 12.  Q3 descriptive statistics of covariates, by PD service availability (facility-year) 
Covariate (one-year lagged value) 
Facilities with no PD 
N=14,168 
 Facilities with PD 
N= 13,137 Sig Diff 
Mean S.E. Mean S.E. 
Market-level characteristics (HRR)       
ESRD patient-specific       
ESRD prevalence (per 10,000) 21.12   .08    20.56   .08   * 
% White, non-Hispanic 27.78   .12    28.09  .13    
% Non-elderly 60.13 .04  59.22 .05 * 
Comorbid conditions 1.29 .004  1.25 .004 * 
% Employed 6.96 .03  6.46 .03 * 
% With Medicare dual coverage 9.48 .04  9.24 .04 * 
General population       
% Urban population 75.75 .14  78.99 .14 * 
Per capita income  22,446 37.58  23,450   41.66 * 
Hospital bed density 4.23   .15    5.38   .17   * 
Nephrologist density .04   .002    .05   .002   * 
Healthcare density a -.02   .008    .03   .009   * 
Dialysis market competition .11 .001  .13 .001 * 
Geographic dispersion of PD .72   .004    .80   .004   * 
Facility-level characteristics       
For-profit ownership, % 78.25   71.20  * 
Chain-affiliation, % 70.53   59.17  * 
Freestanding facilities, % 81.99   77.83  * 
Urban location, % 68.44   84.05  * 
Facility age 7.79 .06  11.33 .07 * 
Facility size  51.60 .33  87.94 .53 * 
HD station occupancy rate 54.21 .22  59.18 .24 * 
Ownership change % 4.86   4.98   
* p< .01   Differences detected by t-test for continuous variables and Chi-square test for dichotomous variables.   
a Healthcare density is a composite measure of supply of hospital beds and nephrologists per HRR square mile.  
For illustrative purposes, hospital bed and nephrology physician densities are presented. 
Table 13.  Q3 correlation matrix of model variables 
N=27,305 1 2 3 4 5 6 7 8 9 10 11 
1. PD Service 1.0000           
2. ESRD prevalence -0.0303 --          
3. % White, non-Hisp 0.0104 -0.2371 --         
4. % Non-elderly -0.0909 -0.0694 -0.3951 --        
5. Comorbid conditions -0.0436 0.1059 0.6802 -0.2522 --       
6. %  Employed -0.0716 0.0008 0.5591 0.0518 0.6879 --      
7. % Dual coverage -0.0239 0.1148 0.4810 -0.1210 0.7014 0.3985 --     
8. % Urban population 0.0960 0.2594 -0.2623 -0.1191 -0.1624 0.0748 -0.2728 --    
9. Per capita income 0.1080 0.0914 -0.0966 -0.1886 -0.2182 0.0753 -0.2259 0.6148 --   
10. Hospital density 0.0311 0.3245 -0.1977 0.0488 -0.1239 -0.0652 -0.0325 0.3089 0.3620 --  
11. Physician density 0.0217 0.2721 -0.1658 0.0377 -0.0889 -0.0330 -0.0014 0.2805 0.3560 0.9679 -- 
12. Healthcare density 0.0270 0.2998 -0.1841 0.0441 -0.1097 -0.0521 -0.0192 0.2974 0.3636 0.9942 0.9874 
13. Dialysis market compet. 0.0670 -0.2680 0.2122 -0.0524 -0.0157 -0.0676 -0.0725 -0.3472 -0.2062 -0.1249 -0.1228 
14. Geographic dispers., PD 0.0852 0.0185 0.0499 -0.1370 0.0606 0.0473 0.0805 -0.0155 0.1833 0.0391 0.0357 
15. For-profit -0.0812 0.0913 -0.0423 0.0187 0.0932 0.0263 0.0514 0.0584 -0.0981 -0.1123 -0.1053 
16. Chain affiliation -0.1191 0.0900 0.1137 -0.0039 0.2353 0.1707 0.1720 -0.0510 -0.1363 -0.1624 -0.1512 
17. Freestanding -0.0519 0.1013 -0.0529 0.0544 0.0821 0.0103 0.0729 0.0349 -0.1083 -0.1163 -0.1071 
18. Urban location 0.1825 0.1284 -0.1185 -0.0668 -0.0852 0.0072 -0.1379 0.5002 0.3331 0.1345 0.1218 
19. Facility age 0.2443 0.0789 0.0249 -0.0231 0.0580 0.0697 0.0474 0.0582 0.0723 0.0987 0.0928 
20. Facility size 0.3383 0.0941 -0.1254 0.0076 -0.0454 -0.0094 -0.0366 0.1992 0.1531 0.1485 0.1316 
21. HD Occupancy  0.0926 0.0337 -0.0305 -0.0381 -0.0320 0.0307 -0.0420 0.1523 0.1506 0.1213 0.1078 
22. Ownership change  0.0028 -0.0315 -0.0238 0.0010 -0.0324 -0.0454 -0.0406 -0.0026 -0.0097 -0.0223 -0.0239 
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N=27,305 12 13 14 15 16 17 18 19 20 21 
13. Dialysis market compet. -0.1250 --         
14. Geographic dispers., PD 0.0375 -0.1422 --        
15. For-profit -0.1103 -0.1384 -0.0235 --       
16. Chain affiliation -0.1591 -0.1244 -0.0036 0.4454 --      
17. Freestanding -0.1132 -0.1464 -0.0398 0.7123 0.5109 --     
18. Urban location 0.1294 -0.1503 -0.0147 0.0251 -0.0060 0.0485 --    
19. Facility age 0.0962 0.0199 0.0429 -0.3222 -0.1135 -0.2687 0.1077 --   
20. Facility size 0.1415 0.0208 0.0512 -0.0461 -0.0067 0.0514 0.3048 0.3859 --  
21. HD Occupancy  0.1159 0.0342 0.0615 -0.1051 -0.0340 -0.0439 0.1374 0.2813 0.5857 -- 
22. Ownership change  -0.0232 0.0161 -0.0067 0.0728 0.0124 0.0667 -0.0005 -0.0345 -0.0021 0.0197 
 
Table 13.  Q3 correlation matrix of model variables (continued) 
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 The multivariate model produced little change when the dispersion variable was added to the 
model.  For comparison, both sets of model estimates and marginal effects (simulated at the mean of 
each covariate’s distribution) are reported in Tables 14 and 15, respectively.  Although coefficients 
and standard errors were different, the majority of the changes were minimal.  Significant change 
occurred in the parameter estimates of the general market-level variables and dialysis units’ structural 
attributes.  The addition of PD geographic dispersion increased parameter estimates of percentage of 
urban residents (from β= .073, p< .10 to β= .113, p< .01), but significantly more for dialysis market 
competition (from β= .585, p< .10 to β= 1.189, p< .01).  Moreover, the effect of per capita income 
becomes non-significant in predicting PD service availability (from β= .034, p< .05 to β= .019, p= 
.23).  Estimates of most facilities’ organizational attributes increased after including the measure of 
spatial dispersion and given minimal change in these parameters’ standard errors, statistical 
significance was not affected.  Despite the differences in these estimates, there was little impact on 
the magnitude of their marginal effects (Table 15).   
 Geographic dispersion of PD services was statistically significant (β= .457, p< .01), and this 
relationship is consistent with my hypothesis.  The value of NNI increased as PD services were less 
more dispersed (or less concentrated) in a market.  Thus, the positive sign on the coefficient indicated 
that as markets became less concentrated in a HRR, facilities were more likely to offer PD services.  
Simulating the marginal effect at the sample distribution’s mean, a 1 standard deviation increase in 
NNI (i.e., more dispersion) was associated with an average increase of .043 in the probability of PD 
service availability, ceteris paribus (Table 15). 
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Table 14.  GEE results from Q2 and Q3 models  
Depend var:  PD Service   N=27,305  Q2 Model 
 
N= 27,497 
 Q3 Model 
(with geographic concentration) 
N= 27,305 
Covariate (one-year lagged value) β S.E.  β S.E. χ2 
Market-level characteristics (HRR)      132.89*** 
ESRD patient-specific     46.99*** 
ESRD prevalence  -.011** .005 -.011** .005  
% White, non-Hispanic (10s) .204*** .054 .221*** .059  
% Non-elderly (10s) -.061 .122 -.018 .119  
Comorbid conditions -.023 .166 -.078 .168  
% Employed (10s) -.998*** .184 -.996*** .189  
% With Medicare dual coverage (10s) .146 .113 .158 .123  
General     54.69*** 
% Urban population (10s) .073* .037 .113*** .040  
Per capita income (1,000s)  .032** .014 .017 .014  
Healthcare density  -.119*** .044 -.115*** .036  
Dialysis market competition  .585* .304 1.189*** .308  
Geographic dispersion of PD   .457*** .097  
Facility-level characteristics     411.44*** 
For-profit ownership .010 .116 -.006 .118  
Chain-affiliation -.524*** .081 -.542*** .081  
Freestanding facilities .042 .124 .085 .127  
Urban location .284*** .103 .307*** .105  
Facility age .043*** .006 .043*** .006  
Facility size (10s) .217*** .017 .220*** .017  
HD station occupancy rate (10s) -.202*** .014 -.210*** .015  
Ownership change, during year .092 .079 .092 .080  
* p<.10      **p<.05      ***p<.01 
Note: Selected covariates were rescaled (denoted in parens) to produce meaningful coefficients. 
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Table 15.  Marginal effects of independent covariates, by model 
  Q2 Model  Q3 Model 
Covariate  Unit increase ME  ME 
Market-level characteristics (HRR)    
ESRD patient-specific    
ESRD prevalence  10 (per 10,000) -.022  -.022 
% White, non-Hispanic  10% .040  .043 
% Employed 1% -.020  -.020 
General     
% Urban population 10% .015  .022 
Per capita income $1,000 .006  -- 
Healthcare density 1 SD   -.023  -.022 
Dialysis market competition  1 SD .000001  .0008 
Geographic dispersion of PD 1 SD --  .043 
Facility-level characteristics     
Chain-affiliation 0 to 1 -.106  -.108 
Urban location 0 to 1 .057  .057 
Facility age 5 years .044  .045 
Facility size 10 patients .048  .048 
HD station occupancy rate 10% -.037  -.038 
Note: Marginal effects represent the average change from each covariate’s average probability of offering PD 
services, given a unit increase from the mean for statistically significant model estimates (p<.10) presented in 
Table 14. 
 In summary, this chapter presented results from analyses examining factors associated with 
the availability of PD services among dialysis facilities in the US between 1995 and 2003.  A profile 
of the US market for dialysis services was presented, describing the characteristics of dialysis 
provider organizations, the availability of PD services, and regional markets for dialysis services.  In 
any given year during the study, less than half of all dialysis provider organizations in the US offered 
PD.  Using GIS mapping techniques, further exploratory analysis revealed that the availability of PD 
services varied, both temporally and geographically, throughout the study period.  The increasing 
incongruities between HRR-level ESRD patient characteristics and PD service offerings suggested 
that the variations in PD services did not appear to be fully explained by ESRD patients’ factors of 
demand.   
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 Bivariate analyses revealed differences between facilities that chose to provide PD versus 
facilities which did not.  Most differences in HRR-level and organizational attributes were 
statistically significant, though small in magnitude.   The most significant differences were found in 
the non-ESRD-specific characteristics of regional markets.  Correlations between PD service 
availability and characteristics of HRRs were both consistent and divergent from hypotheses 
developed from location theory.  Several high correlations raised the concern of multicollinearity, 
threatening the results of subsequent multivariate models.  Factor analysis was used to address the 
extremely high correlation between hospital and physician density, by generating a composite 
measure of healthcare density.  Specification testing of the remaining indicators found little impact of 
other highly correlated explanatory variables.  Thus, all variables were included in the GEE model.   
 Of the 12 hypotheses developed from concepts from location theory (1 unsupported 
hypothesized trend and 11 hypothesized associations), only 7 were found to be significant predictors 
of dialysis provider organizations’ PD service offerings.  Of these 7, only 3 of the hypothesized 
relationships were supported by multivariate analyses.  With minor exceptions, the marginal effects of 
the significant predictors of PD service availability were generally small in magnitude.  A summary 
of results from the hypothesis tests is provided in Table 16.  Discussion of these findings and their 
implications on health policy and practice follow in the next chapter.   
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Table 16. Summary of hypothesis tests 
Market characteristics Hypothesized effect on 
PD service availability 
Result 
ESRD Patient Population   
H1. ESRD prevalence + - 
H2. Percent white  + + 
H3. Percent non-elderly  + Ø 
H4. Co-morbid conditions - Ø 
H5. Percent employment + - 
H6. Percent with Medicare dual-coverage   + Ø 
General Population   
H7. Percent urban + + 
H8. Per capita income + Ø 
H9. Healthcare density + - 
H10. Dialysis market competition + - 
H12. Geographic dispersion of PD         + + 
 
CHAPTER 7 
DISCUSSION 
 
ESRD is a significant and emerging, but understudied, issue in healthcare policy.  The ESRD 
population is large and, with increased incidences of obesity, diabetes, and high blood pressure, the 
projected growth in the numbers of Americans with ESRD is significant.  Nearly all the care for 
ESRD is federally-funded by Medicare.  ESRD is currently the only medical condition eligible for 
near-universal coverage by the Medicare program, regardless of age.  Given the limited amount of 
resources available for this growing ESRD population and related concerns about cost and quality of 
ESRD care, it is a surprise that ESRD is a relatively understudied area in health services research.   
Exploration of issues related to ESRD care in the US revealed a thus far inexplicable 
phenomenon in dialysis treatment of ESRD that is the genesis of this study.  The advent of PD 
offered a clinically effective, less expensive, and convenient option in RRT.  Except where clinical 
indicators suggest otherwise, PD may be considered an equivalent or complementary treatment to 
HD.  When presented with the option of PD, most ESRD patients would prefer it.  Physicians report 
that more ESRD patients are appropriate for PD than actual use suggests.  Medicare, the primary 
payer of dialysis services in the US, initiated coverage and payment policies to encourage utilization 
of home-based dialysis therapies, like PD.  Despite its appeal to patients, provider, and payers, PD is 
a highly underutilized treatment for a growing ESRD population in the US.  My review of the extant 
literature found that the majority of studies examine individual determinants, which have not 
adequately explained the puzzling trends in PD utilization.    
Interestingly, relatively little attention has been paid to the role of dialysis provider 
organizations.  Dialysis facilities influence physician and patients’ utilization because it is unlikely 
 
for physicians and their patients to utilize PD if it is not made available to them.  In this way, the 
availability of PD services at the facility-level is an important factor for its use.  In the nearly three 
decades since the FDA approved it for clinical practice and CMS instituted a financial incentive for 
dialysis facilities to treat more dialysis patients with PD, fewer facilities are offering PD services.  A 
few studies have examined dialysis facilities’ provision of PD services, but overlook the manner in 
which PD services are organized and distributed.   
For the most part, PD is an optional service that dialysis providers willingly make available, 
in addition to their HD services.  Since there have been few patients informed or interested in 
dialyzing through PD, there appeared to be more of an imperative for facilities to selectively locate 
their PD services in areas that maximize their revenue and profit.  The difference in the logistical 
implementation between patients’ thrice weekly HD and monthly PD visits to facilities reduced the 
necessity for facilities to locate their PD services within close proximity to their patients, further 
distinguishing their location decisions for PD.  To date, no study has systematically addressed or 
examined the factors associated with facilities’ PD service offerings over time.  This study sought to 
answer basic questions about the availability and geographic distribution of PD services in the US 
over several years.  Where is PD available?  And, does location matter?  Specifically, the study 
sought answers to the following research questions: 
Q1. Where are PD treatment services available in this US?  What is the distribution of 
dialysis facilities’ PD services and how has this distribution changed over time? 
Q2. What is the effect of local market conditions (e.g., competition, provider density, facility 
regulations) on dialysis facilities’ provision of PD services? 
Q3. How and to what degree are dialysis facilities’ PD treatment services concentrated over 
time?  Does concentration of PD services explain the decline of PD availability among 
dialysis facilities? 
Among viable locations for PD, some locations are more favorable than others.  
Modifications from location theory were used to examine the locational distribution and availability 
of PD services.  Developed in industrial economics, location theory posits that the location decisions 
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of firms are driven by the desire to maximize profit.  Firms maximize profit in a variety of ways, and 
this study looked at 2 general approaches to firm location decisions – the least-cost and market area 
approaches.  Under these frameworks, locations with attributes that enable facilities to incur minimal 
production costs and simultaneously maximize revenue for PD services are optimal.   
Considering the lower costs associated with PD provision and Medicare’s fixed pricing 
structure for dialysis services, the declining frequency of PD availability indicates that least-cost 
factors could not adequately account for facilities’ decision to offer a PD service line.  Instead, the 
locational attributes of interest in this study – believed to be conducive to increasing volume, 
sustaining alternative modes of dialysis treatment, and maximizing profit from a PD service line – 
were distilled to market factors of demand and competition.  Concepts from location theory were used 
to develop 12 hypotheses about the relationships between provider organizations’ decision to offer 
PD in their menu of ESRD services and the characteristics of their local markets.   
To test these hypotheses, empirical analysis was conducted on national, longitudinal 
administrative data from CMS and USRDS.  The study sample included all outpatient dialysis 
providers participating in the Medicare ESRD program between 1995 and 2003.  My analytic 
approach incorporated longitudinal and spatial analysis methods, which are underused tools in the 
study of ESRD practice patterns.    
 
Findings 
Q1: Where is PD Available?  Exploratory analysis of GIS mappings revealed that the 
availability of PD services varied temporally and geographically between 1995 and 2003.  For many 
markets across the country, PD service offerings appeared to increase between 1995 and 1999 and 
gradually decline thereafter.  PD services were more numerous in metropolitan cities and the South, 
and less available in the Northwest region and rural areas.  Moreover, no consistent relationships exist 
between the geographic distributions of PD services and ESRD patient characteristics, suggesting that 
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the variation in PD services was not fully explained by the demographic profile of ESRD patients in 
local markets.     
Q2 – Q3: Does Location Matter?  Further empirical analysis revealed that locational 
attributes do matter for dialysis facilities’ provision of PD, but not necessarily in all the ways that 
were hypothesized in accordance to location theory.  Several findings from the bivariate and 
multivariate analyses stand out and are discussed in detail here.   
Patient Populations.  Few patient drivers of demand were significantly associated with PD 
availability.  Based on concepts from location theory, I reasoned that dialysis facilities would locate 
their PD service in markets with a sizable patient base in order to increase the chance of acquiring 
patients appropriate for PD and thus maximize potential revenue and profit.  Results from the 
bivariate and multivariate analyses did not support this hypothesis, but indicated instead that ESRD 
prevalence was negatively associated with facilities’ likelihood of offering PD.  The explanation of 
this finding may lie in the relationships found between ESRD prevalence, PD utilization, and race.  
My bivariate analysis indicated that high ESRD prevalence was correlated with lower proportions of 
white, non-Hispanic patient populations.  A significant, positive association between PD service 
offerings and the proportion of white, non-Hispanic ESRD patients was also found in the multivariate 
model.  Similarly, studies of dialysis modality selection report white, non-Hispanic race and ethnicity 
to be one of the most prominent predictors of PD utilization [29, 32, 120, 185].  Findings from 
Kendix’s cross-sectional analysis also showed the percentage of black patients at facilities to be the 
most significant and largest negative predictor of facility PD offerings among all the ESRD patient 
characteristics examined [122].  All this evidence suggests that dialysis facilities’ locational strategy 
behind PD offerings is not based on overall ESRD market size, but may target PD in markets bearing 
the strongest characteristic of PD use.   
The negative association between the percentage of employed ESRD patients in HRRs and 
PD service availability was somewhat of a surprise, as it contradicts expectations that dialysis 
facilities would choose to offer PD in markets with employed ESRD patients.  Employment is one of 
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the major characteristics of adult patients on PD [29] and it seemed to follow that for dialysis 
facilities, patients’ employment would signal the potential of resources available for co-insurance 
payments as well as private third-party insurance coverage to supplement Medicare coverage.  But 
since employment was low in the ESRD population, with no less than a quarter of ESRD patients 
employed in a HRR during the study period, it is possible that employment is not a significant 
determinant for facilities considering a PD service line.  Instead, the significance of the negative 
coefficient on the patient employment indicator may be driven by facilities’ locational response to the 
growth of PD among pediatric ESRD patients who are not yet of working age.  According to the 
USRDS, 30% of pediatric ESRD patients dialyze through PD (compared to less than 10% among 
adult patients).  Between 2001 and 2005, pediatric patients aged 0 to 19 represent the only ESRD 
patient category exhibiting growth in incident PD utilization [4].  Although this study categorized 
patients into general categories of elderly and non-elderly, the higher proportion of non-elderly 
patients in markets of PD facilities and the positive, albeit low correlation between the proportions of 
non-elderly and employed ESRD patients may reflect a more focused strategy of locating PD in 
markets with high pediatric dialysis demand.   
 Market Characteristics.  Of all the market-level characteristics examined, general population 
attributes dominated ESRD-patient factors in facilities’ likelihood of offering PD.  In fact, almost all 
the general population market characteristics in this study were significant in bivariate and 
multivariate analyses.  Results not only confirmed the hypothesis that facilities were more likely to 
locate PD services in locations with higher proportions of urban residents, but also demonstrated that 
facilities, themselves located in metropolitan areas, were more likely to offer PD than dialysis 
facilities in non-urban areas.  These results echo Schlesinger and colleagues’ finding that facilities 
with patients on PD were more likely to be located in regions with high population density [118] and 
findings from O’Hare’s study, which found dialysis providers in rural locations to be less likely to 
offer PD than urban facilities [123].  Since prior research has shown that most ESRD patients and 
health care providers are located in urban markets [1, 128, 131, 132, 134], it is not a surprise that 75% 
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of all dialysis facilities in this longitudinal study were located in metropolitan areas.  However, the 
higher frequency of PD offerings in urban facilities is significant.  It is possible that the findings 
reflect the notion that patient proximity and travel to facilities may not be an important factor for 
facilities in locating their PD services.  The less frequent visits required for PD maintenance may not 
preclude rural ESRD patients from receiving PD in urban locales.  At the same time, facilities with 
PD services in urban locations benefit from proximity to most patients and complementary healthcare 
services (e.g., physician services, cardiac, and tertiary care).    
 Contrary to expectations, PD was less likely to be available in HRRs with a high density of 
hospitals and nephrologists. This result is similar to results from Kendix’s cross-sectional study which 
revealed a negative association between provider density and PD availability [122].  Still, these 
results are baffling because hospitals and physicians tend to be located in urban areas and urbanicity 
was positively associated with dialysis facilities’ PD offerings.  Bivariate results from this study 
found 1) facilities with PD to be in markets with more hospitals and nephrologists per square mile on 
average than facilities not offering PD and 2) a positive correlation between PD service availability 
and density of healthcare markets.  The negative coefficient from the multivariate model shows that 
when taking other market and facility characteristics into account, markets with higher density of 
healthcare providers were actually less likely to offer PD.  One interpretation of this finding is that 
facilities may be responding to healthcare providers’ referral patterns.  Healthcare-dense markets tend 
to be in urban areas with more non-white, ethnic minorities.  Further testing found significant 
differential effects of healthcare density on facilities’ PD availability between healthcare providers in 
“white” versus “non-white” markets.  Specifically, stratified analysis of markets in white and non-
white markets (dichotomized at the mean and 1 standard deviation above the sample mean of percent 
white) was performed using the multivariate model from Q2.  Healthcare density was a statistically 
significant and negative predictor of facilities’ PD service availability in “non-white” markets, but not 
statistically significant in “white” markets.  It is thus possible that dialysis facilities are responding to 
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providers in these markets, who may not recommend PD to patients that are less suitable for it, such 
as African American and older, sicker patients.   
Other possible explanations for the significant, negative association of healthcare density on 
PD services cannot be readily tested with the data from this study.  Late detection of ESRD and late 
referral of patients to dialysis often results in HD use.  Since ESRD patients typically remain on their 
initial modality, the negative coefficient in healthcare provider density may reflect providers’ 
avoidance of PD to limit the “sunk costs” associated with a modality switch from HD (e.g., costs and 
procedures related to establishing vascular access) or the investment required for PD training [122].  
Alternatively, the hypothesized positive relationship between healthcare density and PD availability 
assumes that providers are trained and knowledgeable in PD.  The negative coefficient on healthcare 
density in the results may indicate otherwise.  Considering the reported lack of education and training 
of PD in clinical fellowship programs [13, 31, 111, 112], it is possible that facilities’ PD services 
reflect a paucity of healthcare providers skilled enough to educate and provide patients with PD care.  
Based on concepts from market and spatial competition, I hypothesized dialysis facilities’ PD 
service availability to be an outgrowth of competition in the market for dialysis services.  In an effort 
to differentiate themselves from and compete with rival facilities in a growing dialysis industry, I 
expected to find a positive association between dialysis facilities’ PD service offerings and market 
competition for dialysis services.  Results from the analyses did not support this hypothesis.  While 
the magnitude of the effect is small, the Herfindahl index’s positive coefficient indicates that PD 
services are more likely to be offered in facilities located in less competitive, more monopolistic 
markets.  This finding is similar to earlier, though non-significant results of Schlesinger and 
colleagues [118] and the significant findings of CAPD services by Kendix [122], which altogether 
suggest that dialysis facilities do not compete on non-price factors via PD services.  Kendix offers 
plausible explanations for the positive coefficient on the Herfindahl index that extend to this study.  
Facilities may regard training patients to use PD as an investment.  If there are few facilities in a 
market, PD patients are more likely to remain with the facility where they have trained.  In 
98 
competitive or large markets of PD providers, trained patients may be lured away from their training 
facility, providing less of an incentive for facilities to offer PD.  Similarly, a facility in a small, 
monopolistic market has the potential of using its market power to generate profit from PD, which 
increases the likelihood of offering PD [122].   
Concepts from market and spatial competition theories also informed previously untested 
hypotheses about the geographic concentration of PD services over time.  I argued that the case of PD 
represented a modification to the Hotelling effect, where spatial concentration arises from increasing 
and unmet demand for a service and firms’ tendency to locate in a market’s central location of 
demand.  Prior research and anecdotes suggested that low utilization for PD made it less feasible for 
some facilities to offer PD services, resulting in a concentration of PD services in markets over time.  
Thus, I expected to find 1) a trend of geographic concentration of PD services over time and 2) for 
this trend to explain the decline in facilities’ PD offerings.  Results of the descriptive analysis did not 
support my hypothesized trend.  Contrary to claims and anecdotes, facilities’ PD services were 
spreading apart.  Since this geographic dispersion occurred at a time of low and declining utilization 
of PD [4] and if utilization is a proxy for demand, then this finding is actually consistent with the 
conditions and process originally described by Hotelling.   
Relatedly, results from the multivariate analysis indicated that PD services were more likely 
offered by facilities in markets with spatially dispersed distribution of PD services.  Considering the 
inverse of this association, the finding seems to confirm claims that as markets for PD became 
spatially concentrated, facilities were less likely to offer PD.  Although this result is consistent with 
my hypothesis, it does not follow my rationale behind it.  It’s not a trend in geographic concentration, 
but rather dispersion of PD within markets over time that is influencing PD availability.  The 
significance of geographic dispersion in the GEE model suggests that facilities providing PD service 
99 
are further dispersed in HRRs.5  Explanations for facilities’ PD offerings in less competitive, more 
monopolistic markets (i.e., dialysis market competition, Herfindahl index measure) might also apply 
here in markets with geographically dispersed PD services.   
 
Non-Significant Findings 
Several market characteristics, specific to the ESRD patient population, were not significant 
predictors of PD services.  The non-significant results of the proportion of non-elderly ESRD patients 
in HRRs differs from Schlesinger and colleagues [118] who found facilities with patients on PD were 
more likely to be located in regions with non-elderly population.  However, Schlesinger’s study 
design was cross-sectional and used data from the early 1980s.  The nature of ESRD, its patient 
population, and treatment have changed since then.  Such changes have been captured in this more 
recent, longitudinal study.   Still, it is possible that the ESRD patients’ age was too broadly defined 
into proportions of elderly and non-elderly.   Taking into account 1) the largest growth in PD 
utilization is in ESRD patients <20 years old, 2) the average ESRD patient is 58.6 years old, and 3) 
the growth in numbers of ESRD prevalent populations aged 45 to 64 [4], facilities may be locating 
their PD services to more targeted ESRD age groups.  Measures of ESRD patients’ comorbidity and 
Medicare dual coverage were particularly troublesome for a few reasons.  Due to the source and 
process of patient data in the MER, the accuracy of this data varies widely.  Since facilities and 
physicians are required to complete the MER only in cases where a patient begins a new treatment 
modality or treatment at a new facility, report of patients’ comorbidities and insurance may not 
capture important changes in patients’ status in these modifiable characteristics (i.e., compared to 
time invariant characteristics such as age, race).  However, this is the best and the only known source 
of comprehensive data on dialysis patients at the national level.  Aggregation of these minimally 
                                                 
5 It was also possible that facilities’ decision to offer PD is associated with its distance to the nearest facility 
offering PD services (cross geographic boundaries).  Measurement of each facility’s distance to nearest PD 
facility was generated and was not found to be a significant factor in the longitudinal GEE models.   
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variable patient characteristics at the HRR market-level may have further reduced the amount of 
variation in each factor, affecting their significance in the multivariate GEE model.   
 
Limitations  
Weaknesses are inherent in any empirical analysis, and this study is no exception.  Several 
methodological and conceptual limitations are presented here and motivate suggestions for 
improvements in future research.     
The small effect size may also be due to aggregation of market characteristics at the HRR 
market-level, suggesting the presence of the study’s first limitation: market-level characteristics in the 
study are sensitive to area definition.  While much research is limited to available data and area is 
common defined at the county-level in health services research, one benefit from the numerous data 
sources for this study was the ability to use alternative area definitions that better approximate PD 
service areas.  However, a potential source of error known as the modifiable areal unit problem 
(MAUP) may arise, where definitions of market area may differentially impact analytic findings.  
There are two principle components of MAUP, scale and zone effects [214, 215]. Scale effects refer 
to variation in the numerical results due to the number of zones analyzed (e.g., 3077 counties versus 
306 HRRs in the US).  Zone effects occurs when the variation in results arise from aggregating small 
areas into larger units.   
In this study, different definitions of markets for PD services were considered.  It has been 
argued that counties are geopolitical boundaries that may not adequately reflect health service use, 
especially for Medicare or PD services [16].  Hospital service areas were equally problematic since, 
in terms of size, they approximate counties.  The larger size of HRRs better reflects the PD patients’ 
cross-county travel to dialysis facilities and the geographic extent of tertiary care for Medicare ESRD 
beneficiaries [16], but may be too large.  Short of creating my own geographic market for PD 
services, no established geographic definition is an exact fit for this study.  Thus, recognition of zone 
effects is imperative in interpreting this study’s analytic results.  MAUP scale effects may be found in 
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market designations at the county-, health service area-, or HRR-level.  Zone effects may be found in 
ARF-derived variables, which were partitioned from the county-level to zip code and aggregated 
from the zip-level to HRRs.  This zonal effect may exacerbate ecological fallacy, or the assumption of 
homogeneity in aggregate data at the HRR-level.  Together, the effects of MAUP influence the 
geographic trends described in Q1 and the variation, sign and statistical significance of market-level 
characteristics in the multivariate models from Q2-3.  A sensitivity analysis, exploring the extent of 
MAUP in the ESRD literature may be conducted in future methodological research with the rich 
dataset created for this study.   
A second limitation of this study lies in the design of the multivariate models, which did not 
explicitly address temporal change.  Operating under the assumption of continually declining PD 
services between 1995 and 2003, the primary interest of this study was to generate population average 
estimates over the entire study period.  However, results from the exploratory analysis in Q1 indicated 
a temporal trend in PD service offerings in the years of the study, where PD availability in markets 
generally appeared to increase in the first half of the study period and then decrease thereafter.  
Moreover, GIS mappings of the bivariate relationships between facilities’ PD services and market-
level ESRD patient characteristics in Q1 only partially examined the extent to which changes in the 
demographic profiles of ESRD patients and regional markets explained temporal and geographic 
patterns of PD provision.  Inclusion of dummy variables for each year of the study period in the 
multivariate model may reveal a significant temporal effect in the results of the multivariate analysis, 
which may also affect the size of covariate estimates.  Temporal change and its effects on facilities’ 
PD service offerings should be addressed in future research.   
Another limitation of the study may arise from the accuracy of reported data and variable 
measurement.  As previously mentioned, patient information gathered in the MER is subject to the 
vagaries of quality in provider documentation and data reporting process for the patient MER.  For 
instance, report of a patient’s race and comorbid condition may be based on information from a 
patient’s medical chart or the memory of the physician completing the MER.  Measurement of 
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operating statistics for dialysis facilities (i.e., size, HD occupancy) are approximations.  For example, 
calculation of facilities’ HD occupancy rate is based on facility report of station size, but also 
assumptions about treatment duration and facility operating hours.  As a result, the measure may not 
reflect unobserved mitigating factors of HD treatments (e.g., longer dialysis sessions, additional 
treatments in a given week, or missed treatments).  These weaknesses in the data may bias the results, 
but in absence of 1) better known sources of longitudinal data on ESRD patients and facilities at the 
national level and 2) established or validated measures in the peer-reviewed literature, these 
limitations are unavoidable.  Results should therefore be interpreted with caution.     
Fourth, omission of several variables in the national datasets could have accounted for some 
variation in my dependent and independent variables.  As previously mentioned, the availability of 
medical personnel (nurses and licensed practice nurses) trained to provide for PD services and the 
location of clinical fellowships that incorporate PD training may explain variations in awareness and 
interest in PD treatment and consequently, facilities’ availability of PD.  In addition, states’ 
certificate-of-need (CON) legislation may limit the availability of PD services in regional markets, 
influencing facilities’ service offerings.  Ford and Kaserman [216] found states’ CON to constrain 
entry and expansion in the dialysis industry in the 1980s, to the detriment of patients’ quality of care.  
Although their analysis examined growth of firms and expansion of HD stations, it may be 
appropriate to extend their conclusions to PD.  Over the years, vigorous debate over the efficacy of 
CON to regulate entry or expansion in local health care markets has resulted in wide variation in 
CON law – some states do not regulate ESRD facilities under CON, some state CON laws oversee 
dialysis facility growth (with varying degrees of specificity), and other states have since repealed their 
CON policies altogether.   Changes in these regulations and the degree of oversight specific to self-
care treatment services may have had variable effects on facilities’ PD programs in the last decade. 
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Implications and Future Research 
In spite of this study’s limitations, results from this study can be pooled together to inform the 
research questions and central concern about dialysis facilities’ role in the provision and 
underutilization of PD for treatment of ESRD.  Implications of these findings on the research, policy, 
and practice as well as directions for future research are discussed here.   
 Research and Theory.  The advent of PD presented a host of potential clinical, logistical, and 
economic advantages to ESRD patients, providers, and payers.  Considering the nature of the dialysis 
industry over the last 2 decades, it was assumed that dialysis facilities would look to offer PD as a 
way to maximize profit and compete with rival dialysis facilities.  Since most patients would prefer 
PD if the option were presented, but do not recall PD discussed as a treatment option, facilities’ PD 
offerings were assumed to be based on potential demand, as opposed to actual utilization.  The 
motivating idea behind the research questions in this study is that facilities, by making PD less 
available over time, have played a role in the underutilization of PD.  The use of location theory and 
hypotheses from the study imply that by making PD services available, facilities induce utilization of 
PD to profit from its service.   
Results from the study suggest that dialysis facilities probably have not been a large influence 
in the underutilization of PD over the last decade.  Contrary to the underlying assumptions of the 
hypotheses in the study, PD availability does not appear to demonstrate facilities’ inducement of PD, 
but rather a response to PD utilization.  Specifically, the locational distribution of PD seems to reflect 
the effect of PD being a scarcely utilized service.6  Facilities’ PD offerings were narrowly targeted to 
ESRD patient populations considered ideal for PD use.  The decreased likelihood of facilities to offer 
PD services in markets with a high density of referring providers may signal facilities’ response to 
providers’ preference and referral patterns against PD.  The geographic dispersion of PD services 
among few facilities within HRRs exhibits the characteristics of PD as an under-demanded service.  
                                                 
6 It is important to realize, however, that in the case of PD, demand is not the same as utilization.  Given low 
levels of awareness of PD treatment for ESRD and since most patients would prefer PD if the option were 
presented, it may not be fair for utilization to serve as a bellwether for need or demand.   
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PD does not appear to be a favorable means of competition with rival firms, as facilities’ investment 
in training a paucity of PD patients may provide less incentive for facilities in competitive markets to 
offer PD services.  Altogether, the factors associated with facilities’ PD offerings during the study 
period are indicative of PD’s status as a minority modality.   
The findings from this study do not demonstrate dialysis facilities’ profit-seeking behavior in 
ways that reflect PD as the less costly and more profitable treatment modality for facilities.  This 
study’s assumption of profit maximization in dialysis facilities’ PD offerings may still be valid, but 
contingent on other factors not examined in this study.  The regional supply of clinical staff trained in 
PD and the availability of dedicated facility space for PD training, patients’ maintenance 
appointments, and storage of supplies affect the costs and decisions for facilities to invest in a PD 
service line.  Moreover, the addition of PD services requires changes in facility operations, staffing, 
and scheduling.  Considering the low, stagnating utilization of PD, facilities facing such challenges 
may be reluctant to endure the start-up and externality costs associated with PD services.     
Furthermore, there may be more behind the locational distribution of PD than profit-seeking 
among dialysis facilities.  It is possible that other providers may influence dialysis facilities’ 
availability of PD services.  In addition to physicians, nurses, and patient technicians trained to 
provide PD treatment for ESRD, suppliers of PD equipment and surgeons play an instrumental role in 
PD utilization.  PD suppliers deliver dialysis equipment directly to the homes of self-dialyzing 
patients.  The location of supply companies’ distribution hubs and their proximity to dialysis facilities 
and patients may influence dialysis facilities’ PD offerings and subsequent patient utilization.  
Similarly, the availability of surgeons, especially those skilled at surgical placement of PD catheters, 
may impact provider referrals to PD and patient outcomes.  The locational distribution of these 
auxiliary providers of PD has largely been ignored in the ESRD literature, but may also explain the 
geographic variation in the PD offerings among dialysis facilities.   
Thus, in light of the evidence from this study, it is still not entirely clear why fewer facilities 
are offering PD services.  My results indicate that the application of location theory may not 
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adequately explain dialysis facilities’ PD service offerings and their role in PD utilization.  Instead, 
there are many other explanations behind facilities’ provision of PD therapies that have not yet been 
studied and warrant consideration in future research.   
Other Theoretical Considerations.  Several facility characteristics were significantly 
associated with PD availability suggesting that facilities’ internal environments matter as much their 
external conditions.  In fact, facility-level attributes had a larger effect on PD service availability than 
market-level conditions in the multivariate models.  Concepts from organizational theory may provide 
additional explanation and perspective, motivating new inquiry on relationships between notable 
organizational-level variables and the decline of PD in facilities over time.  Two specific examples 
are noted here.    
Chain-affiliated facilities were less likely to offer PD services than those that were 
independently-owned.  This finding is consistent with the extant literature [122, 124] and claims that 
consolidation and increased market share of chain organizations in the dialysis industry contributed to 
the decline in PD availability.  One possible explanation is that chains may standardize modalities 
across their facilities, thereby limiting options for affiliated sites to adjust their menu of services to 
their local conditions.  Pozniak showed that indepedently-owned facilities were more likely to 
discontinue non-HD service offerings within 1 to 3 years of acquisition by a chain organization [124].  
Derived from different data, this study tracked the occurrence of any dialysis facility ownership 
change during the study period.  Results showed the frequency of any ownership change to be similar 
to trends in chain-specific ownership changes from Pozniak’s research [124], however, ownership 
change in prior years (1 – 3 years) was not a significant predictor of facilities’ PD service availability.  
Future research, incorporating detailed data on facilities’ affiliation with specific chain organizations, 
may elucidate concerns regarding systematic suppression of PD services by chain-affiliated dialysis 
facilities.  
Facility age was not examined in previous research, but results from this study indicated that 
older facilities were more likely to offer PD.  Age may be an indicator of a facility’s credibility and 
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experience in the dialysis industry, where reputation and trusted relationships developed over time 
may buffer established facilities from the risks of failure from a nascent PD service line.  Age may 
also be an indication of prior experience with PD.  Even though facility experience with PD services 
was not explicitly examined in this study, 69.5% of facilities consistently offered or did not offer PD 
in every year of operation during the study period.  For the 26.5% of facilities that continually offered 
PD in every participating year of the study, it is possible that earlier and longer experience in treating 
PD patients resulted in facility improvements in care and efficiencies in PD services over time.  
Development of such competencies in PD may increase the likelihood of a facility to continue its 
availability.  Conversely, for the 43% of facilities that continually did not offer PD during the study 
period, the specialization and expertise developed in HD services may have inhibited facilities’ 
discovery of PD.  Facilities’ need to justify their investment in HD services may have reinforced this 
competency trap.  By tracking facility experience with PD back to facilities’ initial year of 
participation, further ecological analysis of facilities’ adoption and discontinuance of PD may identify 
path dependent conditions associated with PD offerings over time. 
 Practice and Policy.  Medicare’s near-universal provision of dialysis treatment to an 
increasing population with ESRD in the current health care environment makes ESRD an important 
concern for health practice and policy.  Projected increases in populations with diabetes and 
hypertension, common causes of kidney failure, will raise the number of Americans with ESRD from 
currently half a million to 2 million by the year 2030 [138] and consequently increase federal 
expenditures to care for this emerging ESRD population.  Cost of ESRD care as a proportion of all 
Medicare expenditures is increasing over time.  Given the limited number of kidneys available for 
transplantation, increases in demand and expenditures for dialysis services will further strain 
Medicare’s resources at time of growing concern about Medicare’s solvency.   
The cost constraints in delivery of dialysis care are being realized, as Medicare considers 
implementing fundamental changes to coverage and payment policies for dialysis services and related 
drugs (e.g., erythropoietin) and initiates efforts in early detection and awareness of kidney disease and 
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ESRD in the next few years.  These proposed changes may limit the incentives for providers to 
dialyze patients on HD and spark interest in less costly, alternative lines of therapy such as PD.  
When all societal costs are considered, PD may be less costly than HD.  Starting more patients on PD 
would not only curtail Medicare’s costs considerably [16-19], but would also better align ESRD care 
with patient preferences.  For dialysis providers, increased demand for services will also increase 
staffing demands that accompany HD provision [94].  At a time of nursing shortages and high 
turnover rates of nurses, aides, and patient care technicians, it may make sense for facilities to put 
more effort into increasing the availability of PD services [139].  The results from this study provide 
empirical evidence on the geographic distribution of PD services over time and shed light on some of 
the mechanisms behind its availability, with implications on systemic change in ESRD practice and 
policy.   
Findings on the geographic variation of PD service availability enable health planners to 
determine the extent to which PD is accessible to ESRD patients.  For dialysis facilities, this may 
motivate plans for future growth in PD service availability in shortage areas.  For policy, federal or 
state requirements may ensure patient access to PD services, by making PD available in ways that 
avoid overt limits on HD services but ties its expansion to regions where patients truly have modality 
choice.  Examples include general requirements for PD availability in facilities or the evidence of a 
reasonable proportion of PD use (relative to a given referral base)  before licensure approval for 
expanding HD capacity [10]. 
HD is currently the mainstay of any dialysis facility’s menu of services and PD is generally 
an optional service that facilities add to their HD services.  Results from this study reveal variation in 
locational attributes of US dialysis facilities and their services, suggesting that there is no ideal 
business model for dialysis facilities.  These findings may be used to inform the development of tools 
supporting the availability and implementation of non-HD services.  For facilities considering PD 
services, a business case for PD could be developed, describing facilitators and barriers to adopting 
and implementing successful PD operations.  Moreover, alternative business models for dialysis 
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services may be developed.  The geographic dispersion of PD services found among facilities in 
HRRs in this study implies that PD patients are concentrated (i.e., concentration of patient volume) in 
a few dispersed facilities.  Facilities and policymakers may want to consider the development and 
support of dialysis units specializing in PD services, especially in regions with a dearth of PD 
services.  These specialized PD facilities would provide the expertise and economies of scale 
necessary for profitability and sustainable operations from PD.   
Sustainable PD services will require the necessary healthcare infrastructure for successful 
marketing of PD to ESRD patients and overall management of ESRD care.  Medicare’s recent efforts 
to increase patients’ awareness and education of dialysis treatment options at the physician-level 7 
could be extended to dialysis facilities.  This would include building 1) the tools and processes for 
engagement with patients in pre-ESRD stages and patient education and 2) a system for proactive, 
early identification of ESRD patients eligible for PD treatment.  Formulation of physician and facility 
toolkits for kidney disease prevention and dialysis education that includes discussion of ESRD 
treatment options would also emphasize the importance of modality choice.  As CMS moves toward 
the use of electronic medical record systems, investment in a system that helps providers identify 
potential cases appropriate for PD may be useful, especially in large public or private healthcare 
systems.  Lastly, in order for this infrastructure for PD to operate effectively, it will be important to 
improve the awareness and education of PD to clinicians.  Results from this study suggest the role of 
other healthcare providers in the diminishing availability and utilization of PD.  And considering the 
purported lack of clinical training in PD, it is incumbent on medical and nursing programs to increase 
coverage of PD in their curricula.   
 
                                                 
7 The recent passage of The Medicare Improvements for Patients and Providers Act of 2008 includes a 
provision requiring Medicare coverage of kidney disease education services by qualified providers (excluding 
dialysis facilities) to help Medicare beneficiaries understand all options for renal replacement therapy.   
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Conclusion 
 The results show that dialysis facilities’ PD service offerings varied temporally and 
geographically between 1995 and 2003.  The locational distribution of facilities’ availability of PD 
was not fully explained by ESRD patient characteristics, but also by other characteristics of regional 
markets.  Contrary to my expectations, market conditions that were considered favorable to 
generating revenue and profit from PD services were, in fact, negatively associated with facilities’ 
likelihood of offering PD.  The factors associated with facilities’ PD offerings exhibit the effect of PD 
as a scarcely utilized service, suggesting that there may be more behind the availability of PD than 
profit-seeking among dialysis facilities.  Furthermore, dialysis facilities may play a small or 
insignificant role in the underutilization of PD treatment in the US availability.   
This study is the first longitudinal analysis of dialysis facilities’ provision of PD services.  
While these findings offer no definitive explanation, they provide some clarity on an understudied 
issue.  Despite the advantages of PD to patients, payers, and providers, it is still not clear why fewer 
dialysis facilities are choosing to offer PD.  Evidence from this study and the extant literature indicate 
the declining availability and use of PD seems to reflect a systematic suppression of a useful therapy.  
Further research is needed to improve our understanding of services for PD therapy and ESRD 
practice patterns.  Medicare’s near-universal provision of dialysis treatment to a growing population 
with ESRD in the current health care environment – marked by limited resources, inequalities in 
access and concerns about quality – makes this an important area for research.   
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DATA STRUCTURE FOR ANALYTIC FILE 
 
 
USRDS-FACILITIES        ESRD DISSERT-FACILITIES 
   
  
  
 
 
USRDS-FACILITIES 
 
 
  
 
 
POS  
   
         ESRD DISSERT-FACILITIES-GEOCODING 
 
 
 
 
 
 
  
 
 
 
 USRDS-PATIENTS 
 
USRDS-PATIENTS 
 
 
 
 
 
 
  USRDS-PATIENTS 
   ESRD DISSERT-PATIENTS 
         
 
 
 
  
ANALYTIC FILE 
 
USRDS Provider ID 
CMS Provider ID 
Zip code 
County code 
HSA/HRR code 
USRDS-FACILITY file 
USRDS Provider ID 
USRDS-crosswalk file 
USRDS Provider ID 
CMS Provider ID 
F1a-
F3
Facility-level Data  F6a-c
 
CMS Provider ID 
Street Address 
Zip code 
F5
F4a-b
CMS-POS file 
CMS Provider ID 
Street Address 
F2a-f
Zip code
CMS POS - Geocoded 
CMS Provider ID 
Zip code 
Zips to FIPS crosswalk 
NCHS HSA crosswalk 
HSA/HRR-crosswalk  
Zip code 
County code 
HSA/HRR code
Point location geocode
Aggregated Patient Data 
Zip code 
County code 
HSA/HRR code
P2a-c
USRDS-PATIENTS file 
USRDS Patient ID 
Zip code 
USRDS-MEDEVID file 
USRDS Patient ID 
USRDS-RESIDENC file 
USRDS Patient ID 
Zip code
P3
P5
P1a-d P4
Market Characteristics 
Zip code 
County code 
HSA/HRR code 
M4
ARF data 
County code
M2a-b
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AHA 
data
AMA 
data
M1
M3
 
 Code Program file Description Dataset created 
FACILITIES - USRDS 
F1a merge_facility_idcrosswalk USRDS-FACILITY + USRDS_idcrosswalk merged_facility_idcrosswalk 
F1b recode_merged_usrdsfacility recoding USRDS file formats 
(source: merged_facility_idcrosswalk) 
recoded_merged_usrdsfacility 
F1c facility_diagnostics 9 create subset of data for analysis  
9 Identify and remove errant provider IDs 
(source: recoded_merged_usrdsfacility) 
usrdsfacility9403 
F1d facility_diagnostics_Aug14 9 Identify and create dataset of errant provider IDs  
(source: recoded_merged_usrdsfacility) 
usrdsfacility9403_iderrors 
F1e merge_facilities_all_Aug1_2
006 oscar 
usrdsfacility9403 +  recoded_oscar2006 
9 in/exclusion criteria 
9 identify matched, unmatched cases 
facility_match_Aug1 
facility_nomatch.sas7dbat / .xls 
F1f provid 
diagnostics_unmatched 
cases 
check to see why facilities in USRDS file don’t match to 
OSCAR file…how many of the USRDS facility surveys have 
hospital IDs?  Create master file of matched and unmatched 
cases with problem flags. 
(sources: usrdsfacility9403, facility_nomatch_Aug1, 
liloscar2006) 
more checks on unmatched cases: 
9 any unmatched cases that are hospitals and associated 
with hospital OP units (duplicate entries)? 
9 Any cases of invalid provider ID? 
flag cases of this and note changes to be made 
usrdsfacility_key.xls 
facility_key_inclunmatch_master 
(.sas7dbat & .xls) 
 
 
 
facility_key_inclunmatched_bystat
e 
facility_nomatch_diagnosed 
facility_nomatch_fix.xls / 
.sas7dbat 
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Code Program file Description Dataset created 
F1g provid diagnostics_iderrors Repeat steps in F1f for USRDS facilities where cms_id are 
not all valid (non-numeric and incomplete IDs) 
(sources: usrdsfacility9403_iderrors, usrdsfacility9403, 
liloscar2006) 
facility_key_iderrors_master 
(.sas7dbat & .xls) 
 
facility_iderrors_diagnosed.xls 
facility_iderrors_fix.xls  
                      “      .sas7dbat 
F1h facility_diagnostics_fix facility_nomatch_fix + facility_iderrors_fix  +  
recoded_merged_usrdsfacility 
9 Fix non-matches and id errors as diagnosed in F1f-g 
(above)…merge back with original USRDS facility 
dataset with corrections 
usrdsfacsurv9403 
FACILITIES - OSCAR 
F2a read_oscar[YEAR] read CMS data into OSCAR files, for years 1995-1999 osc09_[YEAR] 
F2b merge_oscar OSCAR files 1995-2006 merged_osc9506 
F2c recode_merged_oscar recoding OSCAR file formats 
(source: merged_osc9506) 
recoded_merged_oscar 
F2d oscar_diagnostics checking IDs and zip codes for anomalies [NONE] 
F2e recode_oscar2006 recoding OSCAR file formats 
(source: osc09_2006) 
recoded_oscar2006 
F2f liloscar_1994 
liloscar_1999 
liloscar_2004 
liloscar_2006 
Create OSCAR files for reference and checking providers 
(sources:  osc01__[YEAR];  osc09_[YEAR]) 
liloscar[YEAR].sas7dbat / .xls 
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Code Program file Description Dataset created 
FACILITIES – ALL SOURCES 
F3 merge_usrdsoscar_facilities 9 Addresses may change over time, so retain as many of 
these changes with annual OSCAR data (1)  
9 Re-merge unmatched cases to 2006 OSCAR file (2) 
9 Combine (1) and (2)  
merged_usrdsoscar_facilities 
F4 geocode_facilities dataset for geocoding in ArcGIS 
(source: merged_usrdsoscar_facilities) 
Gecoding done in ArcGIS (see details) 
geocode_facilitiesYY.xls / .dbf   
 
geocoded_facilitiesYY. 
F5 facilities_zip merged_geofacsurv9403 + merged_zip_walk03 facilities_zip03crossed 
F6a imputations_ownerchanges recoding file for data analysis 
9 new vars: start dates, ownership, change dates, 
termination dates, new provider id’s for analysis, xy 
coordinates 
9 imputation of duplicate obs due to ownership changes 
9 delete duplicate obs 
 (source: facilities_zip03crossed) 
facilities_tracked 
F6b facilities_tracked_fix 9 bring in addtl vars from USRDS  
9 Impute / Drop missing cases 
9 Remerge facilities w/geo crosswalk file 
facilites_tracked_fixed 
F6c facilities_final 9 Recode discrepancies in chain affiliation variable 
(newvar: chainaff) 
9 Recode discrepancies in ownership variable (newvar: 
forprofit)  
9 Recode facility setting variable to dichotomous (newvar: 
freest) 
9 Drop variables not to be used for final analysis  
(facilities with survey data year before start date, with 
no survey data values) 
9 Create variable i to identify facility-year count 
facilities_final 
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Code Program file Description Dataset created 
PATIENTS - USRDS 
P1a merge_patients_residenc USRDS-PATIENTS + USRDS-RESIDENC (+ inc_age 
from USRDS-MEDEVID) 
9 in/exclusion criteria 
9 generate/impute date of ESRD incidence 
9 drop irrelevant/anomalous cases 
merged_patres 
P1b reconcile_zips_patres 9 checking zipcode formatting – imputing errors or 
missing values 
(source: merged_patres) 
merged_patres_impzip 
P1c recode_merged_patres 9 recoding USRDS file formats  
(source: merged_patres) 
recoded_merged_patres 
P1d transform_patients_residenc 9 drop irrelevant/anomalous cases  
9 annual obs for each patient year, reconciling address 
changes over time 
(source: recoded_merged_patreszips) 
transformed_patres 
P2a merge_patients_medevid USRDS-PATIENTS + USRDS-MEDEVID 
9 in/exclusion criteria 
9 generate/impute date of ESRD incidence 
9 drop irrelevant/anomalous cases 
merged_patmedevid 
P2b recode_merged_patmedevid 
 
9 recoding USRDS file formats 
(source: merged_patmedevid) 
recoded_merged_patmedevid 
P2c transform_patients_medevid 9 drop irrelevant/anomalous cases 
9 annual obs for each patient year, reconciling 
MEDEVID form changes 
(source: recoded_merged_patmedevid) 
transformed_patmedevid 
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Code Program file Description Dataset created 
P3 merge_patientfiles_all transformed_patres + transformed_patmedevid 
(by usrds_id & year) 
merged_patientfiles_all 
P4 patients_zips merged_patientfiles_all + merged_zip_xwalk03 patients_zipcrossed03 
P5 patients_for_analysis 9 create vars for analysis 
9 create aggregate statistics by zipcode 
(source: patients_zipcrossed) 
patients_cntyagg 
patients_hsaagg 
patients_hrragg 
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Code Program file Description Dataset created 
MARKETS 
M1 merge_aha_counts 9 Merge AHA annual survey data files, 1994-2003 
9 Keeping only community-based hospitals in 50 US 
states with valid zip codes 
9 Create annual aggregate statistics by 3 market 
levels:  county, HSA, HRR 
allhospital_counts 
hosp_cnty 
hosp_hsa 
hosp_hrr 
M2a merge_arf 9 Merge ARFdata files, 2002-2006, cut by Randy 
Randolph @ Sheps Center 
9 Incorporating modifications of county statistics due to 
modifications (as per modified FIPS counties, noted 
in ARF documentation) 
9 Dropping counties outside 50 US states, and 
independent cities that are now included in county 
statistics (as per ARF documentation) 
arf_final 
M2b split_arftozips 9 Split county-level ARF data down to zip code, based 
on land-area weighting 
arf_county 
arf_HSA 
arf_HRR 
M3 merge_ama_counts 9 Merge AMA survey files: 1996, 2001, 2003 
9 Dropping zip codes in territories 
9 Create annual aggregate statistics by 3 mkt levels: 
county, HSA, HRR 
md_cnty 
md_HSA 
md_HRR 
M4 merge_allmkt_cnty 
merge_allmkt_hsa 
merge_allmkt_hsa 
9 Merge all annual aggregate market-level variables: 
county, HSA,HRR 
9 Create health care density variables: hospital density, 
physician density 
allmkt_cnty 
allmkt_hsa 
allmkt_hrr 
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Code Program file Description Dataset created 
ANALYTIC FILES 
 
revise_lag.do 
 
9 Create lead dep var (pdsvc), whereby analysis 
independent variables are lagged by one year  
9 Create new variables that indicate an observations’ 
referent year for lagged analysis 
9 Create facility patient load based on prev year’s 
patient load data 
9 Recode facility report of 0 HD stations 
 
facilities_final_lagged 
 
 facilities_explore 
 
 
 
 
facilities_explore_23June 
9 Bring in laggec vars 
9 Facility exclusion criteria – limit to fac’s 1995-2003, 
drop VA facilities 
9 Create variables of interest 
9 Assign 1996, 2001, 2003 physician data to missing 
years 
facilities_for_analysis 
 
 
 
 
facilities_for_analysis_23June 
ANALYTIC FILES:  Q1 
 facility_for_analysis_explore 
 
 
facility_for_analysis_explore_
23June 
9 Descriptive statistics 
9 created aggregate service counts for each market-
level 
(source: facilities_for_analysis) 
means_all.xls;  means_anypd.xls 
facility_allcounts2 
fac_cnty2 
fac_hsa2 
fac_hrr2 
 esrd_mktsplit_county 
esrd_mktsplit_hsa 
esrd_mktsplit_hrr 
split esrd data by market-level, using 
9 facility file data (service counts) 
9 patient file data (demographics) 
fac9403_cnty  _hsa  _hrr 
pts9403_cnty   _hsa  _hrr 
cntyYY     hsaYY    hrrYY 
fac9503_hrrchng 
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Code Program File Description Dataset created 
 Map files HRR-level map shapefiles developed for each year 1995-
2003 
(sources hrrYY + HRR) 
mapYY 
ANALYTIC FILES:  Q2 
 factoranalysis_transform.do Creation of healthcare density variable via factor analysis 
Transformation/rescaling select explanatory variables for 
multivariate analysis 
(source: facilities_for_analysis_23June) 
diss_q2data 
ANALYTIC FILES:  Q3 
 ann_5june2008.py 
 
 
near_distance_script_final_11
june2008.py 
Generating nearest-neighbor index for each HRR for each 
year of study period 1996-2003. 
 
Generating nearest distance measures for facilities, by 
HRR for each year of study period 1996-2003. 
 
 ANN_diagnostics Diagnostics & merging of annual NNI measures all_ann 
 nd_calc (step 1: Stata) 
nd_diagnostics (step 2: SAS) 
Diagnostics & merging of facility nearest distance 
measures and  
nd_calcYY 
all_nd 
 combine_ann_nd  Combining NNI and nearest distance measures into one 
file 
spatmeas 
 annual_spatmeas Creating file of annual spat meas for mapping spatmeasYY 
 neardist_to_pd Diagnostics and file merge of annual measures of 
facilities’ nearest distance to a facility with PD 
all_neardist 
 merge_spatmeasure Merging all spatial distance measures to dissertation 
dataset for analysis 
(sources: diss_q3data + spatmeas + all_neardist) 
diss_q3data_final 
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 DATA ISSUES & SOLUTIONS 
Facility Files 
FILE ISSUE SOLUTION PROGRAM FILE 
FACILITY 
(1994- 2003) 
 
 
 
 
 
 
(n=39,820) 
incomplete provider IDs (cms_id < 6 characters), n=15 
(0.04% of original FACILITY sample) 
cms_id does not resolve to a number (these are federal 
hospitals), n=222 (0.56% of original FACILITY sample) 
For these n=236 cases, examine and fix problems: 
9 cases have hospital IDs that are already accounted for 
via hospital outpatient unit (i.e., double counting) 
9 non-existent or invalid provider IDs 
9 hospital responses to replace missing OP hospital unit 
surveys 
 
 
 
 
drop n= 216 cases  (.54% sample) 
replace n= 20 cases 
 
facility_diagnostics 
 
 
 
provid diagnostics_iderrors 
FACILITY 
 
 
 
(n=35,125) 
n=5,370 cases do not match to CMS-POS file.  Problems: 
9 cases have hospital IDs that are already accounted for 
via hospital outpatient unit (i.e., redundant obs) 
9 non-existent or invalid provider IDs 
9 hospital responses to replace missing OP hospital unit 
surveys 
drop n= 4693 cases  (11.8% 
sample) 
replace n= 913 cases 
provid diagnostics_unmatched 
cases (to identify) 
 
facilties_diagnostics_fix (to 
apply solution) 
FACILITY-
POS  
(n=35,125) 
invalid zip codes (i.e., do not match to HSA/HRR 
crosswalk) 
modify invalid zip codes 
n= 296 cases 
facilities_zip 
FACILITY-
POS 
 
 
(n=35,096) 
Many addresses don’t automatically match to an XY 
coordinate when geocoded in ArcGIS. 
 
Duplicate cases found (n=29, < .01% sample). 
Update/correct address that don’t 
match.  After corrections, those 
addresses that don’t match are 
assigned to zip code’s centroid. 
Drop duplicate cases (n=29, <01% 
sample) 
(geocoding process) 
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 DATA ISSUES & SOLUTIONS 
Facility Files 
FILE ISSUE SOLUTION PROGRAM FILE 
FACILITY-
POS 
 
 
(n=34,811) 
duplicate / redundant observations (usually due to duplicate 
survey entries during year of ownership change) 
missing case-year (n=169, ~ .50% sample) 
9 id’s with multiple years of missingness (n=128 Æ 285) 
9 single year of missingness (n=52, <.15% sample) 
drop n= 285 cases (.81% sample) 
 
impute n= 52 cases (<.15% 
sample) 
imputations_ownerchanges 
 
facilities_tracked_fix 
FACILITY-
POS 
 
 
 
 
 
 
 
(n=34,863) 
discrepancy in the chain affiliation variables from USRDS 
(chain_id) and POS (chain) 
• POS file indicates chain affiliation, including the chain's 
name, which includes chains of all sizes.   
• USRDS indicates chain affiliation with only the 6 largest 
chains in the US (what year the big 6 refers to is 
unclear from reps from USRDS).   
• Accurate accounting of chain affiliation necessitates 
using the POS file.  POS data misses chain affiliation of 
roughly 8,700 facilities that USRDS has identified as 
part of the big 6 dialysis chain providers.  This is too 
large to ignore. 
n= 12,186 (35.1% sample) 
9 fix POS chain var based on 
2006 POS data  
9 recode discrepancies, where 
POS file takes precedence 
over USRDS 
facilities_final 
FACILITY-
POS 
 
 
 
 
 
(n=34,863) 
discrepancy in the 3 different ownership variables from 
USRDS (typowner, nu_p_np) and POS (owner) 
• USRDS typowner is more specific re: different types of 
ownership (18 types), but missing un-imputable 2002-
2003 data (n=911). 
• USRDS nu_p_np (FP indicator) does not correlate 
perfectly with typowner (same file), so this doesn’t help 
settle the discrepancy (but it IS missing the least 
amount of values). 
• POS owner is less specific (3 types), more complete, 
and possibly less accurate. 
(~ 2.4 – 10.2% of sample) 
recode discrepancies, where order 
of accuracy is nu_p_np, owner, 
and typowner 
facilities_final 
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DATA ISSUES & SOLUTIONS 
Facility Files 
FILE ISSUE SOLUTION PROGRAM FILE 
FACILITY-
POS 
(n=34,863) 
discrepancy in the facility setting variables from USRDS 
(nu_hbfs) and POS (hospital) 
n= 1200 (3.4% sample) 
facility setting variable based on 
USRDS data (nu_hbfs) 
facilities_final 
FACILITY-
POS 
(n=34,843) 
AFS data entry contains no info 
n=20 (<.01% sample) 
drop cases, n=20  
(<.10% sample) 
facilities_final 
FACILITY-
POS 
(n=34,750) 
VA facilities not previously identified  
(n=93, .27% sample) 
drop if VAMC n=93  
(.27% sample) 
revise_lag (stata) 
FACILITY-
POS 
(n=34,750) 
discrepancy in the reporting of HD stations.  Cases where 
HD stations = 0 or missing in USRDS AFS data 
n=99 (.28% sample) 
If USRDS file = 0 or missing, 
then replace stations with POS file 
value (hdstat) 
revise_lag (stata) 
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 DATA ISSUES & SOLUTIONS 
Patient Files 
FILE ISSUE SOLUTION PROGRAM FILE 
MEDEVID Beginning in 1995, ESRD providers are required to 
complete the patient Medical Evidence form for all patients 
(before it was only required for Medicare patients).  This 
perhaps explains why there are so few matches  
Some records in 1995 are Medical Evidence data 
(especially before mid-March 1995). 
Limit analysis to 1995 to present. 
 
(all patient file programs) 
PATIENT 
RESIDENC 
Inconsistent coding of zip codes between 2 files…   
RESIDENC file tracks patients as they move, noting dates 
of changes of residence til death.  So the file may contain 
multiple entries per patient.  However, the quality of zip 
code in this file is not so good (e.g., lots of miscodings, 
incomplete zip codes, zips running 6+ digits, zips w/letters). 
PATIENT file contains the most accurate zip code data – 
quality of data is better than in the RESIDENC file but still 
not perfect.  However, this file uses the last residence as the 
zip code entry (i.e., does not take into account patients’ 
moving locations during ESRD period). 
NOTE:  These instances constitute < .20% of total patient 
records in dataset. 
Truncate all zip codes to 5 digits. 
valid zip codes from RESIDENC 
file trumps zips from PATIENTS 
missing/invalid zips from 
RESIDENC to be replaced by zip 
from PATIENTS  
Drop cases of unknown, 
incomplete, or invalid zip codes in 
both PATIENTS or RESIDENC 
 
reconcile_zips_patres 
PATIENTS-
RESIDENC 
patients with multiple zips in a year 
 
 
patient assigned to zip where lived 
most days during year 
 
transform_patients_residenc 
PATIENTS-
RESIDENC 
some patients have same ESRD incidence and death date 
 
drop cases 
 
transform_patients_residenc 
PATIENTS-
RESIDENC 
patients die on Jan 1st patient does not count in year of 
Jan 1 death 
transform_patients_residenc 
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DATA ISSUES & SOLUTIONS 
Patient Files 
FILE ISSUE SOLUTION PROGRAM FILE 
PATIENTS-
MEDEVID 
missing ESRD incidence date impute, where incidence = birth 
date + age of ESRD incidence  
merge_patients_medevid 
PATIENTS-
MEDEVID 
ESRD incidence date precedes birth date drop cases merge_patients_medevid 
PATIENTS-
MEDEVID 
patient’s dates of ESRD incidence, first ESRD service, and 
death are the same 
drop cases transform_patients_medevid 
PATIENTS-
MEDEVID 
multiple MEDEVID forms keep most complete data in that 
given year 
transform_patients_medevid 
PATIENTS-
MEDEVID 
year of annual observation < 1995 or year of ESRD 
incidence 
drop cases transform_patients_medevid 
 no clinical info or record of zip code drop cases merge_patientfiles_all 
 no match to HRR/HSA zip code crosswalk drop cases merge_patientfiles_all 
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 Zips to FIPS crosswalk 
NCHS HSA crosswalk 
HSA/HRR-crosswalk  
Zip code 
County code 
HSA/HRR code 
 
 
 
 
 
 
 
 
ZipstoFIPS file    (2003: n= 44,560   var=7  2004: n= 46,067   var=9) 
Var Description Values  
zip Zip code (use this to merge) <char> 
zip_geo Zip code used for geography <char> 
fips State+County FIPS code (year=2004) <char> 
coname County name <char> 
state_abbrev State <char> 
latitude Latitude of zip code <num> 
longitude Longitude of zip code <num> 
lat_deliv Delivery point – weighted centroid latitude <num> 
long_deliv Delivery point – weighted centroid longtitude <num> 
cbsaflag2003 CBSA 2003 metropolitan flag 0= non CBSA  1= Metro    2= Micro 
metflag1999 Metro 1999 flag 0= Non metro   1= Metro 
* crosswalk files available for years 2001-2005 through Dartmouth Atlas of Health Care 
 
 
HSA/HRR-crosswalk file    (2003: n= 41,373  var= 7   2004: n= 41,272   var=7) 
Var Description Values  
Zipcode04 Zip code <num> 
HSAnum HSA number <num> 
HSAcity HSA city <char> 
HSAstate HSA state <char> 
HRRnum HRR number <num> 
HRRcity HRR city <char> 
HRRstate HRR state <char> 
* crosswalk files available for years 2001-2005 through Dartmouth Atlas of Health Care website – see also NCHS website 
 
 
merge_zip_xwalk03/04 
Sources: claritas_zipships_2003/4c  (CLARITAS Zips to FIPS file) 
                dartmouth_zipshsahrr_2003/4  (Dartmouth Atlas of Healthcare zips to HSA/HRR file) 
created:  merged_zip_xwalk03/04 
 
9 Incorporate modifications to FIPS county codes as per ARF documentation (new var: 
mfipcnty) 
9 exclude ZIPStoFIPS cases where FIPS state code is missing or out of 50 states (code >56) 
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 USRDS-FACILITY file 
USRDS Provider ID 
USRDS-crosswalk file 
USRDS Provider ID 
CMS Provider ID 
F1a-h 
 
 
 
 
 
 
 
USRDS-Facility file  (n= 64,870  var= 45) 
Var Description Values  
fs_year USRDS Survey year  <char> 
provusrd USRDS provider ID USRDS provider ID 
provst State abbrev <char> 
Network ESRD Network identifier 1= CT, ME, MA, NH, RI, VT 
2=NY 
3=NJ, PR, VI 
4=PA 
5=VA, WV, MD, DC 
6=GA, NC, SC 
7=FL 
8=AL, MS, TN 
9=IN, KY, OH 
10=IL 
11=MN, MI, ND, SD, WI 
12=IA, KS, MO, NE 
13=AK, LA, OK 
14=TX 
15=AZ, CO, NV, NM, UT, WY 
16=AK, ID, MT, OR, WA 
17=AS, GU, MH, HI, NoCA 
18=SoCA 
certdate Date of CMS certification to provide renal svcs <date> 
certcode  CMS Certification type 1=transplant ctr 
2=dialysis  ctr 
3=dialysis facil, hospital 
4=dialysis facil, freestanding 
5=transpl & dialysis ctr 
6=obsoleted category 
7=inpatient care only 
termdate Termination date <date> 
termcode Termination reason 1=involuntary withdrawal 
2=failure to meet std 
3=failure to meet util rate 
4=failure to meet need reqrm 
5=closed 
6=other 
ptrmdate Date of prior termination  Numeric (format: BEST22) 
ptrmcode Reason for prior facility termination 1=involuntary withdrawal 
2=failure to meet std 
3=failure to meet util rate 
4=failure to meet need reqrm 
5=closed 
6=other 
nu_hbfs Facility setting 1= hospital-based  
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 2= freestanding 
med_va VA facility A= non-VA facility 
V= non-Medicare VA facility 
W= Medicare VA facility 
Y= Other 
typowner Ownership type 
(NOTE: missing years 2002-2003) 
01= indiv FP 
02= partnership FP 
03= corp FP 
04= other FP 
05= indiv NFP 
06= partnership NFP 
07= corp NFP 
08= other NFP 
09= state Gov – Non Fed 
10= county Gov – Non Fed 
11= city Gov – Non Fed 
12= city/County Gov – Non 
Fed 
13= hospital Auth Gov – Non 
Fed 
14= other Gov – Non Fed 
15= VA HCFA Cert 
15a= VA HCFA non-Cert 
16= PHS – Gov Fed 
17= military – Gov Fed 
18= other – Gov Fed 
99= Missing 
nu_p_np  For_profit ownership indicator For-profit    
Non-profit    
Unknown 
chain_id Number id of chain affiliate DAVITA= DaVita 
DCI= Dialysis Clinic, Inc. 
Everest= Everest 
FRESENIUS= Fresen Med 
Care 
Gambro= Gambro H.C. 
NATIONAL= Ntl Nephrol Assoc 
RCG= Renal Care Group, Inc. 
RTC= Renal Treatment 
Centers  
VIVRA= VIVRA 
totstas Total dialysis stations in facility <numeric> 
peri Staff assisted PD  N=no      Y= yes 
capd CAPD  N=no      Y= yes 
ccpd CCPD  N=no      Y= yes 
perisc In-unit self-care PD  N=no      Y= yes 
peritrng PD training  N=no      Y= yes 
hemo Staff assisted HD  N=no      Y= yes 
hemosc In-unit self-care HD  N=no      Y= yes 
hemotrng HD training  N=no      Y= yes 
op_htrt Treatment volume: outpatient HD <count> 
htrgtrt Treatment volume: HD training <count> 
op_ptrt Treatment volume: outpatient PD <count> 
ptrgtrt Treatment volume: PD training <count> 
catrgtrt Treatment volume: CAPD training <count> 
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 cctrgtrt Treatment volume: CCPD training <count> 
tot_txpl Treatment volume: Transplants (any) <count> 
hemslstf Patient volume: outpatient HD <count> 
perslstf Patient volume: outpatient PD <count> 
hemintrg Patient volume: HD training <count> 
perintrg Patient volume: PD training <count> 
capintrg Patient volume: CAPD training <count> 
ccpintrg Patient volume: CCPD training <count> 
iu_end Patient volume: Total outpatient <count> 
hemhome Patient volume: home-based HD <count> 
perhome Patient volume: home-based PD <count> 
caphome Patient volume: home-based CAPD <count> 
ccphome Patient volume: home-based CCPD <count> 
ih_end Patient volume: Total home-based <count> 
end_tot Patient volume: Total - dialysis  <count> 
txpl_pat Patient volume: Total - transplant <count> 
 
USRDS-crosswalk file   (n= 73,995  var= 3) 
Var Description Values  
PROVHCFA CMS assigned provider number <char> 
PROVUSRD USRDS assigned provider number <char> 
FS_YEAR Facility survey year <num> 
 
 
F1a:  merge_facility_idcrosswalk 
Source: facility, idcrosswalk 
Created:  merged_facility_idcrosswalk 
 
 
F1b: recode_merged_usrdsfacility 
Source: merged_facility_idcrosswalk 
Created:  recoded_merged_usrdsfacility 
9 recode USRDS file formats 
 
 
F1c: facility_diagnostics 
Source:  recoded_merged_usrdsfacility 
Created:  usrdsfacility9403 
9 create subset of data for analysis, years1994-2003 
9 identify and eliminate cases of errant provider ID’s from analysis.  Cases dropped include: 
o n=15 cases where cms_id < 6 characters, all in 2002 (0.04% of USRDS facility sample) 
o n=222 cases where cms_id does not resolve to a number (0.56% of USRDS Facility 
sample).  Most of these facilities are federal hospitals (e.g., VA, military) and do not 
participate in the Medicare program (various years).  The others (n=14, occurring in 
2002-3) do not appear in the POS file.   
o These 236 cases are to be later used for “iderror” diagnostics (below, next) 
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 F1d: facility_diagnostics_Aug14 
Source:  recoded_merged_usrdsfacility 
Created:  usrdsfacility9403_iderrors 
9 create subset of data of errant provider ID’s (n=236) for diagnostic check against OSCAR files 
and merged master file 
 
 
F1e: merge_facilities_all_Aug1_2006oscar 
Source:  usrdsfacility9403 +  recoded_oscar2006 
Created:  facility_match_Aug1; facility_nomatch.sas7dbat / .xls 
9 In/exclusion criteria 
9 Identify matched, unmatched cases 
 
 
F1f: provid diagnostics_unmatched cases 
Sources: usrdsfacility9403; facility_nomatch_Aug1; liloscar2006 
Created:  usrdsfacility_key.xls; facility_key_inclunmatched_master (.sas7dbat & .xls); 
facility_key_incunmatch_bystate.xls; facility_nomatch_diagnosed.xls; facility_nomatch_fix.xls 
9 Create masterfile of matched (n= 34,214) and unmatched (n=5,370) cases with problem 
flags. 
9 Check to see why facilities in USRDS file don’t match to OSCAR file…how many of the 
USRDS facility surveys have hospital IDs?    
 
Sources: facility_key_inclunmatch_master 
Created:  facility_key_inclunmatch_bystate; facility_nomatch_diagnosed; 
facility_nomatch_fix.xls/.sas7dbat 
9 More checks on unmatched cases:   
o How many of the USRDS facility surveys have hospital IDs that are already 
accounted for via outpatient hospital unit surveys submitted? 
o How many facility ID’s are bad/non-existent? 
o How many cases of hospital responses need to replace missing outpatient hospital 
unit surveys?   
9 Flag cases of this and note changes to be made 
o Total n=5370 – drop n= 4477   replace n=893 
 
 
F1g: provid diagnostics_iderrors 
Sources: usrdsfacility9403; usrdsfacility9403_iderrors; liloscar2006 
Created:  usrdsfacility_key_iderrors _master (.sas7dbat & .xls); facility_iderrors_diagnosed; 
facility_iderrors_fix.xls/.sas7dbat 
9 Same as F1f, above, but for USRDS facilities where cms_id are not all valid (non-numeric 
and incomplete IDs)  
9 Flag cases of this and note changes to be made 
o Total n=236 – drop n= 216   replace n=20 
 
 
F1i: facility_diagnostics_fix 
Sources: facility_nomatch_fix + facility_iderrors_fix + recoded_merged_usrdsfacility 
Created:  usrdsfacsurv9403 
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 9 Fix non-matches and id errors as diagnosed in F1f-g (above) and merge back with original 
USRDS facility dataset with corrections 
9 Dropped n= 4695    Replaced n= 913 
9 1994-2003 Total n=35125 
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 CMS-POS file 
CMS Provider ID 
Street Address 
Zip code 
F2a-f
 
 
 
 
 
CMS-POS file 
New Var Orig Var Description Values  
cms_id PROV1680 CMS provider ID CMS provider ID 
skel PRV2045 Skeleton record locator Y = if only ltd set of provider 
data is available 
rel_id PROV1755 Related provider ID When provider’s facility 
contains more than one distinct 
provider – provider ID of 
highest level of care. 
xref_id PROV0300 Cross reference provider ID ID previously assigned to 
particular provider 
name PROV0475 Facility name <char> 
addr PROV2720 Street address <char> 
city PROV3225 City (name of) <char> 
zip PROV2905 Zip code <char> 
state 
fipst 
PROV3230 
FIPSTATE 
State State abbrev <char> 
FIPS state code <char> 
fipcnty FIPCNTY County code FIPS county code <char> 
msa SSAMSACD MSA <char> 
msa_sz SSAMSASZ MSA size code <char> 
cms_elig PROV0455 CMS eligibility 1= yes 2=no 
partdate PROV1565 Participation date (first CMS approv) <date> 
certpurp PROV2880 Certification action: purpose for 
certification 
1=initial 
2=recertification 
3=termination 
4=change of ownership 
ownchng PROV0095 # times ownership changed  <num> 
chngdate PROV0100 Date of (recent) ownership change <date> 
prchngdate PROV1615 Date of prior change of ownership <date> 
trmdat PROV4500 Termination date <date> 
trmcod PROV4770 Termination reason  00= active 
01= vol merg, close 
02= vol reimburse 
03= risk invol 
04= vol - other 
05= invol - fail req 
06= invol - agreemnt 
07= other - status chg 
08= missing 
hospital PROV0565 Hospital-based indicator Y= yes 
owner PROV2885 Ownership type 01= FP 
02= NFP 
03= Public 
13=?? 
24=?? 
chain PROV0675 Multi-facility org owned Y= yes 
chainname PROV0680 Multi-facility org name <char> 
appstat PROV2855 Total (approved) dialysis stations <num> 
hdstat PROV1230 Total HD stations <num> 
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 F2a: read_oscar[YEAR] 
Sources:  OSCAR files, 1994-1999 
Created: osc09_[YEAR] 
 
9 read CMS POS files (raw data) and retain ESRD facilities (PROV0075=09) 
9 1994 and 1995 files:  recode variables in same format as 1996-2004 data 
9 NOTE:  1995 data missing chain name and chain affiliation indicator 
9 NOTE:  2000-2004 data previously cut by Ann Howard at Sheps Center (permission granted by 
Becky Slifkin, Ann Howard provided program to read 1994-1999 files) 
 
 
F2b: merge_oscar 
Sources:  all OSCAR files (osc09_1994 through 2006) 
Created: merged_osc9406 
 
 
F2c: recode_merged_oscar 
Source: merged_osc9406 
Created:  recoded_merged_oscar 
 
F2d: oscar_diagnostics 
Source: recoded_merged_oscar 
Created:  N/A 
 
F2e: recode_oscar2006 
Source: osc09__2006 
Created:  recoded_oscar2006 
 
F2f: liloscar_[YEAR] 
Source: osc01__[YEAR];  osc09_[YEAR]   for years 1994, 1999, 2004, 2006 
Created:  liloscar[YEAR].sas7dbat / .xls
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USRDS-FACILITY file 
USRDS Provider ID 
USRDS-crosswalk file 
USRDS Provider ID 
CMS Provider ID
F3 Facility-level Data  
CMS Provider ID 
Street Address 
Zip code 
Zips to FIPS crosswalk 
NCHS HSA crosswalk 
HSA/HRR-crosswalk  
Zip code 
County code 
HSA/HRR code
F6a-c
F5 
F4a-b 
CMS POS - Geocoded 
CMS Provider ID 
Zip code 
Point location geocode 
CMS-POS file 
CMS Provider ID 
Street Address 
Zip code
Market Characteristics 
Zip code 
County code 
HSA/HRR code 
HSA/HRR number 
 
 
 
F3: merge_usrdsoscar_facilities 
Source:  usrdsfacsurv9403 + recoded_merged_oscar 
Created:  merged_usrdsoscar_facilities 
9 (1) Addresses may change over time, so retain as many of these changes with annual OSCAR 
data 
9 (2) Re-merge unmatched cases (n=1,715) to 2006 OSCAR file 
9 Combine (1) and (2)  Æ  n=35,125  variables=73 
 
 
F4a: geocode_ facilities 
Source:  merged facilities 
Created:  geocode_facilities[YY].xls/.dbf ; geocoded[YY]_facilities.dbf/.xls/.sas7dbat 
Geocoding processes: 
1. Geocode 1994 facilities 
2. Replace errant with corrected 1994 addresses.  (see facilities_addfix94, below) 
3. Geocode addresses 1994 addresses again. 
4. For those “unmatched cases”, lat/long coordinates will be zip code centroid 
5. Merge 1994 facility lat/long codes to 1995 facilities.   
6. Of 1995 facilities with no lat/long coordinates (i.e., not existing in 1994), repeat steps 1 
through 4 
7. For 1996 – 2003 facilities, repeat steps 1-6. 
(see more detailed processes, next page) 
 
F4b: merge_geofacsurv9403 
Source:  allmatchedYY + addfixed03 
Created:  merged_geofacsurv9403 
 
 
F5:  facilities_zip   
Source:  merged_geofacsurv9403 + merged_zip_xwalk03 
Created:  facilities_zip03crossed 
9 Fix non-valid zip codes (i.e., do not match to HSA/HRR crosswalk)  
9 Merge geocoded facility file to zip code crosswalks to FIPS county, Dartmouth HSA and HRR 
designations 
 
 GEOCODING PROCESS 
 
DESCRIPTION PROGRAM FILE DATA FILE CREATED 
Cut annual file – how many do not match to a zip? 
1.  Create annual file with facility address where XY matches to cms_id 
and addr variables established from previous geocoded “full” file.   
 
2.  From allfacilitiesYY.sas7dbat file, create cut of facilities with no XY 
from previous year 
 
 
Data\ESRDDissertation\Facilities
\Geocoding\geocodeYY_facilitie
s.sas 
 
 
 
Data\ESRDDissertation\Facilities\Geocoding\YYYY\all
facilitiesYY.sas7dbat 
 
Data\ESRDDissertation\Facilities\Geocoding\YYYY\ge
ocode_facilitiesYY.xls 
Convert to dbf format: geocode_facilitiesYY.dbf
Geocoding – Round 1 
3.  Using ArcMap, open YYYY\geocode_facilitiesYY.dbf file and geocode addressess 
Address Locator:  Streetmaps 2005 with alt names 
 Geocode settings: spelling sensitivity = 80 
  minimum candidate score = 10 
  minimum match score = 60 
  side offset = 100 feet 
 
 
YYYY\GeocodeYY_Result.dbf  .prj  .shp  .shp.xml   
.shx 
 
Identifying addresses that don’t initially match to lat/long coordinates 
4.  Open YYYY\GeocodeYY_Result.dbf and create file of geocoding results identifying matches, ties, and 
unmatched addresses and create temporary file of unmatched addresses 
 
 
YYYY\examinegeocodeYY.xls      
YYYY\bah.xls
Fixing errant addresses that don’t initially match to lat/long coordinates 
5.  List address error fixes in files 
 
YYYY\Address_fixYY.xls  (later convert to .sas7dbat) 
YYYY\City_fixYY.xls  (later convert to .sas7dbat) 
YYYY\Zip_fixYY.xls  (later convert to .sas7dbat) 
Geocoding\ save_xy.xls
6.  Incorporate address corrections to previous geocoded “full file”  
Data\ESRDDissertation\Facilities
\Geocoding\YYYY\facilities_add
fixYY.sas
 
Data\ESRDDissertation\Facilities\addfixedYY.sas7dbat 
Geocoding – Round 2 
7.  Repeat steps 1 and 2:  Create annual file with facility address where 
lat/long coordinate matches to cms_id and addr variables established 
from addfixedYY file 
 
 
Data\ESRD 
Dissertation\Facilities\Geocoding
\ 
YYYY\geocodeYY_facilities_2.s
as 
 
Data\ESRDDissertation\Facilities\Geocoding\YYYY\all
facilitiesYY.sas7dbat  (overwrite) 
 
Data\ESRDDissertation\Facilities\Geocoding\YYYY\ge
ocode_facilitiesYY.xls (overwrite) 
 
Convert to dbf format: YYYY\geocode_facilitiesYY.dbf 
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8.  Geocode again as in step 3.  Using ArcMap, open 
YYYY\geocode_facilitiesYY.dbf file and geocode addressess 
Address Locator:  Streetmaps 2005 with alt names 
 Geocode settings:  spelling sensitivity = 80 
  minimum candidate score = 10 
  minimum match score = 60 
  side offset = 100 feet 
  
YYYY\matchedYY_result.dbf  .prj  .shp  .shp.xml   .shx 
 
Convert YYYY\matchedYY_result.dbf to .sas7dbat, 
where cms_id $10, addr $38, city $28, zip $5 
Identifying addresses that don’t initially match to lat/long coordinates 
9.  From YYYY\matchedYY_result.dbf cut file of remaining unmatched addresses 
 
YYYY\unmatchedYY_zip.xls  & .sas7dbat 
Assigning unmatched addresses to zip code centroid lat/long 
coordinates 
10.  Match unmatched addresses to XY of zip code centroids.  Then 
merge XY-matched zip codes, XY-matched addresses, and XY-
matches from previous year into final XY file for the year. 
 
Data\ESRDDissertation\Facilities
\Geocoding\YYYY\match_allYY
_results.sas 
 
YYYY\allmatchedYY.sas7dbat   
 
Create shapefile of final geocoded annual facilities 
11.  Using ArcCatalog, create feature class from XY table 
  
YYYY\allmatchedYY.dbf  .prj  .shp  .shp.xml   .shx 
DELETE files: 
YYYY\GeocodeYY_Result.dbf  .prj  .shp  .shp.xml   .shx 
YYYY\bah.xls 
YYYY\Matched95_Result.dbf  .prj  .shp  .shp.xml   .shx 
  
 F6a: imputations_ownerchanges 
Source:  facilities_zip03crossed; fac_missown_bystate.xls; imputations on select vars.xls  
Created:  facilities_tracked 
 
Programming new data cleaning/imputations to final dataset, order of corrections: 
1. org start dates  (startdat) 
2. org change dates (chngdate) 
3. prev org change dates (prchngdate) 
4. end dates (enddate) 
5. ownership type (typowner) 
6. xy coordinates (x, y, geostat) 
7. imputation of duplicate obs’ pt/tx volumes  
8. establishing new provider id’s (study_id) 
9. delete duplicate / redundant obs (n=285) 
 
start:  n=35,096  var=88 
end:   n=34,811  var=91 
 
Detail 
 Dates 
o change date:  in year of change and year after change 
o previous change date:  beginning 2 years after change occurred, continuing until 
new change, 2003 or close date 
o termination/end date 
 Ownership type: especially in years 2002-2003, where data not collected 
 XY coordinates: for same addresses with different XY coordinates 
 New id: for facilities with multiple provider id’s 
o For cases of duplicate facility-year observations where id1 and id2 represent the 
same facility undergoing ownership in respective year: 
  Example:  id1 1999  (has data from 1995-1999) 
        id2 1999   (has data from 1999-2003) 
  
 When facilities “close” they complete close out data to submit to ESRD Networks 
which  then forward the information to CMS.  Typically, treatment volume appears to 
represent  partial year for each id.  Ppatient volume typically appears to represent entire 
year for one  of the ids (though not always). 
 
 Solution:  Keep the newer id, dropping the older facility id.  Add reported volumes (id1 
 volume + id2 volume) –  for patient and/or treatment volume, case dependent. 
o Cases are linked based on  
1) related ID noted in POS file 
2) same street address and end/start date within 3 months of each other 
3) (2) above and total number of HD stations 
 Obs to drop: due to duplication (imputation for volume to follow, see below) 
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 F6b: facilities_tracked_fix 
Source:  facilities_tracked; imputations_missingcases.xls; miss_msa 
Created:  facilities_tracked_fixed 
 
Fix-up of facility data: 
1. bring in additional variables from USRDS file (explanation, see below) 
2. missing cases:  impute cases with single year of missingness (explanation, see below) 
3. re-merge facilities with county/HSA/HRR crosswalk file 
 
Data issues identified 
Re: Data values 
• Patient volume 
So far, I’m using patient volume defined as those numbers of patients “receiving care at the 
end of the survey period”.  This does not take into account the loss of the following types of 
patients during the study period due to  
o Death  
o Recovered kidney function 
o Transplanted patients  
o Transferred out to other dialysis unit 
o Discontinued dialysis 
o Loss to follow up
This data is available.  Should I be incorporating this into my patient volume variable? 
Æ Bring in beginning patient volume from USRDS Facility file (3 vars: iu_beg, ih_beg, 
beg_tot) 
 
Re: Missingness 
• Total n=169 missing (0.48% of total sample) 
• Single year of missingness: n=41 
Æ Average of preceding and following years of data 
Æ For those years of data lacking either preceding year or following year of data, impute 
using the following year of data (e.g., missing 1996 – starting year of provider, impute 
using 1997 data) 
• Multiple years of missingness – majority of which are consecutive years of missingness 
(exception, n=1) 
Æ Keep missing.  This would constitute somewhere < 1% of the provider sample, depending 
on how one determines what the total provider sample actually is. 
  
 
F6c: facilities_final 
Source:  facilities_tracked_fixed 
Created:  facilities_final 
 
Data issues identified 
• Chain affiliation – discrepancy in 2 data sources 
o POS file indicates chain affiliation, including the chain's name, which includes chains of all 
sizes.   
o USRDS indicates chain affiliation with only the 6 largest chains in the US (what year the big 6 
refers to is unclear from reps from USRDS).   
o Accurate accounting of chain affiliation necessitates using the POS file.  POS data misses 
chain affiliation of roughly 8,700 facilities that USRDS has identified as part of the big 6 
dialysis chain providers.  This is too large to ignore. 
Æ Recode discrepancies between USRDS & POS data, where POS file takes precedence over 
USRDS. 
 
• Ownership - discrepancy in the 3 variables from 2 data sources 
o USRDS typowner is more specific re: different types of ownership (18 types), but missing un-
imputable 2002-2003 data (n=911). 
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 o USRDS nu_p_np (FP indicator) does not correlate perfectly with typowner (same file), so this 
doesn’t help settle the discrepancy (but it IS missing the least amount of values). 
o POS owner is less specific (3 types), more complete, and possibly less accurate. 
 
 
F6c: facilities_final (cont.) 
o Example:  Definition of public ownership under POS file differs from USRDS designation. 
Æ Recode discrepancies between 2 USRDS and 1 POS ownership variable, where order of 
accuracy is nu_p_np (USRDS), owner (POS), and typowner (USRDS).   
 
Fix-up of facility data: 
1. Imputations of facilities submitting annual survey, but with no data (n=7) 
2. Recode discrepancies in chain affiliation variable (newvar: chainaff) 
3. Recode discrepancies in ownership variable (newvar: forprofit)  
4. Recode facility setting variable to dichotomous (newvar: freest) 
5. Recode facility report of HD stations (newvar: stations)  
6. Drop variables not to be used for final analysis (facilities with survey data year before start 
date, with no survey data values) 
7. From checking spatial join (XY coord to HRR boundary file): corrections to HRR assignments, 
counties, zip codes 
8. Create variable i to identify facility-year count 
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USRDS-PATIENTS file 
USRDS Patient ID 
Zip code 
USRDS-RESIDENC file 
USRDS Patient ID 
Zip code 
P1a-d 
 
 
 
 
 
USRDS-PATIENT file  (n= 1,600,693  var= 11) 
Var Description Values  
usrds_id Patient ID USRDS patient ID 
born Date of birth <date> 
died Date of death <date> 
incyear Year of first ESRD service <date> 
race Race 1= Native American 
2= Asian 
3= Black 
4= White 
5= Unknown (– set to missing) 
9= Other (– set to 6) 
#, T= all (– set to 5) 
sex Gender 1= Male 
2= Female 
#, T= All 
Other= Unknown  
disgrpc Primary disease causing renal failure 1= diabetes 
2= hypertension 
3= glomeruloneph. 
4= cystic kidney 
5= other urologic 
6= other cause 
7= unknown (– set to missing) 
8= missing (– set to missing) 
**OTHER**= missing  
first_se Date of 1st ESRD service <date> 
county FIPS County code <char> 
state FIPS State code 01-98 
zipcode Zip code <char> 
 
USRDS-RESIDENC file  (n= 2,388,928  var= 6) 
Var Description Values  
usrds_id Patient ID USRDS patient ID 
county (cnty) FIPS County code <char> 
state (st) FIPS State code 01-98 
zipcode (zpcd) Zip code <char> 
begres Date of (residence) beginning period <date> 
endres Date of (residence) ending period <date> 
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 P1a: merge_patients_residence 
Sources: patients, residenc, medevid (only inc_age) 
Created:  merged_patres 
 
9 exclude:  deaths before 1995;  patients residing outside 50 states   
9 Impute/generate date of ESRD incidence, where incidence date (incid_dt) is  
o birth date (born) + age of ESRD incidence (inc_age)    OR if inc_age is unavailable, then 
o date of first ESRD service (first_se) 
 
P1a: merge_patients_residence (cont.) 
9 drop irrelevant obs where incidence date and period of residence both will not apply to study 
period (many records where patients have residence prior to incidence and/or study period) 
9 drop cases where ESRD first service/incident date precedes birth date  
 
P1b:  reconcile_zips_patres 
Source: merged_patres 
Created:  merged_patres_impzip 
 
9 zip code diagnostics 
9 imputation of errors or missing values 
o imputation 1:  drop cases where no zip is available 
o imputation 1:  replace missing missing or incomplete zips from patients file w/valid zip 
from residenc file  (explanation:  since we want to track patient movement over time, the 
zips from residenc file trumps zips from patients file)  
o imputation 2:  drop cases of non-valid, incomplete zip codes in both patients & residence 
files (e.g., 124Z8, ITALY, 928) 
 
PATIENTS  
zip 
RESIDENC 
zip 
IMPUTATION 
UNK 
<missing> 
UNK 
<missing> 
NONE:  dropped from dataset and further analysis 
22204 <missing> PATIENT file zipcode replaces RESIDENC file zipcode 
(implication: patients who may have moved over time will be 
assigned to the  zipcode of last known residence or 
residence upon death) 
22204 654 PATIENT file zipcode replaces RESIDENC file zipcode 
(implication: patients who may have moved over time will be 
assigned to the  zipcode of last known residence or 
residence upon death) 
873 10952 NONE:  patient observation will be kept in dataset and (any 
changes in) zip will be tracked accurately 
<missing> 10952 NONE:  patient observation will be kept in dataset and (any 
changes in) zip will be tracked accurately 
  pt_obs1 ≠ 
pt_obs2 
(and so 
on…) 
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 P1c:  recode_merged_patres 
Source: merged_patres_impzip 
Created: recoded_merged_patres 
 
9 recode USRDS file formats  
 
P1d:  transform_patients_residenc 
Source: recoded_merged_patres 
Created: transformed_patres 
 
9 drop cases where patient has the same ESRD incidence (incid_dt), first ESRDservice (first_se) 
and death (died) date are the same 
9 generate annual obs for each year alive during study 
P1d:  transform_patients_residenc (cont.) 
o patients count if they are alive during the study period 
o patient record begins in 1995 or year of ESRD onset (if after 1995) 
o patient record ends 2005 or upon year of death (if before 2005)  
o patient-year observation is not counted if death date is Jan 1st 
o patients moving with a given year from zip1 to zipN are assigned to zip code where they 
lived the most days during the year 
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P2a-c
USRDS-MEDEVID file 
USRDS Patient ID 
USRDS-PATIENTS file 
USRDS Patient ID 
Zip code 
 
 
 
 
 
USRDS-PATIENT file  (n= 1,600,693  var= 11) 
Var Description Values  
usrds_id Patient ID USRDS patient ID 
born Date of birth <date> 
died Date of death <date> 
incyear Year of first ESRD service <date> 
race Race 1= Native American 
2= Asian 
3= Black 
4= White 
5= Unknown (– set to missing) 
9= Other (– set to 6) 
#, T= all (– set to 5) 
sex Gender 1= Male 
2= Female 
#, T= All 
Other= Unknown  
disgrpc Primary disease causing renal failure 1= diabetes 
2= hypertension 
3= glomeruloneph. 
4= cystic kidney 
5= other urologic 
6= other cause 
7= unknown (– set to missing) 
8= missing (– set to missing) 
**OTHER**= missing  
first_se Date of 1st ESRD service <date> 
county FIPS County code <char> 
state FIPS State code 01-98 
zipcode Zip code <char> 
 
USRDS-MEDEVID file   (n= 896,447  var= 33) 
Var Description Values  
usrds_id Patient ID USRDS patient ID 
ctdate Date physician signed Med Evidence Form <date> 
inc_age Age at ESRD incidence <numeric> 
ethn Ethnicity (Hispanic) 1= Hispanic, Mexican 
2= Hispanic, Other 
3= Non-Hispanic 
4= Unknown (– set to missing) 
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mdcd 
mdcr 
empgrp 
nocov 
mdcrcod 
othcov 
 
Medical coverage: Medicaid 
Medical coverage: Medicare 
Medical coverage: Emply group HI  
Medical coverage: None 
Medical coverage: M’care app pending 
Other medical coverage 
1= Yes 
2= No 
3 = Unknown (– set to missing) 
9= Unknown (– set to missing) 
N= No 
U= Unknown (– set to missing) 
Y= Yes 
**OTHER**= Unknown 
empcur 
empprev 
Employment status (current) 
Employment status (previous) 
1= Unemployed 
2= Employed, FT 
3= Employed, PT 
4= Homemaker 
5= Retired-age 
6= Retired-disability 
7= Medical leave of absence 
8= Student 
9= Other 
bmi Body Mass Index <numeric> 
pdis Primary disease causing renal failure <code for specific disease> 
 
carfail 
ihd 
mi 
cararr 
dysrhyt 
pericar 
cva 
pvasc 
hyper 
diabprim 
diabins 
pulmon 
smoke 
cancer 
alcoh 
drug 
noabmul 
notrans 
 
hiv 
aids 
Co-morbidities: 
congestive heart failure 
ischemic heart disease (CAD) 
myocardial infarction 
cardiac arrest 
cardiac dysrhythmia 
pericarditis 
cerebrovascular disease (CVA) 
peripheral vascular disease 
history of hypertension 
diabetes (primary/contributing) 
diabetes, currently on insulin 
chronic obstructive pulmonary disease 
tobacco use, current smoker 
malignant neoplasm, cancer 
alcohol dependence 
drug dependence 
inability to ambulate 
inability to transfer 
 
HIV + status 
AIDS 
 
1= Yes 
2= No 
3 = Unknown (– set to missing) 
9= Unknown (– set to missing) 
N= No 
U= Unknown (– set to missing) 
Y= Yes 
**OTHER**= Unknown 
 
 
 
 
 
 
 
 
 
 
 
C= cannot disclose  
N= no 
Y= yes 
 
P2a:  merge_patients_medevid 
Sources: patients, medevid 
Created:  merged_patmedevid 
 
9 exclude:  deaths before 1995;  patients residing outside 50 states   
9 Impute/generate date of ESRD incidence, where incidence date (incid_dt) is  
o birth date (born) + age of ESRD incidence (inc_age)    OR if inc_age is unavailable, then 
o date of first ESRD service (first_se) 
9 drop cases where ESRD first service/incident date precedes birth date 
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P2b:  recode_merged_patmedevid 
Source: merged_patmedevid 
Created: recoded_merged_patmedevid 
 
9 recode USRDS file formats  
 
 
P2c:  transform_patients_medevid 
Source: recoded_merged_patmedevid 
Created: transformed_patmedevid 
 
9 drop cases where patient has the same ESRD incidence (incid_dt), first ESRD service (first_se) 
and death (died) date are the same 
P2c:  transform_patients_medevid (cont.) 
9 for patients completing MED EVID form > 1/year, keep the record with the most complete data 
in that given year  
9 generate annual obs for each patient-year, accounting for changes in the MED EVID form 
(based on form signature date, ctdate) 
9 the code for creating annual obs isn’t perfect….run additional command to  drop records where 
the year observation < 1995 or year of ESRD incidence 
9 NOTE:  other anomalous cases slip through, but will be reconciled when merging the 
patients+medevid file with the patients+residenc file 
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Zips to FIPS cross
NCHS HSA crossw
HSA/HRR-crossw
Zip code 
walk 
alk 
alk  
County code 
 
 
 
 
 HSA/HRR code
 
 
 
 
 
 
 
 
 
P3:  merge_patientfiles_all 
Source:  transformed_patres;  transformed_patmedevid 
Created:  merged_patientfiles_all 
 
9 Merge 
9 Drop cases where there is  
o record of clinical info, but no record of zipcode 
o death on Jan 1 (since there is no record of patient in zip for the Jan 01 year)  
 
P4:  patients_zips 
Source:  merged_patientfiles_all  +  merged_zip_xwalk03 
Created:  patients_zipcrossed 
 
9 Merge, keeping only cases where there is a zipcode match 
 
P5:  patients_for_analysis 
Source:  patients_zipcrossed 
Created:   patients_cntyagg 
  patients_hsaagg 
  patients_hrragg 
 
9 Creating new variables for analysis 
9 Generate frequencies and means of variables for analysis 
9 Changes in ESRD patient sample 
o Possible data error in birth date entries, resulting in outlier ages (e.g., age=187).  Drop 
cases of  patients born on or before 1900 and still alive  
 patients born on or before 1890 
(dropped n=166, less than .01% of ESRD patient sample). 
o Recalculate age where record year and year of birth is the same (in this case, age=1) 
o Imputation of comorbid condition indicators:   
 true missing if all comorbidity indicators are missing.  Otherwise,  
 if var=. and not all comorbidities are missing then var=0 
9 Create aggregate statistics by 3 market levels:  county, HSA, HRR 
USRDS-RESIDENC  
USRDS Patient ID 
Zi
P4
Aggregated Patients 
Zip code 
County code 
HSA/HRR code
USRDS-PATIENTS  
USRDS Patient ID 
Zip code 
p code
P3
USRDS-MEDEVID 
USRDS Patient ID P5
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M1:  merge_aha_counts 
Source:  aha94-03 files + merged_zip_xwalk03 
Created:   allhospital_counts 
hosp_cnty 
hosp_hsa 
  hosp_hrr 
 
 
9 Merge AHA annual survey data files, 1994-2003 
9 Keeping only community-based hospitals in 50 US states with valid zip codes 
9 Create annual aggregate statistics by 3 market levels:  county, HSA, HRR 
9 Variable: total number of hospitals 
 
M2a:  merge_arf 
Source:  arf02-06 files + arf_fixes.xls 
Created:  arf_final 
 
9 Merge ARFdata files, 2002-2006, cut by Randy Randolph @ Sheps Center 
9 Incorporating modifications of county statistics due to modifications (as per modified FIPS 
counties, noted in ARF documentation) 
9 Dropping counties outside 50 US states, and independent cities that are now included in county 
statistics (as per ARF documentation) 
 
M2b:  split_arftozips 
Source:  arf_final + zip_county_sqmi_2003 + merged_zip_xwalk03 
Created:  ARF_county;  ARF_HSA;  ARF_HRR 
 
9 Split county-level ARF data down to zip codes, based on land-area weighting 
9 Create annual aggregate statistics by 3 market levels: county, HSA, HRR 
9 Variables: population, total personal income, per capita income, urban population, % urban pop, 
land area 
 
Market Characteristics 
Zip code 
County code 
HSA/HRR code 
HSA/HRR number
ARF file 
County code 
M4
Aggregated Patient Data 
Zip code 
County code 
HSA/HRR code 
P M2a-b
AHA data 
Zip code
AMA data 
Zip code 
M1 M3 
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 M3:  ama_counts 
Source:  neph1996, neph2001, neph2003, merged_zip_xwalk03 
Created:  md_cnty;  md_HSA;  md_HRR 
 
9 Merge AMA survey files: 1996, 2001, 2003 
9 Create annual aggregate statistics by 3 market levels: county, HSA, HRR 
9 Variables: total number of nephrologists (FTE) 
 
 
 
 
 
 
M4:  merge_allmkt_cnty/_hsa/_hrr 
Source:  arf_county arf_hsa arf_hrr; hosp_cnty hosp_hsa hosp_hrr; md_cnty md_hsa md_hrr; 
patients_cntyagg; patients_hsaagg; patients_hrragg  
Created:  allmkt_cnty allmkt_hsa allmkt_hrr 
 
9 Merge all annual aggregate market-level variables: county, HSA,HRR 
9 Create health care density variables: hospital density, physician density 
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Facility-level Data  
 
CMS Provider ID 
Street Address 
Zip code 
Zips to FIPS crosswalk 
NCHS HSA crosswalk 
HSA/HRR-crosswalk  
Zip code 
County code 
HSA/HRR code 
ANALYTIC FILE 
 
USRDS Provider ID 
CMS Provider ID 
Zip code 
County code 
HSA/HRR code 
F
Market Characteristics 
Zip code 
County code 
HSA/HRR code 
HSA/HRR number
M
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FILES FOR ANALYSIS: 
 
revise_lag 
Source:  facilities_final 
Created:  facilities_final_lagged  (done in Stata) 
9 Create lead dep var (pdsvc), whereby analysis independent variables are lagged by one year 
(and examine why some pdsvc values are missing) 
9 Create new variables that indicate an observations’ referent year for lagged analysis (versus year 
of actual facility survey)  
9 Create facility patient load based on previous year’s patient load data 
o Home dialysis patients and total facilities’ patients (beginning & end of survey period) 
o Account for cases where facilities are missing previous year’s data 
9 For facilities reporting 0 HD stations in USRDS file, replace with POS data value or previous/later 
year’s USRDS data (based on POS data, newvar: stations)  
 
facilities_explore 
Source:  facilities_final + facilities_final_lagged 
Created:  facilities_for_analysis 
9 Bring in lagged variables (pdsvc, year indicators, patient lods, hd station corrections)  
9 More facility exclusion criteria – limit to facilities 1995-2003; drop VA facilities  Æ  n=32,253 
9 Create vars of interest: regional identifiers; facility urban location; service lines; treatment load; 
patient load; HD station occupancy rate; facility size; ownership change; facility age; HHI 
o Independent variables lagged by one year, with adjustments for lagged variables 
whereby cases with missing years of data or the last observation of a facility are 
corrected to accurately reflect temporal trend 
anypd_or = dep var (non-lagged)  &  pdserv = dep var of interest (lagged model) 
9 Adjustments to new variables where years of data missing and where Medicare start/end date do 
not concur with years of survey data available (data available before opening or after closing) 
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9 HRR-level only:  Assign 1996, 2001, 2003 physician density values to other years  
9 Revise facility-year count (i) 
 
 
facilities_explore_for_analysis 
Source:  facilities_for_analysis 
Created:  facilities_allcounts; fac_cnty; fac_hsa; fac_hrr 
9 Generate initial univariate statistics 
9 Create counts of facilities by county-  hsa-  and hrr-levels….for Q1 mapping 
 
 
 (n= 32,253  var=194) 
Var Source Description Values  
addr POS Street address <char> 
age <created> Facility age (from partdate) <num> 
anypd_and <created>  0= no CAPD & CCPD 
1= CAPD & CCPD 
anypd_or <created>  0= no CAPD or CCPD 
1= CAPD or CCPD 
area_lnd ARF Land area in square miles, 2000, 
county 
<num> 
assoc_id POS Previous provider ID <char> 
avdist <created> Average distance within HRR <num> 
avgcnty_comorb <created> Avg patient comorbidities, in county <num> 
avghrr_comorb <created> Avg patient comorbidities, in HRR <num> 
avghsa_comorb <created> Avg patient comorbidities, in HSA <num> 
avnd <created> Average nearest neighbor within 
HRR 
<num> 
beg_tot AFS Total dialysis patients, beginning 
survey period 
<num> 
beg_totalt <created> Total dialysis patients, beginning 
survey period (altered) 
<num> 
capd AFS CAPD  0=no      1= yes 
caphome AFS Patient volume: home-based CAPD <num> 
capintrg AFS Patient volume: CAPD training <num> 
catrgtrt AFS Treatment volume: CAPD training <num> 
cbsaflag2003 ZIPtoFIPS CBSA 2003 Flag 0= non-CBSA 
1= metropolitan 
2= micropolitan 
ccpd AFS CCPD  0=no      1= yes 
ccphome AFS Patient volume: home-based CCPD <num> 
ccpintrg AFS Patient volume: CCPD training <num> 
cctrgtrt AFS Treatment volume: CCPD training <num> 
certcode  AFS CMS Certification type 1=transplant ctr 
2=dialysis  ctr 
3=dialysis facil, hospital 
4=dialysis facil, 
freestanding 
5=transpl & dialysis ctr 
6=obsoleted category 
7=inpatient care only 
certpurp POS Certification action: purpose for 
certification 
1=initial 
2=recertification 
3=termination 
4=change of ownership 
chainaff AFS / 
POS 
Chain affiliation 0 = Not chain affiliated 
1= Chain affiliated 
chngdate POS Date of (recent) ownership change <date> 
city POS City (name of) <char> 
claritas <created> CLARITAS source indicator 0= not from CLARITAS 
1= from CLARITAS 
cms_elig POS CMS eligibility 0= no    1= yes 
cms_id AFS CMS assigned provider number <char> 
cms_id POS CMS provider ID <char> 
cnty_incdnt <created> ESRD incident cases, county <num> 
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 cnty_incrate <created> ESRD incidence rate, county <num> 
cnty_prevlnt <created> ESRD prevalent cases, county <num> 
cnty_prevrate <created> ESRD prevalence rate, county <num> 
cnty_totpdhd <created> Total PD & HD patients, county <num> 
cntyhdens <created> Hospital density (from AHA, ARF), 
county 
<num> 
cntyhdens_bd <created> Hospital bed density (from AHA, 
ARF), county 
<num> 
cntymddens <created> Nephrologist density (from AMA, 
ARF), county 
<num> 
county ARF County name <char> 
ctyname ARF County name with state abbreviation <char> 
dartatl DARTATL Dartmouth Atlas source indicator 0= not from Dartmouth 
Atlas 
1= from Dartmouth Atlas 
dualcovpct <created> % Medicare dual coverage, HRR <num> 
emplypct <created> % Employed (FT and PT), HRR <num> 
enctrl <created> East North Central US region 0= no    1= yes 
end_tot AFS Patient volume: Total - dialysis  <num> 
end_totalt <created> Total dialysis patients, end survey 
period (altered) 
<num> 
esctrl <created> East South Center US region 0= no    1= yes 
fipcnty POS County code FIPS county code <char> 
forprofit  AFS / 
POS 
For_profit ownership indicator 0= Non-profit  
1= For-profit   
freest AFS Facility setting 0= hospital-based  
1= freestanding 
geostatus <created> Geocoding status F= manually fixed 
coordinates 
M= address match 
P= match to previous 
record 
T= tied, address match 
U= unmatched, zip centroid 
hcdens <created> Healthcare density, HRR <num> 
hdoccp <created> HD occupancy rate, HRR <num> 
hdoccp_trn <created> HD occupancy rate, HRR (truncated) <num> 
hdonly <created> HD service only indicator 0= no    1= yes  
hemhome AFS Patient volume: home-based HD <num> 
hemintrg AFS Patient volume: HD training <num> 
hemo AFS Staff assisted HD  0=no      1= yes 
hemosc AFS In-unit self-care HD  0=no      1= yes 
hemotrng AFS HD training  0=no      1= yes 
hemslstf AFS Patient volume: outpatient HD <num> 
hhi_cnty <created> Hirschman Herfindahl Index, county <num> 
hhi_hrr <created> HHI, HRR <num> 
hhi_hsa <created> HHR, HSA <num> 
hrr DARTATL HRR code <num> 
hrr_incdnt <created> ESRD incident cases, HRR <num> 
hrr_incrate <created> ESRD incidence rate, HRR <num> 
hrr_prevlnt <created> ESRD prevalent cases, HRR <num> 
hrr_prevrate <created> ESRD prevalence rate, HRR <num> 
hrr_totpdhd <created> Total PD & HD patients, HRR <num> 
hrrarea <created> Land area in square miles, HRR <num> 
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 hrrcity <created> HRR city <char> 
hrrhdens <created> Hospital density, HRR <num> 
hrrhdens_bd <created> Hospital bed density, HRR <num> 
hrrhdens_bd2 <created> Hospital bed density, HRR (ArcGIS 
area) 
<num> 
hrrhdens2 <created> Hospital density, HRR (ArcGIS area) <num> 
hrrmddens <created> Nephrologist density, HRR <num> 
hrrmddens2 <created> Nephrologist density, HRR (ArcGIS 
area) 
<num> 
hrrnd <created> Nearest neighbor within HRR <num> 
hrrpcturb <created> % urban population, 2000, HRR <num> 
hrrst DARTATL HRR state <char> 
hrrurbpop <created> Urban population, HRR <num> 
hsa DARTATL HSA code <num> 
hsa_incdnt <created> ESRD incident cases, HSA <num> 
hsa_incrate <created> ESRD incidence rate, HSA <num> 
hsa_prevlnt <created> ESRD prevalent cases, HSA <num> 
hsa_prevrate <created> ESRD prevalence rate, HSA <num> 
hsa_totpdhd <created> Total PD & HD patients, HSA <num> 
hsaarea <created> Land area in square miles, HSA <num> 
hsacity DARTATL HSA city <char> 
hsahdens <created> Hospital density, HSA <num> 
hsahdens_bd <created> Hospital bed density, HSA <num> 
hsamddens <created> Nephrologist density, HSA <num> 
hsapcturb <created> % urban population, 2000, HAS <num> 
hsast <created> HSA state <char> 
hsaurbpop <created> Urban population, HSA <num> 
htrgtrt AFS Treatment volume: HD training <num> 
i <created> facility-record counter <num>   
ih_beg <created> Total HD patients, beginning survey 
period 
<num> 
ih_begalt <created> Total HD patients, beginning survey 
period (altered) 
<num> 
ih_end AFS Patient volume: Total home-based <num> 
ih_endalt <created> Total HD patients, end survey period 
(altered) 
<num> 
imp_source <created> source year of imputed case-year <num> 
imp_vol <created> Imputation indicator (volume imputed 
due to ownership change) 
0= no    1= yes 
inc_cnty ARF Personal income, county <num> 
inc_hrr <created> Personal income, HRR <num> 
inc_hsa <created> Personal income, HSA <num> 
iu_beg AFS Total in-unit patients, beginning 
survey period 
<num> 
iu_end AFS Patient volume: Total outpatient <num> 
lyear <created> Dependent var lead year, lagged 
covariate 
<num> 
med_va AFS VA facility 1= non-VA facility 
2= non-Medicare VA facility 
3= Medicare VA facility 
4= Other 
metflag1999 ZIPStoFIP
S 
MSA flag 1999 0= non-metropolitan 
1= metropolitan 
mfipcnty <created> Modified FIPS county code <num> 
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 midatl <created> Mid-Atlantic US subregion 0= no    1= yes 
midwest <created> Midwest US region 0= no    1= yes 
mindist <created> Minimum distance to nearest PD 
facility 
<num> 
missdata <created> Survey data values imputed indicator 0= no    1= yes 
missyr <created> Missing year indicator, imputed 0= no    1= yes 
mtn <created> Mountain US subregion 0= no    1= yes 
name POS Facility name <char> 
ne / variabl0 <created> New England US subregion 0= no    1= yes 
network AFS ESRD Network identifier 1= CT, ME, MA, NH, RI, VT 
2=NY 
3=NJ, PR, VI 
4=PA 
5=VA, WV, MD, DC 
6=GA, NC, SC 
7=FL 
8=AL, MS, TN 
9=IN, KY, OH 
10=IL 
11=MN, MI, ND, SD, WI 
12=IA, KS, MO, NE 
13=AK, LA, OK 
14=TX 
15=AZ, CO, NV, NM, UT, 
WY 
16=AK, ID, MT, OR, WA 
17=AS, GU, MH, HI, NoCA 
18=SoCA 
nn_rat <created> Nearest neighbor ratio (ArcGIS calc) <num> 
nn_scr <created> Nearest neighbor Z score (ArcGIS 
calc) 
<num> 
nnindex <created> Nearest neighbor ration (hand calc) <num> 
noneldpct <created> % nonelderly, HRR <num> 
northeast <created> Northeast US region 0= no    1= yes 
op_htrt AFS Treatment volume: outpatient HD <num> 
op_ptrt AFS Treatment volume: outpatient PD <num> 
ownchng0 POS # times ownership changed in year 0= no change 
1 = change in year 
ownchng1 POS # times ownership changed in 
previous year 
0= no change 
1 = change in previous year 
ownchng2 POS # times ownership changed in 
previous 2 years 
0= no change 
1 = change in pervious 2 
years 
pac <created> Pacific US subregion 0= no    1= yes 
partdate POS Participation date (first CMS 
approval) 
<date> 
pci_cnty <created> Per capita income, county <num> 
pci_hrr <created> Per capita income, HRR <num> 
pci_hsa <created> Per capita income, HSA <num> 
pctcnty_anycov <created> % with any ins coverage, county <num> 
pctcnty_dualcov <created> % with Medicare dual coverage, 
county 
<num> 
pctcnty_emplyd <created> % employed (FT or PT), county  <num> 
pctcnty_noneld <created> %non-elderly, county <num> 
pctcnty_white <created> % white, non-Hispanic, county <num> 
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 pcthrr_anycov <created> % with any ins coverage, HRR <num> 
pcthrr_dualcov <created> % with Medicare dual coverage, 
HRR 
<num> 
pcthrr_emplyd <created> % employed (FT or PT), HRR <num> 
pcthrr_noneld <created> % non-elderly, HRR <num> 
pcthrr_white <created> % white, non-Hispanic, HRR <num> 
pcthsa_anycov <created> % with any ins coverage, HSA <num> 
pcthsa_dualcov <created> % with Medicare dual coverage, 
HSA 
<num> 
pcthsa_emplyd <created> % employed (FT or PT), HSA <num> 
pcthsa_noneld <created> % non-elderly, HSA <num> 
pcthsa_white <created> %white, non-Hispanic, HSA <num> 
pcturb <created> % urban population, 2000, county <num> 
pdsvc <created> Any PD service indicator (1-year 
lead) 
0= no    1= yes 
perhome AFS Patient volume: home-based PD <num> 
peri AFS Staff assisted PD  0=no      1= yes 
perintrg AFS Patient volume: PD training <num> 
perisc AFS In-unit self-care PD  0=no      1= yes 
peritrng AFS PD training  0=no      1= yes 
perslstf AFS Patient volume: outpatient PD <num> 
points <created> Number of points/fac’s within HRR <num> 
pop_cnty ARF Total population, county <num> 
pop_hrr <created> Total population, HRR <num> 
pop_hsa <created> Total population, HSA <num> 
pos_year POS POS file year <num> 
prchngdate POS Date of prior change of ownership <date> 
provusrd AFS USRDS provider ID <char> 
pt_hd <created> Total HD patients <num> 
pt_hdall <created> Total HD + HD training patients <num> 
pt_pd <created> Total PD patients <num> 
pt_pdall <created> Total PD + PD training patients <num> 
pt_pdtrn <created> Total PD training patients <num> 
pt_totall <created> Total patients, all in facility <num> 
pt_totalt <created> Total patients, all in facility (altered) <num> 
pt_tothome <created> Total home-based dialysis patients <num> 
pt_totop <created> Total center-based dialysis patients <num> 
pt_totpdhd <created> Total PD + HD patients <num> 
ptrgtrt AFS Treatment volume: PD training <num> 
region <created> US region code 1= Northeast 
2= Midwest 
3= South 
4= West 
satl <created> South Atlantic US subregion 0= no    1= yes 
size <created> Facility size <num> 
south <created> South US region 0= no    1= yes 
sqmi <created> Land area in square miles (ArcGIS), 
HRR 
<num> 
state 
fipst 
POS State State abbrev <char> 
FIPS state code <char> 
stations AFS / 
POS 
Total dialysis stations in facility <num> 
study_id <created> Provider ID (ownership tracked, for 
analysis) 
<char> 
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subregion <created> US subregion code 1= New England 
2= Mid-Atlantic 
3= East North Central 
4= West North Central 
5= South Atlantic 
6= East South Central 
7= West South Central 
8= Mountain 
9= Pacific 
termcode AFS Termination reason 1=involuntary withdrawal 
2=failure to meet std 
3=failure to meet util rate 
4=failure to meet need 
reqrm 
5=closed 
6=other 
tot_txpl AFS Treatment volume: Transplants (any) <num> 
trmcod POS Termination reason  0= active 
1= vol merg, close 
2= vol reimburse 
3= risk invol 
4= vol - other 
5= invol - fail req 
6= invol - agreemnt 
7= other - status chg 
trmdat POS Termination date <date> 
tx_all <created> Total treatments <num> 
tx_hd <created> Total HD treatments <num> 
tx_pd <created> Total PD treatments <num> 
tx_train <created> Total dialysis training treatments <num> 
txpl_pat AFS Patient volume: Total - transplant <num> 
urb00pop ARF Total urban population, 2000, county <num> 
urbfac <created> Facility urban location (from 
CBSAflag2003) 
0= non-metropolitan  
1= metropolitan 
urbpct <created> % urban population, 2000, HRR <num> 
west <created> West US region 0= no    1= yes 
whitepct <created> % white, non-Hispanic, HRR <num> 
wnctrl <created> West North Central US subregion 0= no    1= yes 
wsctrl <created> West South Central US subregion 0= no    1= yes 
x <created> Longitude coordinate <num> 
y <created> Latitude coordinate <num> 
year AFS USRDS Survey year  <num> 
zip POS Zip code <num> 
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 Annual Facility Counts of PD Service Availability 
by HRR 
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 Annual Facility Counts of PD Service Availability 
by HRR (cont.) 
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 Annual Facility Counts of PD Service Availability 
by HRR (cont.) 
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 Annual Percent PD Service Availability in Dialysis Facilities 
by HRR 
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 Annual Percent PD Service Availability in Dialysis Facilities 
by HRR (cont.) 
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Annual Percent PD Service Availability in Dialysis Facilities 
by HRR (cont.) 
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 APPENDIX C 
Results of multicollinearity tests 
Depend var:  PD Service    
N=27,497 
Full Model  Test 1: drop  
% white 
 Test 2: drop 
Avg comorbidity 
Covariate (one-year lagged value) β  S.E  β S.E  β S.E 
Market-level characteristics (HRR)       
ESRD patient-specific      
ESRD prevalence  -.011 .005 -.018 .004  -.011 .005 
% White, non-Hispanic (10s) .204 .054 -- --  .202 .051 
% Non-elderly (10s) -.061 .122 -.272 .118  -.057 .120 
Comorbid conditions -.023 .166 .165 .159  -- -- 
% Employed (10s) -.998 .184 -.679 .174  -1.013 .173 
% With Medicare dual coverage (10s) .146 .113 .199 .115  .138 .096 
General        
% Urban population (10s) .073 .037 .036 .035  .073 .037 
Per capita income (1,000s)  .032 .014 .035 .013  .033 .013 
Healthcare density  -.119 .044 -.116 .044  -.119 .044 
Dialysis market competition  .585 .304 .837 .300  .587 .304 
Facility-level characteristics        
For-profit ownership .010 .116 -.011 .116  .010 .116 
Chain-affiliation -.524 .081 -.513 .081  -.525 .081 
Freestanding facilities .042 .124 .051 .126  .042 .124 
Urban location .284 .103 .317 .104  .284 .103 
Facility age .043 .006 .043 .006  .043 .006 
Facility size (10s) .217 .017 .210 .016  .217 .017 
HD station occupancy rate (10s) -.202 .014 -.197 .014  -.202 .014 
Ownership change, during year .092 .079 .086 .079  .092 .078 
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 Results of multicollinearity tests (continued) 
Depend var:  PD Service    
N=27,497 
Full Model  Test 3a: drop  
% urban popul. 
 Test 3b: drop 
freestanding 
Covariate (one-year lagged value) β  S.E  β S.E  β S.E 
Market-level characteristics (HRR)       
ESRD patient-specific       
ESRD prevalence  -.011 .005 -.010 .005  -.011 .005 
% White, non-Hispanic (10s) .204 .054 .181 .052  .204 .054 
% Non-elderly (10s) -.061 .122 -.106 .118  -.059 .121 
Comorbid conditions -.023 .166 -.019 .164  -.023 .166 
% Employed (10s) -.998 .184 -.903 .184  -1.001 .186 
% With Medicare dual coverage (10s) .146 .113 .101 .114  .147 .113 
General        
% Urban population (10s) .073 .037 -- --  .073 .037 
Per capita income (1,000s)  .032 .014 .041 .012  .032 .014 
Healthcare density  -.119 .044 -.110 .050  -.119 .044 
Dialysis market competition  .585 .304 .453 .302  .582 .305 
Facility-level characteristics        
For-profit ownership .010 .116 .031 .117  .032 .088 
Chain-affiliation -.524 .081 -.536 .081  -.516 .082 
Freestanding facilities .042 .124 .048 .124  -- -- 
Urban location .284 .103 .362 .102  .285 .103 
Facility age .043 .006 .043 .006  .042 .006 
Facility size (10s) .217 .017 .217 .017  .217 .017 
HD station occupancy rate (10s) -.202 .014 -.200 .014  -.202 .014 
Ownership change, during year .092 .079 .091 .079  .094 .079 
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Results of multicollinearity tests (continued) 
Depend var:  PD Service    
N=27,497 
Full Model  Test 4: drop  
size 
 Test 5a: drop 
HD occupancy 
Covariate (one-year lagged value) β  S.E  β S.E  β S.E 
Market-level characteristics (HRR)       
ESRD patient-specific      
ESRD prevalence  -.011 .005 -.012 .005  -.010 .005 
% White, non-Hispanic (10s) .204 .054 .088 .053  .178 .054 
% Non-elderly (10s) -.061 .122 -.068 .117  -.030 .122 
Comorbid conditions -.023 .166 .103 .158  .054 .166 
% Employed (10s) -.998 .184 -.943 .176  -1.061 .185 
% With Medicare dual coverage (10s) .146 .113 .207 .112  .161 .114 
General        
% Urban population (10s) .073 .037 .065 .038  .055 .036 
Per capita income (1,000s)  .032 .014 .032 .014  .029 .013 
Healthcare density  -.119 .044 -.069 .042  -.123 .037 
Dialysis market competition  .585 .304 1.003 .281  .493 .299 
Facility-level characteristics        
For-profit ownership .010 .116 .017 .111  .079 .113 
Chain-affiliation -.524 .081 -.487 .071  -.528 .082 
Freestanding facilities .042 .124 .420 .121  .088 .128 
Urban location .284 .103 .751 .101  .413 .101 
Facility age .043 .006 .073 .006  .041 .006 
Facility size (10s) .217 .017 -- --  .135 .012 
HD station occupancy rate (10s) -.202 .014 .0001 .012  -- -- 
Ownership change, during year .092 .079 .027 .074  .018 .077 
 
  
 
 REFERENCES 
 
1. US Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in 
the United States. 2006, National Institutes of Health, National Institute of Diabetes and 
Digestive and Kidney Diseases: Bethesda, MD. 
2. General Accounting Office (GAO), Medicare Dialysis Facilities: Beneficiary access stable and 
problems in payment system being addressed.  Report to Congressional Committees, GAO-04-
450. 2004, General Accounting Office: Washington, DC. 
3. Nissenson, A.R. and R.A. Rettig, Medicare's end-stage renal disease program: current status and 
future prospects. Health Aff (Millwood), 1999. 18(1): p. 161-79. 
4. US Renal Data System, USRDS 2007 Annual Data Report: Atlas of End-stage Renal Disease in 
the United States. 2007, National Institutes of Health, National Institute of Diabetes and 
Digestive and Kidney Diseases: Bethesda, MD. 
5. National Institute of Diabetes and Digestive Kidney Diseases. End-Stage Renal Disease: 
Choosing a Treatment That's Right For You.  Publication No. 94-2412.  1997 October 17 [cited 
September 20, 2005]; Available from: www.niddk.nih.gov/health/kidney/pubs/esrd.esrd.htm. 
6. Medicare Payment Advisory Commission (MedPAC), End-stage renal disease payment policies 
in traditional Medicare.  In Report to Congress: Medicare Payment Policy. 2001, Medicare 
Payment Advisory Commission: Washington, DC. 
7. Meyer, K.B. and J.P. Kassirer, Squeezing more cost and care out of dialysis: our patients would 
pay the price. Am J Med, 2002. 112(3): p. 232-4. 
8. Horl, W.H., F. de Alvaro, and P.F. Williams, Healthcare systems and end-stage renal disease 
(ESRD) therapies--an international review: access to ESRD treatments. Nephrol Dial Transplant, 
1999. 14 Suppl 6: p. 10-5. 
9. US Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in 
the United States. 2005, National Institutes of Health, National Institute of Diabetes and 
Digestive and Kidney Diseases: Bethesda, MD. 
10. Blake, P.G., The complex economics of modality selection. Perit Dial Int, 2004. 24(6): p. 509-
11. 
11. Blake, P.G. and F.O. Finkelstein, Why is the proportion of patients doing peritoneal dialysis 
declining in North America? Perit Dial Int, 2001a. 21(2): p. 107-14. 
12. Neumann, M.E., Has consolidation hurt the growth of PD? Nephrol News Issues, 2002. 16(9): p. 
15. 
13. Khawar, O., et al., Is the declining use of long-term peritoneal dialysis justified by outcome 
data? Clin J Am Soc Nephrol, 2007. 2(6): p. 1317-28. 
167 
 
 14. Mehrotra, R., et al., Chronic peritoneal dialysis in the United States: declining utilization despite 
improving outcomes. J Am Soc Nephrol, 2007. 18(10): p. 2781-8. 
15. Medicare Payment Advisory Commission (MedPAC), Payment for dialysis.  In Report to 
Congress: Issues in a Modernized Medicare Program. 2005, Medicare Payment Advisory 
Commission: Washington, DC. p. 85-102. 
16. Hirth, R.A., P.J. Tedeschi, and J.R. Wheeler, Extent and sources of geographic variation in 
Medicare end-stage renal disease expenditures. Am J Kidney Dis, 2001. 38(4): p. 824-31. 
17. Lee, H., et al., Cost analysis of ongoing care of patients with end-stage renal disease: the impact 
of dialysis modality and dialysis access. Am J Kidney Dis, 2002. 40(3): p. 611-22. 
18. Mehrotra, R., et al., Patient education and access of ESRD patients to renal replacement 
therapies beyond in-center hemodialysis. Kidney Int, 2005. 68(1): p. 378-90. 
19. Mendelssohn, D.C., PD and the future: the role of PD in the overall management of ESRD. 
Blood Purif, 2003. 21(1): p. 24-8. 
20. Xue, J.L., et al., Forecast of the number of patients with end-stage renal disease in the United 
States to the year 2010. J Am Soc Nephrol, 2001. 12(12): p. 2753-8. 
21. Gokal, R., Peritoneal dialysis, B: Techniques, indications, and complications of peritoneal 
dialysis, in Massry & Glassock's Textbook of Nephrology, Fourth Edition, S.G. Massry and R.J. 
Glassock, Editors. 2001, Lippincott Williams & Wilkins: Philadelphia, PA. 
22. Blake, P.G., Factors affecting international utilization of peritoneal dialysis: Implications for 
increasing utilization in the United States. Semin Dial, 1999. 12(5): p. 365-369. 
23. Coles, G.A. and J.D. Williams, What is the place of peritoneal dialysis in the integrated 
treatment of renal failure? Kidney Int, 1998. 54(6): p. 2234-40. 
24. Kiser, M., Personal communication, July 10, 2006. 2006: Carrboro, NC. 
25. Medicare Payment Advisory Commission, Outpatient dialysis services.  In: Report to the 
Congress, Medicare Payment Policy. 2006, Medicare Payment Advisory Commission: 
Washington, DC. p. 104-129. 
26. Miskulin, D.C., et al., Comorbidity and other factors associated with modality selection in 
incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-
Stage Renal Disease. Am J Kidney Dis, 2002. 39(2): p. 324-36. 
27. Mottl, A., Personal communication (via electronic mail), April 6, 2006, May 5, Editor. 2006: 
Chapel Hill, NC. 
28. Rubin, H.R., et al., Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis. 
Jama, 2004. 291(6): p. 697-703. 
29. Stack, A.G., Determinants of modality selection among incident US dialysis patients: results 
from a national study. J Am Soc Nephrol, 2002. 13(5): p. 1279-87. 
168 
 
 30. Stack, A.G., et al., Impact of dialysis modality on survival of new ESRD patients with 
congestive heart failure in the United States. Kidney Int, 2003. 64(3): p. 1071-9. 
31. Thamer, M., et al., US nephrologists' recommendation of dialysis modality: results of a national 
survey. Am J Kidney Dis, 2000. 36(6): p. 1155-65. 
32. Xue, J.L., et al., Peritoneal and hemodialysis: I. Differences in patient characteristics at 
initiation. Kidney Int, 2002a. 61(2): p. 734-40. 
33. Maiorca, R., The rational choice of treatments in nephrology. Contrib Nephrol, 1994. 109: p. 25-
32. 
34. Venkataraman, V. and K.D. Nolph, Socioeconomic aspects of peritoneal dialysis in North 
America: role of non medical factors in the choice of dialysis. Perit Dial Int, 1999. 19 Suppl 2: p. 
S419-22. 
35. Moran, J. and E. Vonesh, Peritoneal dialysis, E: Morbidity and mortality, in Massry & 
Glassock's Textbook of Nephrology, Fourth Edition, S.G. Massry and R.J. Glassock, Editors. 
2001, Lippincott Williams & Wilkins: Philadelphia, PA. 
36. Vale, L., et al., Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home 
haemodialysis for end-stage renal disease in adults. Cochrane Database of Systematic Reviews, 
2004: p. Issue 4.  Article No.: CD003963.pub2.  DOI: 10.1002/14651858.CD003963.pub2. 
37. Foley, R.N., et al., Mode of dialysis therapy and mortality in end-stage renal disease. J Am Soc 
Nephrol, 1998. 9(2): p. 267-76. 
38. Bloembergen, W.E., et al., A comparison of mortality between patients treated with 
hemodialysis and peritoneal dialysis. J Am Soc Nephrol, 1995. 6(2): p. 177-83. 
39. Canada-USA Peritoneal Dialysis Study Group, Adequacy of dialysis and nutrition in continuous 
peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal 
Dialysis Study Group. J Am Soc Nephrol, 1996. 7(2): p. 198-207. 
40. Disney, A.P., Demography and survival of patients receiving treatment for chronic renal failure 
in Australia and New Zealand: report on dialysis and renal transplantation treatment from the 
Australia and New Zealand Dialysis and Transplant Registry. Am J Kidney Dis, 1995. 25(1): p. 
165-75. 
41. Fenton, S., et al., Renal replacement therapy in Canada: a report from the Canadian Organ 
Replacement Register. Am J Kidney Dis, 1995. 25(1): p. 134-50. 
42. Held, P.J., et al., Continuous ambulatory peritoneal dialysis and hemodialysis: comparison of 
patient mortality with adjustment for comorbid conditions. Kidney Int, 1994. 45(4): p. 1163-9. 
43. Locatelli, F., et al., 1983 to 1992: report on regular dialysis and transplantation in Lombardy. 
Am J Kidney Dis, 1995. 25(1): p. 196-205. 
44. Maiorca, R., et al., A multicenter, selection-adjusted comparison of patient and technique 
survivals on CAPD and hemodialysis. Perit Dial Int, 1991. 11(2): p. 118-27. 
169 
 
 45. Piccoli, G., et al., Regional registry of dialysis and transplantation of Piedmont, Italy (RPDT). 
Thirteen years of experience. Regional Registry of Dialysis and Transplantation. Nephrol Dial 
Transplant, 1995. 10(4): p. 444-7. 
46. Serkes, K.D., et al., Comparison of patient and technique survival in continuous ambulatory 
peritoneal dialysis (CAPD) and hemodialysis: a multicenter study. Perit Dial Int, 1990. 10(1): p. 
15-9. 
47. Vonesh, E.F. and J. Moran, Mortality in end-stage renal disease: a reassessment of differences 
between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol, 1999. 
10(2): p. 354-65. 
48. Vonesh, E.F., et al., The differential impact of risk factors on mortality in hemodialysis and 
peritoneal dialysis. Kidney Int, 2004. 66(6): p. 2389-401. 
49. Fenton, S.S., et al., Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality 
rates. Am J Kidney Dis, 1997. 30(3): p. 334-42. 
50. Jaar, B.G., et al., Comparing the risk for death with peritoneal dialysis and hemodialysis in a 
national cohort of patients with chronic kidney disease. Ann Intern Med, 2005. 143(3): p. 174-
83. 
51. Gokal, R., Peritoneal dialysis in the 21st century: an analysis of current problems and future 
developments. J Am Soc Nephrol, 2002b. 13 Suppl 1: p. S104-16. 
52. Bruns, F.J., et al., The cost of caring for end-stage kidney disease patients: an analysis based on 
hospital financial transaction records. J Am Soc Nephrol, 1998. 9(5): p. 884-90. 
53. Ahmad, M., et al., Advantages of peritoneal dialysis in comparison to hemodialysis, in cardiac 
allograft recipients with end stage renal disease. Int Urol Nephrol, 2008. 
54. Collins, A.J., et al., Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis, 
1999. 34(6): p. 1065-74. 
55. Heaf, J.G., H. Lokkegaard, and M. Madsen, Initial survival advantage of peritoneal dialysis 
relative to haemodialysis. Nephrol Dial Transplant, 2002. 17(1): p. 112-7. 
56. Korevaar, J.C., et al., Effect of starting with hemodialysis compared with peritoneal dialysis in 
patients new on dialysis treatment: a randomized controlled trial. Kidney Int, 2003. 64(6): p. 
2222-8. 
57. Lameire, N., et al., Peritoneal dialysis in Europe: an analysis of its rise and fall. Blood Purif, 
2006. 24(1): p. 107-14. 
58. Termorshuizen, F., et al., Hemodialysis and peritoneal dialysis: comparison of adjusted mortality 
rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the 
Adequacy of Dialysis 2. J Am Soc Nephrol, 2003. 14(11): p. 2851-60. 
59. Murphy, S.W., et al., Comparative mortality of hemodialysis and peritoneal dialysis in Canada. 
Kidney Int, 2000a. 57(4): p. 1720-6. 
170 
 
 60. Gokal, R., et al., Outcomes in peritoneal dialysis and haemodialysis--a comparative assessment 
of survival and quality of life. Nephrol Dial Transplant, 1999. 14 Suppl 6: p. 24-30. 
61. Jung, B., et al., Attitudes of Canadian nephrologists toward dialysis modality selection. Perit 
Dial Int, 1999. 19(3): p. 263-8. 
62. Schaubel, D.E. and S.S. Fenton, Trends in mortality on peritoneal dialysis: Canada, 1981-1997. J 
Am Soc Nephrol, 2000. 11(1): p. 126-33. 
63. Tanna, M.M., E.F. Vonesh, and S.M. Korbet, Patient survival among incident peritoneal dialysis 
and hemodialysis patients in an urban setting. Am J Kidney Dis, 2000. 36(6): p. 1175-82. 
64. Thodis, E., et al., Peritoneal dialysis: better than, equal to, or worse than hemodialysis? Data 
worth knowing before choosing a dialysis modality. Perit Dial Int, 2001. 21(1): p. 25-35. 
65. Van Biesen, W., et al., An evaluation of an integrative care approach for end-stage renal disease 
patients. J Am Soc Nephrol, 2000. 11(1): p. 116-25. 
66. Winkelmayer, W.C., et al., Comparing mortality of elderly patients on hemodialysis versus 
peritoneal dialysis: a propensity score approach. J Am Soc Nephrol, 2002. 13(9): p. 2353-62. 
67. Xue, J.L., et al., Peritoneal and hemodialysis: II. Mortality risk associated with initial patient 
characteristics. Kidney Int, 2002b. 61(2): p. 741-6. 
68. Guo, A. and S. Mujais, Patient and technique survival on peritoneal dialysis in the United States: 
evaluation in large incident cohorts. Kidney Int Suppl, 2003(88): p. S3-12. 
69. Shahab, I., R. Khanna, and K.D. Nolph, Peritoneal dialysis or hemodialysis? A dilemma for the 
nephrologist. Adv Perit Dial, 2006. 22: p. 180-5. 
70. Kutner, N.G., et al., Health status and quality of life reported by incident patients after 1 year on 
haemodialysis or peritoneal dialysis. Nephrol Dial Transplant, 2005. 20(10): p. 2159-67. 
71. Blake, P.G., Integrated end-stage renal disease care: the role of peritoneal dialysis. Nephrol Dial 
Transplant, 2001b. 16 Suppl 5: p. 61-6. 
72. Blake, P.G., PD underutilized as ESRD therapy. Semin Dial, 2002. 15(3): p. 151-153. 
73. Burkart, J.M., PD underutilized as ESRD therapy. Semin Dial, 2002. 15(3): p. 157-161. 
74. Davies, S.J., et al., Integrated care. Perit Dial Int, 2001. 21 Suppl 3: p. S269-74. 
75. Agarwal, M., P. Clinard, and J.M. Burkart, Combined peritoneal dialysis and hemodialysis: our 
experience compared to others. Perit Dial Int, 2003. 23(2): p. 157-61. 
76. Kawanishi, H. and C. McIntyre, Complementary use of peritoneal and hemodialysis: therapeutic 
synergies in the treatment of end-stage renal failure patients. Kidney Int Suppl, 2008(108): p. 
S63-7. 
77. Nesrallah, G. and D.C. Mendelssohn, Modality options for renal replacement therapy: the 
integrated care concept revisited. Hemodial Int, 2006. 10(2): p. 143-51. 
171 
 
 78. Heaf, J., Underutilization of peritoneal dialysis. Jama, 2004. 291(6): p. 740-2. 
79. De Vecchi, A.F., M. Dratwa, and M.E. Wiedemann, Healthcare systems and end-stage renal 
disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD 
therapies. Nephrol Dial Transplant, 1999. 14 Suppl 6: p. 31-41. 
80. Moore, R. and N. Marriott, Cost and price in the NHS: the importance of monetary value in the 
decision-making framework--the case of purchasing renal replacement therapy. Health Serv 
Manage Res, 1999. 12(1): p. 1-14. 
81. Nissenson, A.R., Health-care economics and peritoneal dialysis. Perit Dial Int, 1996. 16 Suppl 1: 
p. S373-7. 
82. de Wit, G.A., P.G. Ramsteijn, and F.T. de Charro, Economic evaluation of end stage renal 
disease treatment. Health Policy, 1998. 44(3): p. 215-32. 
83. Ploth, D.W., et al., Prospective analysis of global costs for maintenance of patients with ESRD. 
Am J Kidney Dis, 2003. 42(1): p. 12-21. 
84. Rodriguez-Carmona, A., et al., The economic cost of dialysis: a comparison between peritoneal 
dialysis and in-center hemodialysis in a Spanish unit. Adv Perit Dial, 1996. 12: p. 93-6. 
85. Salonen, T., et al., Cost analysis of renal replacement therapies in Finland. Am J Kidney Dis, 
2003. 42(6): p. 1228-38. 
86. Sennfalt, K., M. Magnusson, and P. Carlsson, Comparison of hemodialysis and peritoneal 
dialysis--a cost-utility analysis. Perit Dial Int, 2002. 22(1): p. 39-47. 
87. Tediosi, F., et al., Cost analysis of dialysis modalities in Italy. Health Serv Manage Res, 2001. 
14(1): p. 9-17. 
88. Zelmer, J.L., The economic burden of end-stage renal disease in Canada. Kidney Int, 2007. 
72(9): p. 1122-9. 
89. McMurray, S.D. and J. Miller, Impact of capitation on free-standing dialysis facilities: can you 
survive? Am J Kidney Dis, 1997. 30(4): p. 542-8. 
90. Shih, Y.C., et al., Impact of initial dialysis modality and modality switches on Medicare 
expenditures of end-stage renal disease patients. Kidney Int, 2005. 68(1): p. 319-29. 
91. Goeree, R., et al., Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin 
Invest Med, 1995. 18(6): p. 455-64. 
92. US Renal Data System, Economic costs of ESRD., in USRDS 2000 Annual data report. 2000, 
National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: 
Bethesda, MD. p. 163-166. 
93. Dor, A., et al., End-stage renal disease and economic incentives: the International Study of 
Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ, 2007. 7(2-
3): p. 73-111. 
172 
 
 94. Jager, K.J., et al., The effect of contraindications and patient preference on dialysis modality 
selection in ESRD patients in The Netherlands. Am J Kidney Dis, 2004. 43(5): p. 891-9. 
95. Troidle, L., A. Kliger, and F. Finkelstein, Barriers to utilization of chronic peritoneal dialysis in 
network #1, New England. Perit Dial Int, 2006. 26(4): p. 452-7. 
96. Chow, K.M., et al., Impact of early nephrology referral on mortality and hospitalization in 
peritoneal dialysis patients. Perit Dial Int, 2008. 28(4): p. 371-6. 
97. Lameire, N., et al., The referral pattern of patients with ESRD is a determinant in the choice of 
dialysis modality. Perit Dial Int, 1997. 17 Suppl 2: p. S161-6. 
98. Jungers, P., et al., Late referral to maintenance dialysis: detrimental consequences. Nephrol Dial 
Transplant, 1993. 8(10): p. 1089-93. 
99. Schmidt, R.J., et al., Early referral and its impact on emergent first dialyses, health care costs, 
and outcome. Am J Kidney Dis, 1998. 32(2): p. 278-83. 
100. Sesso, R. and A.G. Belasco, Late diagnosis of chronic renal failure and mortality on 
maintenance dialysis. Nephrol Dial Transplant, 1996. 11(12): p. 2417-20. 
101. Wuerth, D.B., et al., Patients' descriptions of specific factors leading to modality selection of 
chronic peritoneal dialysis or hemodialysis. Perit Dial Int, 2002. 22(2): p. 184-90. 
102. Tonelli, M., et al., Use and outcomes of peritoneal dialysis among Aboriginal people in Canada. 
J Am Soc Nephrol, 2005. 16(2): p. 482-8. 
103. Asif, A., et al., Peritoneal dialysis underutilization: the impact of an interventional nephrology 
peritoneal dialysis access program. Semin Dial, 2003. 16(3): p. 266-71. 
104. Prichard, S.S., Treatment modality selection in 150 consecutive patients starting ESRD therapy. 
Perit Dial Int, 1996. 16(1): p. 69-72. 
105. Schreiber, M., et al., Preliminary findings from the National Pre-ESRD Education Initiative. 
Nephrol News Issues, 2000. 14(12): p. 44-6. 
106. Ahlmen, J., L. Carlsson, and C. Schonborg, Well-informed patients with end-stage renal disease 
prefer peritoneal dialysis to hemodialysis. Perit Dial Int, 1993. 13 Suppl 2: p. S196-8. 
107. Wolcott, D.L. and A.R. Nissenson, Quality of life in chronic dialysis patients: a critical 
comparison of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. Am J 
Kidney Dis, 1988. 11(5): p. 402-12. 
108. Wu, A.W., et al., Changes in quality of life during hemodialysis and peritoneal dialysis 
treatment: generic and disease specific measures. J Am Soc Nephrol, 2004. 15(3): p. 743-53. 
109. Bass, E.B., et al., How strong are patients' preferences in choices between dialysis modalities 
and doses? Am J Kidney Dis, 2004. 44(4): p. 695-705. 
110. US Renal Data System, The USRDS dialysis morbidity and mortality study: Wave 2., in USRDS 
Annual data report. 1997, National Institutes of Health, National Institute of Diabetes and 
Digestive and Kidney Diseases: Bethesda, MD. p. 49-68. 
173 
 
 111. Furth, S.L., et al., Relation between pediatric experience and treatment recommendations for 
children and adolescents with kidney failure. Jama, 2001. 285(8): p. 1027-33. 
112. Mehrotra, R., et al., An analysis of dialysis training in the United States and Canada. Am J 
Kidney Dis, 2002. 40(1): p. 152-60. 
113. Charest, A.F. and D.C. Mendelssohn, Are North American nephrologists biased against 
peritoneal dialysis? Perit Dial Int, 2001. 21(4): p. 335-7. 
114. Mendelssohn, D.C., et al., What do American nephrologists think about dialysis modality 
selection? Am J Kidney Dis, 2001. 37(1): p. 22-29. 
115. Gadallah, M.F., et al., Changing the trend: a prospective study on factors contributing to the 
growth rate of peritoneal dialysis programs. Adv Perit Dial, 2001. 17: p. 122-6. 
116. Piraino, B., The choice study. Perit Dial Int, 2006. 26(4): p. 423-5. 
117. Schaubel, D.E., P.G. Blake, and S.S. Fenton, Effect of renal center characteristics on mortality 
and technique failure on peritoneal dialysis. Kidney Int, 2001. 60(4): p. 1517-24. 
118. Schlesinger, M., P.D. Cleary, and D. Blumenthal, The ownership of health facilities and clinical 
decisionmaking. The case of the ESRD industry. Med Care, 1989. 27(3): p. 244-58. 
119. Furth, S.L., et al., For-profit versus not-for-profit dialysis care for children with end stage renal 
disease. Pediatrics, 1999. 104(3 Pt 1): p. 519-24. 
120. Kendix, M., Dialysis modality selection among patients attending freestanding dialysis facilities. 
Health Care Financ Rev, 1997. 18(4): p. 3-21. 
121. Diaz-Buxo, J.A. and T. Crawford-Bonadio, The continuum home program concept. Clin 
Nephrol, 2008. 69(5): p. 326-30. 
122. Kendix, M., Provision of home dialysis by freestanding renal dialysis facilities. Health Care 
Financ Rev, 1995. 17(2): p. 105-22. 
123. O'Hare, A.M., K.L. Johansen, and R.A. Rodriguez, Dialysis and kidney transplantation among 
patients living in rural areas of the United States. Kidney Int, 2006. 69(2): p. 343-9. 
124. Pozniak, A.S., An examination of organizational change and structure in the healthcare industry, 
in Health Services Organization and Policy. 2006, University of Michigan: Ann Arbor, MI. 
125. Cleary, P.D., M. Schlesinger, and D. Blumenthal, Factors affecting the availability and use of 
hemodialysis facilities. Health Care Financ Rev, 1991. 13(2): p. 49-55. 
126. de Lissovoy, G., et al., The relationship of provider organizational status and erythropoietin 
dosing in end stage renal disease patients. Med Care, 1994. 32(2): p. 130-40. 
127. Dor, A., P.J. Held, and M.V. Pauly, The Medicare cost of renal dialysis. Evidence from a 
statistical cost function. Med Care, 1992. 30(10): p. 879-91. 
128. Farley, D.O., Competition under fixed prices: effects on patient selection and service strategies 
by hemodialysis providers. Med Care Res Rev, 1996. 53(3): p. 330-49. 
174 
 
 129. Frankenfield, D.L., et al., Impact of facility size and profit status on intermediate outcomes in 
chronic dialysis patients. Am J Kidney Dis, 2000. 36(2): p. 318-26. 
130. Griffiths, R.I., et al., The production of dialysis by for-profit versus not-for-profit freestanding 
renal dialysis facilities. Health Serv Res, 1994. 29(4): p. 473-87. 
131. Held, P.J. and M.V. Pauly, Competition and efficiency in the end stage renal disease program. J 
Health Econ, 1983. 2(2): p. 95-118. 
132. Hirth, R.A., M.E. Chernew, and S.M. Orzol, Ownership, competition, and the adoption of new 
technologies and cost-saving practices in a fixed-price environment. Inquiry, 2000. 37(3): p. 
282-94. 
133. Hirth, R.A., et al., Practice patterns, case mix, Medicare payment policy, and dialysis facility 
costs. Health Serv Res, 1999. 33(6): p. 1567-92. 
134. Ozgen, H. and Y.A. Ozcan, A national study of efficiency for dialysis centers: an examination of 
market competition and facility characteristics for production of multiple dialysis outputs. 
Health Serv Res, 2002. 37(3): p. 711-32. 
135. Garg, P.P., et al., Effect of the ownership of dialysis facilities on patients' survival and referral 
for transplantation. N Engl J Med, 1999. 341(22): p. 1653-60. 
136. Ozgen, H. and Y.A. Ozcan, Longitudinal analysis of efficiency in multiple output dialysis 
markets. Health Care Manag Sci, 2004. 7(4): p. 253-61. 
137. Newhouse, J.P., Geographic access to physician services. Annu Rev Public Health, 1990. 11: p. 
207-30. 
138. Gilbertson, D., et al. Projecting the U.S. ESRD population by 2030.  US Renal Data System: 
Data presented at the American Society of Nephrology Annual Meeting.  2003  [cited; Available 
from: http://www.usrds.org/2003/pres/html/5U_ASN_projections_files/v3_document.htm. 
139. Pulliam, J., R. Hakim, and M. Lazarus, Peritoneal dialysis in large dialysis chains. Perit Dial Int, 
2006. 26(4): p. 435-7. 
140. Beckmann, M., Location Theory. 1968, New York, NY: Random House. 
141. Miller, E.W., A Geography of Industrial Location. The Brown foundations of  geography series. 
1970, Dubuque, IO: W.C. Brown Company. 
142. Webber, M.J., Industrial Location. Scientific Geography Series, ed. G.I. Thrall. Vol. 3. 1984, 
Beverly Hills, CA: Sage Publications. 
143. McCann, P. and S. Sheppard, The rise, fall, and rise again of industrial location theory. Regional 
Studies, 2003. 37: p. 649-663. 
144. Thisse, J., Location theory, regional science, and economics. Journal of Regional Science, 1987. 
27(4): p. 519-528. 
175 
 
 145. Ghosh, A. and G. Rushton, Introduction: Progress in location-allocation modeling, in Spatial 
Analysis and Location-Allocation Models, A. Ghosh and G. Rushton, Editors. 1987, Van 
Nostrand Reinhold Company: New York, NY. 
146. Greenhut, M.L., Integrating the leading theories of plant location. Southern Economic Journal, 
1952. 18(4): p. 526-538. 
147. Greenhut, M.L., A general theory of plant location. Metroeconomica, 1955. 7(fasc II): p. 59-72. 
148. Greenhut, M.L., Plant Location in Theory and in Practise. 1956, Chapel Hill, NC: The 
University of North Carolina Press. 
149. Chapman, K. and D. Walker, Industrial Location: Principles and Policies. 1987, New York, NY: 
Basil Blackwell. 
150. Weber, A., Uber den Standort der Industrien. (Translated by Carl J. Friedrich (1929) Alfred 
Weber's Theory of the Location of Industries). 1909, New York, NY: Russell and Russell. 
151. Moses, L.N., Location and the theory of production. Quarterly Journal of Economics, 1958. 
72(2): p. 259-272. 
152. Hoover, E.M., The Location of Economic Activity. 1948, New York, NY: McGraw-Hill. 
153. Losch, A., The Economics of Location. 1954, New Haven, CT: Yale University Press. 
154. McCann, P., The Economics of Industrial Location: A Logistics-Costs Approach. 1998, New 
York, NY: Springer Verlag. 
155. Christaller, W., Die Zentralen Orte in Suddeutschland. (Translated by C.W. Baskin (1966) 
Central Placed in Southern Germany). 1933, Englewood Cliffs, NJ: Prentice-Hall. 
156. Eswaran, M., Y. Kanemoto, and D. Ryan, A dual approach to the locational decision of the firm. 
Journal of Regional Science, 1981. 21(4): p. 469-489. 
157. Miller, S.M. and O.W. Jesen, Location and the theory of production. Regional Science and 
Urban Economics, 1978. 8: p. 117-128. 
158. Hotelling, H., Stability in competition. Economic Journal, 1929. 39(153): p. 41-57. 
159. Bresnahan, T.F. and P.C. Reiss, Entry and competition in concentrated markets. Journal of 
Political Economy, 1991. 99(5): p. 977-1009. 
160. Gabszewicz, J.J. and J.F. Thisse, Spatial competition and the location of firms, in Location 
Theory, J.J. Gabszewicz, et al., Editors. 1986, Harwood Academic Publishers: New York. 
161. Irmen, A. and J.F. Thisse, Competition in multi-characteristic spaces: Hotelling was almost 
right. Journal of Economic Theory, 1998. 78: p. 76-102. 
162. Netz, J.S. and B.A. Taylor, Maximum of minimum differentiation? Location patterns of retail 
outlets. Review of Economics and Statistics, 2002. 84(1): p. 162-175. 
176 
 
 163. Ridley, D.B., F.A. Sloan, and Y. Song, Retail zoning and competition (working paper). 2007: 
Durham, North Carolina. 
164. Fischer, J.H. and J.E. Harrington, Product variety and firm agglomeration. RAND Journal of 
Economics, 1996. 27(2): p. 281-309. 
165. Parr, J.B. and L. Budd, Financial services and the urban system: An exploration. Urban Studies, 
2000. 37(3): p. 593. 
166. Lawlor, A.C. and J.T. Reid, Hierarchical patterns in the location of physician specialists among 
counties. Inquiry, 1981. 18(1): p. 79-90. 
167. Cromley, E.K. and S.L. McLafferty, GIS and Public Health. 2002, New York, NY: Guilford 
Press. 
168. Brasure, M., et al., Competitive behavior in local physician markets. Med Care Res Rev, 1999. 
56(4): p. 395-414. 
169. Connor, R.A., S.D. Hillson, and J.E. Krawelski, Competition, professional synergism, and the 
geographic distribution of rural physicians. Med Care, 1995. 33(11): p. 1067-78. 
170. Knesper, D.J., J.R. Wheeler, and D.J. Pagnucco, Mental health services providers' distribution 
across countries in the United States. Am Psychol, 1984. 39(12): p. 1424-34. 
171. Koran, L.M., Psychiatrists' distribution across the 50 states, 1978. Arch Gen Psychiatry, 1981. 
38(10): p. 1155-9. 
172. Newhouse, J.P., et al., Does the geographical distribution of physicians reflect market failure? 
Bell Journal of Economics, 1982. 13(2): p. 493-505. 
173. Richards, J.M. and G.D. Gottfredson, Geographic distribution of US psychologists. American 
Psychologist, 1978. 33: p. 1-8. 
174. Schwartz, W.B., et al., The changing geographic distribution of board-certified physicians. N 
Engl J Med, 1980. 303(18): p. 1032-8. 
175. Cull, W.L., C.H. Chang, and D.C. Goodman, Where do graduating pediatric residents seek 
practice positions? Ambul Pediatr, 2005. 5(4): p. 228-34. 
176. Joroff, S. and V. Navarro, Medical manpower: a multivariate analysis of the distribution of 
physicians in urban United States. Med Care, 1971. 9(5): p. 428-38. 
177. Wing, P. and C. Reynolds, The availability of physician services: a geographic analysis. Health 
Serv Res, 1988. 23(5): p. 649-67. 
178. Rosenthal, M.B., A. Zaslavsky, and J.P. Newhouse, The geographic distribution of physicians 
revisited. Health Serv Res, 2005. 40(6 Pt 1): p. 1931-52. 
179. Pathman, D.E., T.C. Ricketts, 3rd, and T.R. Konrad, How adults' access to outpatient physician 
services relates to the local supply of primary care physicians in the rural southeast. Health Serv 
Res, 2006. 41(1): p. 79-102. 
177 
 
 180. McLafferty, S., The geographical restructuring of urban hospitals: spatial dimensions of 
corporate strategy. Soc Sci Med, 1986. 23(10): p. 1079-86. 
181. Wholey, D.R. and J.B. Christianson, Product differentiation among health maintenance 
organizations: causes and consequences of offering open-ended products. Inquiry, 1994. 31(1): 
p. 25-39. 
182. Fennell, M.L., The effects of environmental characteristics on the structure of hospital clusters. 
Administrative Science Quarterly, 1980. 25(3): p. 485-510. 
183. Fennell, M.L., Context in organizational groups: The case of hospital clusters. Journal of Health 
and Social Behavior, 1982. 23: p. 65-84. 
184. Succi, M.J., S.Y. Lee, and J.A. Alexander, Effects of market position and competition on rural 
hospital closures. Health Serv Res, 1997. 31(6): p. 679-99. 
185. Winkelmayer, W.C., et al., Late referral and modality choice in end-stage renal disease. Kidney 
Int, 2001. 60(4): p. 1547-54. 
186. Luke, R.D. and S.L. Walston, Strategy in an institutional environment, in Advances in Health 
Care Organization Theory, S.S. Mick and M.E. Wyttenbach, Editors. 2003, Jossey-Bass: San 
Francisco. 
187. Pfeffer, J. and G. Salancik, The External Control of Organizations: A Resource Dependence 
Perspective. 1978, New York, NY: Harper and Row. 
188. Scott, W.R., Organizations: Rational, Natural, and Open Systems, Fifth Edition. 2003, Upper 
Saddle River, NJ: Prentice Hall. 
189. Gaynor, M. and W.B. Vogt, Antitrust and competition in health care markets.  NBER Working 
Paper 7112. 1999, National Bureau of Economic Research: Cambridge, MA. 
190. Diggle, P.J., et al., Analysis of Longitudinal Data. 2002, Oxford, UK: Oxford University Press. 
191. Menard, S., Longitudinal Research (Second edition). 2002, Thousand Oaks, CA: Sage 
Publications. 
192. Center for the Evaluative Clinical Sciences and Dartmouth Atlas of Health Care Working 
Group, The Dartmouth Atlas of Health Care in the United States, J.E. Wennberg and M.A. 
Cooper, Editors. 1999, American Hospital Association: Chicago, IL. 
193. Center for the Evaluative Clinical Sciences and Dartmouth Atlas of Health Care Working 
Group, Geographic Boundary Files: Hospital Referral Region. 2006, Center for the Evaluative 
Clinical Sciences: Lebanon, NH. 
194. ESRI, StreetMap USA. 2004: Redlands, CA. 
195. Stata Corporation, Stata Version 8. 2003: College Station, TX. 
196. Folland, S., A.C. Goodman, and e. al., The Economics of Health and Health Care, 3rd edition. 
2001, Upper Saddle River, NJ: Prentice-Hall, Inc. 
178 
 
 197. Yamaguchi, K., Event History Analysis. 1991, Newbury Park, CA: Sage Publications. 
198. Allison, P.D., Survival Analysis Using SAS: A Practical Guide. 1995, Cary, NC: SAS 
Publishing. 
199. StataCorp, Stata Survival Analysis and Epidemiological Tables.  Reference Manual, Release 8.0. 
2003, College Station, TX: Stata Press. 
200. Ballinger, G.A., Using generalized estimating equations for longitudinal analysis. Organizational 
Research Methods, 2004. 7: p. 127-150. 
201. Kennedy, P., A Guide to Econometrics.  Fourth Edition. 2001, Cambridge, MA: MIT Press. 
202. Zeger, S.L. and K.Y. Liang, Longitudinal data analysis for discrete and continuous outcomes. 
Biometrics, 1986. 42(1): p. 121-130. 
203. Norton, E.C., et al., Analysis of prevention program effectiveness with clustered data using 
generalized estimating equations. J Consult Clin Psychol, 1996. 64(5): p. 919-26. 
204. Young, M.L., et al., Comparison of subject-specific and population averaged models for count 
data from cluster-unit intervention trials. Stat Methods Med Res, 2007. 16(2): p. 167-84. 
205. Zeger, S.L. and K.Y. Liang, An overview of methods for the analysis of longitudinal data. Stat 
Med, 1992. 11(14-15): p. 1825-39. 
206. Zeger, S.L., K.Y. Liang, and P.S. Albert, Models for longitudinal data: A generalized estimating 
equation approach. Biometrics, 1988. 44(4): p. 1049-1060. 
207. SAS Institute Inc., SAS Version 9.1. 2003: Cary, NC. 
208. Earickson, R.J. and J.M. Harlin, Geographic Measurement and Quantitative Analysis. 1994, 
New York, NY: Maxwell College Publishing Company. 
209. Clark, P.J. and F.C. Evans, Distance to nearest neighbor as a measure of spatial relationships in 
populations. Ecology, 1954. 35(4): p. 445-453. 
210. Mitchell, A., The ESRI Guide to GIS Analysis.  Volume 2: Spatial Measurement and Statistics. 
2005, Redlands, CA: ESRI Press. 
211. Lai, P.C., et al., Understanding the spatial clustering of severe acute respiratory syndrome 
(SARS) in Hong Kong. Environ Health Perspect, 2004. 112(15): p. 1550-6. 
212. Ebdon, D., Statistics in Geography. 1985, Oxford, UK: Basil Blackwell. 
213. Rabe-Hesketh, S., A. Skrondal, and A. Pickles, GLLAMM Manual, in University of California, 
Berkeley Division of Biostatistics Working Paper Series. 2004, Berkeley Electronic Press: 
Berkeley, CA. p. Downloaded from the internet: http://www.bepress.com/ucbbiostat/paper160/. 
214. Mobley, L.R., T.M. Kuo, and L. Andrews, How sensitive are multilevel regression findings to 
defined area of context?: a case study of mammography use in California. Med Care Res Rev, 
2008. 65(3): p. 315-37. 
179 
 
 180 
 
215. Openshaw, S. and P. Taylor, Million or so correlation coefficients: Three experiments on 
modifiable areal unit problem, in Statistical Application in the Spatial Sciences, N. Wrigley, 
Editor. 1979, London: Pion. 
216. Ford, J.M. and D.L. Kaserman, Certificate-of-need regulation and entry: Evidence from the 
dialysis industry. Southern Economic Journal, 1993. 59: p. 783-791. 
 
 
